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General introduction
My thesis on adult attention-deficit/hyperactivity disorder (ADHD) follows a path from 
the clinical appearance of the disorder to the genetic factors that contribute to its 
etiology. In the introduction, I describe the clinical features of ADHD as well as key 
cognitive deficits observed in patients and what is known about altered brain anatomy 
and functionality in the disorder. Lastly, I introduce facts about the genetics of ADHD 
and the concept of endophenotypes, which is the focus of my own work described in 
the subsequent chapters. 
ADHD: clinical aspects
Attention-deficit/hyperactivity disorder (ADHD) is known as a neuropsychiatric disorder 
with prevalence rates estimated at 5-6 % in childhood (APA, 2000; Polanczyk et al., 2007). 
More boys than girls are diagnosed with ADHD (Ramtekkar et al., 2010). The core clinical 
symptoms of ADHD are divided into two domains, symptoms of inattention on the one 
hand and symptoms of hyperactivity and impulsivity on the other. For a clinical 
diagnosis of ADHD according to the Diagnostic and Statistical Manual of Mental 
Disorders (DSM-IV-TR), one needs to display 6 out of 9 symptoms of inattention and/or 
6 out of 9 symptoms of hyperactivity/impulsivity (see Box 1). If criteria for both domains 
are met over a prolonged period of time, the ‘combined’ subtype of ADHD is diagnosed; 
passing the threshold of criteria in only a single domain can lead to either an inattentive 
subtype or a hyperactive/impulsive subtype diagnosis. In addition to having these 
symptoms of ADHD, impairment in two or more settings (i.e. school and at home) must 
be present. Most affected children display the combined subtype of ADHD (68%), the 
hyperactive/impulsive subtype is observed in about 23%, and the inattentive type in 
approximately 9% of patients (Nøvik et al., 2006).
 More often than not, ADHD patients are diagnosed with at least one co-morbid 
psychiatric disorder (Jensen et al., 2001). The most predominant co-morbidities in 
childhood are externalizing disorders like oppositional defiant disorder and conduct 
disorder (30-50%) (Angold et al., 1999; Biederman et al., 1991) as well as internalizing 
disorders like anxiety (seen in about 25%) and mood disorders, observed in approximately 
38% of cases (Gillberg et al., 2004). In addition the criteria for autism spectrum disorders 
are met in 20-50% of the ADHD children and approximately 50% of patients also have 
developmental coordination disorder (Kadesjö and Gillberg, 1998; Pitcher et al., 2003; 
Rommelse et al., 2011).
ADHD in adulthood
Follow-up studies of children with ADHD show lower academic and occupational 
achievements (Barkley et al., 1991; Barkley et al., 2008), next to higher rates of health 
problems (i.e. more car accidents, sexually transmitted diseases and drug abuse (Barkley 
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Box 1  DSM-IV Diagnostic criteria for Attention-Deficit Hyperactivity Disorder
A. Either (1) or (2):
(1)  six (or more) of the following symptoms of inattention have persisted for at least 6 months 
to a degree that is maladaptive and inconsistent with developmental level:
Inattention
(a)  often fails to give close attention to details or makes careless mistakes in schoolwork, work, 
or other activities
(b)  often has difficulty sustaining attention in tasks or play activities
(c)  often does not seem to listen when spoken to directly
(d)  often does not follow through on instructions and fails to finish schoolwork, chores, 
or duties in the workplace (not due to oppositional behavior or failure to understand 
instructions)
(e)  often has difficulty organizing tasks and activities
(f)  often avoids, dislikes, or is reluctant to engage in tasks that require sustained mental effort 
(such as schoolwork and homework)
(g)  often loses things necessary for task or activities (e.g., toys, school assignment, pencils, 
books, or tools)
(h)  is often easily distracted by extraneous stimuli
(i)  is often forgetful in daily activities
(2)  six (or more) of the following symptoms of hyperactivity-impulsivity have persisted for at 
least 6 months to a degree that is maladaptive and inconsistent with developmental level:
Hyperactivity
(a) often fidgets with hands or feet or squirms in seat
(b)  often leaves seat in classroom or in other situation in which remaining seated is expected
(c)  often runs about or climbs excessively in situations in which it is inappropriate (in 
adolescents or adults, may be limited to subjective feelings of restlessness)
(d)  often has difficulty playing or engaging in leisure activities quietly
(e)  is often “on the go” or often acts as if “driven by a motor”
(f)  often talks excessively
Impulsivity
(g) often blurt out answers before questions have been completed
(h) often has difficulty awaiting turn
(i) often interrupts or intrudes on others (eg. butts into conversation or games)
B.  Some hyperactive-impulsive or inattentive symptoms that causes impairment were present 
before age 7 years.
C.  Some impairment from the symptoms is present in two or more settings (e.g., at school  
[or work] and at home).
D.  There must be clear evidence of clinically significant impairment in social, academic, or 
occupational functioning.
E.  The symptoms do not occur exclusively during the course of a Pervasive Developmental 
Disorder, Schizophrenia, or Psychotic Disorder and are not better accounted for by another 
mental disorder (e.g., Mood Disorder, Anxiety Disorder, Dissociative Disorder, or a Personality 
Disorder) 
Code based on type:
314.01 Attention-Deficit/Hyperactivity Disorder, Combined Type:
If both Criteria A1 and A2 are met for the past 6 months
314.02 Attention-Deficit/Hyperactivity Disorder, Predominantly Inattentive Type:
If Criterion A1 is met but Criterion A2 is not met for the past 6 months
314.01 Attention-Deficit/Hyperactivity Disorder, Predominantly Hyperactive-Impulsive Type:
If Criterion A2 is met but Criterion A1 is not met for the past 6 months
Coding note: For individuals (especially adolescents and adults) who currently have symptoms
that no longer meet full criteria, “In partial remission” should be specified (APA, 1994, 1998).
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et al., 2006; Biederman et al., 1995; Gayton et al., 1986)) in comparison to normally 
developing children. Social problems, such as higher rates of divorce, arrests and young 
parenthood (Barkley et al., 2006; Satterfield and Schell, 1997) are frequently observed, 
too. Not only that, ADHD and its symptoms also frequently persist into adulthood. A 
meta-analysis of follow-up studies reported that more than 50% of the patients 
diagnosed with ADHD in childhood still show ADHD symptoms in their adult life and 
15% still meet criteria for the full clinical disorder (Faraone et al., 2006). Prevalence rates 
of ADHD in adulthood are estimated to be between 2.5 and 4.9 (Simon et al., 2009). 
According to the DSM-IV-TR, ADHD by definition emerges in childhood, before the age 
of seven years. For a diagnosis of ADHD in adult age, the diagnostic procedures therefore 
include a retrospective diagnosis of childhood ADHD. For that, available school reports 
are evaluated and a hetero anamnesis of the parents or other informants is performed. 
There are no specific or official criteria for adult ADHD; the presence of ADHD in 
adulthood is simply the syndromatic persistence of childhood ADHD. Although 
diagnosis of ADHD in adulthood seems difficult, it is a valid diagnosis as evidenced by 
the impairment shown in these patients (Kooij et al., 2005) as well as by genetic and 
imaging studies in adult ADHD samples (discussed later in this chapter). 
 The clinical manifestation of adult ADHD differs from that of children in having less 
obvious symptoms of hyperactivity/impulsivity like gross motor activity (running and 
climbing) however more inner restlessness is present in adults with ADHD. Also, the 
inability to plan and organize is more prominent in adults with ADHD (Buitelaar et al., 
2011; Haavik et al., 2010). Some studies suggest that the threshold of symptoms needed 
for an ADHD diagnosis should be lower for adults than for children. For example, the 
work by Kooij et al. suggests that having 4 symptoms of either of the two domains in 
adulthood is already associated with impairment in daily life (Kooij et al., 2005). In the 
new version of the DSM, expected to be released in 2013, the number of criteria to be 
met by an adult will indeed be lowered from 6 to 4. In addition, the age of onset will be 
12 instead of 7 years (www.dsm5.org).   
 Comparable to children with ADHD, co-morbid disorders are frequently present in 
adults with ADHD, too (Kessler et al., 2006; McGough et al., 2005). Wilens and coworkers 
showed that only a minority of patients (8%) had no co-morbid disorders, 10% had one 
co-morbid psychiatric disorder and patients with two (14%), three (15%) and four (53%) 
co-morbidities were even more prevalent (Wilens et al., 2009). Co-morbid disorders 
most frequently present in adults with ADHD are substance use disorders and major 
depressive disorder (Wilens et al., 2009). The presence of co-morbid disorders seems 
related to the persistence of ADHD (Biederman et al., 1996). 
In conclusion, patients with ADHD comprise a heterogeneous group characterized by a 
diversity of behavioral symptoms. Given the large number of affected individuals and 
the long term impact of the disorder on the patient, his/her family and social network 
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as well as the health care system, ADHD is a serious financial burden to our society 
(Matza et al., 2005). Treatment of ADHD consist of using medication (either stimulants 
like methylphenidate or non stimulants like atomoxetine) often in addition to behavioral 
therapy or other alternative treatment approaches like diet adjustments. However, 
treatment of ADHD is symptomatic rather than curative and there is no evidence that 
these treatments have a positive effect on long term prognosis of ADHD (Buitelaar et al., 
2011; Nigg et al., 2012). This might be due to the fact that relatively little is known about 
the actual underlying mechanisms causing disease. A better understanding of such 
mechanisms seems imperative before we can identify ways to improve disease 
prognosis, prevention of persistence or even attempt to cure the patient. Looking closer 
at the brain as well as the molecular components contributing to the clinical symptoms 
might help achieve this goal.
Cognition and the brain in ADHD
Many cognitive dysfunctions are proposed to be linked to ADHD covering the cognitive 
domains of attention, memory, executive functioning and temporal and reinforcement 
processing (Fair et al., 2012; Nigg, 2005). However, only approximately 30-50% of patients 
appear to have any cognitive dysfunctions, and deficits seen among these patients do 
not always overlap (Doyle et al., 2000; Seidman, 2006; Smalley et al., 2007). In other 
words, no single cognitive deficit or profile fits all patients. 
 Researchers have sought for a core cognitive deficit in ADHD for a long time. Now 
it is clear, that such a single deficit explaining the entire spectrum of behavioral problems 
is unlikely to exist (Sonuga-Barke, 2002). One of the leading theories about cognitive 
dysfunctioning in ADHD patients in recent years has been the ‘Dual Pathway’ hypothesis 
of Sonuga-Barke (Sonuga-Barke, 2002). This theory states, that ADHD patients are 
characterized by executive dysfunctioning as well as having motivational problems. An 
initial study in support of this theory showed that performance on a response inhibition 
task (executive functioning pathway) and a delay aversion task (motivational pathway) 
were not correlated, and that ADHD patients performed worse than controls on both 
tasks. The results of both tasks together could identify 90% of cases (Sonuga-Barke, 
2002). Executive functions are higher order cognitive processes which include, for 
example, set shifting, working memory, planning and impulse control. Although 
executive dysfunctioning plays a key role in ADHD, as also illustrated by its predictive 
value for occupational dysfunctioning in adults with ADHD (Barkley and Murphy, 2010), 
many studies have shown deficiencies in executive functioning not to be universal 
among ADHD patients; such deficits were neither necessary nor sufficient to cause or 
characterize ADHD (Schoechlin and Engel, 2005; Willcutt et al., 2005). According to the 
‘dual pathway’ model, motivation is the other cognitive domain involved in ADHD. One 
of the key mechanisms of the motivational pathway is reinforcement processing, which 
is altered in ADHD. A paradigm often studied in ADHD is choosing between immediate 
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small rewards and larger delayed rewards. In such tests, ADHD patients often choose 
the smaller immediate reinforcements over larger delayed reinforcements compared to 
controls (Antrop et al., 2006). Other examples of deviant motivational behavior in ADHD 
patients are atypical responses to positive reinforcement (Luman et al., 2005), altered 
decision making (Toplak et al., 2005), and altered sensitivity to rewards and response 
costs (Iaboni et al., 1995). Like the executive functioning problems, altered reinforcement 
processing is not specific or always present in ADHD patients (Tripp and Wickens, 2008). 
The ‘dual pathway’ model of ADHD was recently extended with a third component: 
deficient temporal processing (Sonuga-Barke et al., 2010). ADHD patients often have 
problems with duration discrimination, time reproduction, time estimation and finger 
tapping (Toplak et al., 2006). 
 Fewer studies have yet been performed on cognitive functioning in adults than in 
children with ADHD. However, the studies in adults generally indicate that cognitive 
impairments are similar to those observed in children with ADHD (Hervey et al., 2004; 
Nigg et al., 2005; Seidman, 2006). A meta-analysis of 33 cognitive studies in adults with 
ADHD found medium effect sizes for executive functioning but also for non-executive 
functioning domains (Boonstra et al., 2005). 
Structural magnetic resonance imaging (MRI) studies in children with ADHD have 
revealed global reductions in total brain volume of around 3% (Castellanos et al., 2002), 
but also reductions in the volume of specific brain regions like in the frontal lobes, basal 
ganglia, cerebellum and parietotemporal regions (Valera et al., 2007). Two recent 
meta-analysis of volumetric studies in ADHD highlighted the basal ganglia as one of the 
structures to be most affected in ADHD (Frodl and Skokauskas, 2012; Nakao et al., 2011). 
Most of these studies have used candidate-driven approaches specifically focused on 
the brain regions associated with cognitive impairments in ADHD. 
 Some studies suggest altered brain volume at a young age to be a result of delayed 
brain maturation, e.g., Shaw and coworkers found local cortical thickness maturation 
lagging behind by approximately 3 years in children with ADHD compared to controls 
(Shaw et al., 2011). Also, a normalization of grey matter reductions was found in ADHD 
patients (Nakao et al., 2011). 
 The few brain volumetry studies in adult ADHD patients reported reductions of 
brain volume largely overlapping the areas observed in children; decreased volumes of 
the prefrontal cortex (Almeida et al., 2010; Cubillo and Rubia, 2010), caudate nucleus 
(Almeida Montes et al., 2010; Seidman et al., 2010) and amygdala (Frodl et al., 2010) have 
been observed, but a marginal increase of nucleus accumbens volume was also 
reported (Cubillo and Rubia, 2010). Only some of these findings have been replicated, to 
date (Perlov et al., 2008; Seidman et al., 2010). The reasons for this could be the generally 
small sample size of the studies and the resulting low power to detect differences. Also, 
brain volume alterations might be less pronounced in adult ADHD as evidenced by 
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normalization of brain volume reductions with increasing age in patient samples (Amico 
et al., 2011; Nakao et al., 2011). In addition, heterogeneity of the study samples due to 
medication effects and presence of co-morbid disorders could be the cause (Cubillo 
and Rubia, 2010). The problem of heterogeneity of samples cannot be solved, because 
heterogeneity is part of the ADHD phenotype. However, the sample size of neuroimaging 
studies will (and should) increase, due to the growth of the databases of ongoing 
studies like our own IMpACT study (for more information see the description of this 
study at the end of this chapter), and also by performing meta-analyses of published 
studies to increase power.
The three above-mentioned behavioral components deficient in ADHD have known 
neurobiological substrates: executive dysfunctions are associated with frontodorsal 
(dorsolateral and medial prefrontal cortex) network deficiencies (Miller and Cohen, 
2001), motivational problems are associated with frontoventral (orbitofrontal cortex and 
ventral striatum) deficiencies (McClure et al., 2004; Pothuizen et al., 2005), and temporal 
processing is linked with cerebellar functioning (Wiener et al., 2010). These substrates 
have also been studied in ADHD using neuroimaging methods, functional magnetic 
resonance imaging (fMRI) in particular.
 Comparable to the behavioral studies, most literature on neuroimaging in ADHD 
concerns studies in children. The fMRI studies in children with ADHD generally show 
decreased activation of inferior frontostriatal, temporoparietal and cerebellar regions in 
the brain (Paloyelis et al., 2007). Functional MRI studies in adults with ADHD have been 
reviewed by Cubillo and colleagues (Cubillo and Rubia, 2010). Many different tasks were 
used during scanning, roughly covering tasks related to the dual pathway model. The 
handful of studies using an inhibition task in adults with ADHD showed decreased 
frontostriatal activation, paralleling the results in children (Cubillo et al., 2010; Epstein et 
al., 2007). In addition, compensatory increased activation was seen in other parts of the 
brain, which could be an effect of long term medication use or other yet undetermined 
factors to be studied in future research. Attention, cognitive interference and working 
memory performance are other cognitive domains relating to the executive pathway 
that have been studied in adults. Despite having fewer attentive symptoms compared 
with ADHD children, adults with ADHD did show results comparable to children on fMRI 
tasks of sustained, selective and flexible attention, as decreased activation of left inferior 
cortex and dorsolateral prefrontal cortex were found. Stroop-like tasks are well suited to 
test cognitive interference inside the MRI scanner and have consistently shown reduced 
anterior cingulate and inferior prefrontal cortex activity in adult ADHD (Bush et al., 1999; 
Bush et al., 2005). Also during working memory tasks, decreased activation of task-related 
areas in the brain, i.e. inferior/ventrolateral prefrontal, parietal temporo-occipital and 
cerebellar regions, was found in adult ADHD patients (Ehlis et al., 2008; Hale et al., 2007; 
Valera et al., 2010a; Valera et al., 2005; Wolf et al., 2009). The fMRI results on cognitive 
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interference were comparable to the results of studies in children with ADHD; for 
working memory there is only one published study in children (Fassbender et al., 2011), 
nothing has been published for adult ADHD, yet. 
 The motivational pathway was covered primarily by studies using the Monetary 
Incentive Delay Task, or a modified version of a task originally published by Knutson 
(Knutson et al., 2001). During this task, activation of striatal areas is induced by 
anticipating a reward. The results of three studies were consistent in finding reduced 
striatal activation in adult ADHD patients (Plichta et al., 2009; Scheres et al., 2007; Ströhle 
et al., 2008). Also other tasks, such as gambling tasks or reward-related attention tasks 
have shown decreased activation in striatum, amygdala, and ventromedial orbitofrontal 
cortex in adult ADHD patients (Cubillo et al., 2009; Ernst et al., 2003).
 The third cognitive domain often disturbed in ADHD, timing/temporal processing, 
has not been studied very often. The only motor timing study in adult ADHD showed 
less activity in a number of regions associated with sensorimotor timing, including basal 
ganglia and cerebellum (Valera et al., 2010b).
 In conclusion, fMRI studies using various cognitive tasks show reduced activation of 
target areas in the brain in adult ADHD, which are comparable to those found in ADHD 
children. Sometimes, compensatory increased activity is found and should be subject 
of further research to understand the reduced brain responses in ADHD.
Next to showing deficient task-related brain activity, ADHD patients also show altered 
brain activity during rest. This has been shown in studies using resting state paradigms 
inside the fMRI scanner. A well-known network of resting state activity, the default 
mode network, normally shows more activity during rest than during task performance. 
This default mode network activity is predictive of performance on attention tasks 
(Sandrone and Bacigaluppi, 2012). Although default mode network studies in ADHD are 
yet limited, there is first evidence for disturbed default mode network activity in these 
patients (Konrad and Eickhoff, 2010). For example, in children with ADHD functional 
connections in the default network previously shown to play a key role during 
development were altered, which showed that atypical consolidation of this network 
over development plays a role in the pathophysiology of ADHD (Fair et al., 2010). In 
adults alterations in resting state activation were found in connections between anterior 
cingulate and precuneus, and precuneus-prefrontal connections (Castellanos et al., 
2008). 
Neurochemistry of ADHD
The dopamine neurotransmission seems to be implicated in ADHD in several ways. The 
first one is that the primary treatment for ADHD, psychostimulants as fast release or 
extended release methylphenidate are effective in reducing ADHD symptoms by 
influencing the dopamine system. One of methylphenidate core effects is blocking the 
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dopamine transporters, and as a result inhibits the uptake of dopamine, leaving more 
dopamine in the extracellular space (Volkow et al., 1998). The second piece of evidence 
is found in studies showing an enrichment of dopaminergic cells in the regions of the 
brain altered in morphology and/or function in ADHD (see above), i.e. the frontal cortex 
and striatal areas (Jackson and Westlind-Danielsson, 1994). Also, many PET-scan studies 
investigating dopamine availability and dopamine transporter levels in ADHD have 
found alterations in patients. Although with inconsistent results (some studies found 
increased dopamine transporter binding and therefore less dopamine available in 
the striatum in ADHD (Dougherty et al., 1999; Spencer et al., 2007), while others finding 
the opposite (Hesse et al., 2009; Volkow et al., 2007)), this does suggest disturbed 
dopaminergic functioning in ADHD. The final indication of a prominent role of dopamine 
in ADHD is its involvement in reward-related behavioral processes also known to be 
deficient in ADHD (Tripp and Wickens, 2008). 
 In summary, dopamine plays an important, yet not completely characterized role in 
ADHD. Even though the subject of most neurochemical studies in ADHD has been 
dopamine, etiological mechanisms involving noradrenalin and serotonin neurotrans-
mission also appear to play a role in ADHD (Del Campo et al., 2011; Pliszka et al., 1996; 
Russell, 2007).
Genetics of ADHD
Genetic components strongly influence the etiology of ADHD. Adoption and twin 
studies have shown heritability rates ranging between 70 and 80% (Burt, 2009; Faraone 
et al., 2005). Persistent or adult ADHD has been associated with comparable or even 
stronger genetic influences (Faraone et al., 2000; Franke et al., 2011). Although ADHD is 
under such strong genetic influences, it has been difficult to identify the actual genes 
involved. The reason for this is twofold: 1. ADHD is a phenotypically complex disorder 
characterized by different symptom domains, co-morbidities and neurobiological 
systems involved; as eluded to above, the group of ADHD patients is a very 
heterogeneous group. 2. The genetic component of ADHD is polygenic; not one but 
many genes are thought to be involved in ADHD at the same time, each contributing 
only as a risk factor of small effect size. In addition, environmental factors can interact 
with genetic variation, which makes ADHD multifactorial in its etiology. Given the high 
prevalence of ADHD in the population and the decrease of risk for ADHD between first 
and second degree relatives, we expect multiple common genetic variants, genetic 
polymorphisms, to be the causative genetic risk factors.
 To find genes associated with ADHD, various methodologies have been used. One 
of the approaches is the study of individual candidate genes for the disorder. These 
genes are often chosen based on their neurobiological function. Many candidate gene 
studies for ADHD have focused on genes related to catecholaminergic functioning, i.e. 
the genes underlying dopaminergic, noradrenergic and serotonergic neurotransmis-
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sion (Volkow et al., 2009). Meta-analyses of these candidate gene studies showed indeed 
that genes related to dopaminergic (DAT1, DRD4, DRD5) and serotonergic neurotrans-
mission (5-HTT/SLC6A4, HTR1B) play a role in ADHD in childhood, as does an additional 
gene involved in neurotransmission (SNAP25) (Gizer et al., 2009). 
 Candidate gene studies are based on prior knowledge and/or a priori hypotheses. 
This is a clear limitation for identifying new risk genes for ADHD. Linkage analysis is a 
hypothesis-free method, which has been applied to ADHD over many years. The idea 
behind linkage analysis is that neighboring parts of chromosomes have a tendency to 
stick together when passed on to offspring. Therefore, if some disease is often passed 
to offspring along with a specific marker (i.e. a polymorphism), it can be concluded that 
a gene which contributes to disease etiology is located close to that marker on the 
chromosome. Several genome-wide linkage studies have been performed in ADHD 
(see for a review (Banaschewski et al., 2010)). A meta-analysis of seven linkage studies 
identified a single genome-wide significant linkage finding for ADHD on chromosome 
16q (Zhou et al., 2008), implicating a rather large area of the chromosome containing 
multiple genes. In addition, the LPHN3 gene was recently identified as the gene 
contributing to a linkage finding for ADHD on chromosome 4 (Arcos-Burgos et al., 2010).
 While linkage analysis is best suited for the identification of genetic factors of large 
effect size, these are quite unlikely to explain the majority of the genetic contribution to 
ADHD. New techniques have enabled us to go beyond linkage analysis and scan the 
entire genome on a gene or single nucleotide polymorphism (SNP) level in a so-called 
genome-wide association study (GWAS). In 2008, the first ADHD GWAS was published, 
which was carried out in 958 Caucasian case–parent-trios, but did not result in a 
genome-wide significant hit (Neale et al., 2008). Subsequent GWASs did not identify 
new ADHD risk alleles at genome-wide significance levels either (Mick et al., 2010; Neale 
et al., 2010b), but a symptom-based analysis of the data from one of these studies 
showed genetic variants in CDH13 and GFOD1 to be involved (Lasky-Su et al., 2008). 
These first GWASs in childhood ADHD did not result in the outcome that had been 
hoped for, and therefore, considering the genetic component to be stronger in adults 
with ADHD, a first genome-wide scan in adult ADHD was done. This GWAS in a relatively 
small sample of 343 patients and 250 controls (all adults) again failed to find genome-wide 
significant hits but, in conjunction with a linkage analysis in an overlapping sample, did 
hint at some interesting genes, like CDH13 (Lesch et al., 2008). A review of ADHD GWASs 
reported only CDH13 to overlap between studies (Franke et al., 2009). Interestingly, 
CDH13 is located within the only meta-analytically genome-wide significant linkage 
region on chromosome 16q (see above). This gene codes for cadherin 13 (Patel et al., 
2003), a regulator of neural cell growth. Recently, a meta-analysis of the available ADHD 
GWASs was performed. This study included 2.064 parent-case trios, 896 cases and 2.455 
controls, but still failed to provide a genome-wide significant finding (Neale et al., 2010a), 
as did also the latest GWASs in children with ADHD (Elia et al., 2012; Hinney et al., 2011).
20
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 Recently also copy number variations (CNV) were investigated in ADHD patients. 
CNV’s are larger regions of the genome that are deleted or duplicated. These studies 
have resulted in some interesting findings. The first CVN study in ADHD patients showed 
a duplication of a gene encoding neuropeptide Y (NPY) (Lesch et al., 2011). In the 
successive CNV studies, deletions of genes encoding glutamate receptors, excess of 
chromosome 16p13.11 duplications, deletions in ASTN2 and TRIM32, and duplications of 
CHRNA7 were associated with ADHD (Elia et al., 2012; Lionel et al., 2011; Williams et al., 
2012; Williams et al., 2010). The high effect sizes of these CNV’s suggest promising and 
could play an important role in ADHD’s etiology (Williams et al., 2012).  
 And finally, additional statistical techniques are performed to find genes associated 
with ADHD. Considering the small effects of genes, combining the effects of multiple 
genes might result in increased power. A recent publication reported the combined 
analysis of genes with a sub-threshold association in ADHD GWAS studies. Using bio-
informatics tools to search for enrichment of any neuromolecular process among those 
top genes resulted in an enrichment of neurite outgrowth genes (Poelmans et al., 2011). 
 To conclude, despite new, more powerful techniques and growing study samples, 
identifying new genes for ADHD remains difficult. Still very little is known about 
individual genes involved in ADHD, and genes that do show an association, have only 
very small effects. 
Endophenotypes and their use in genetic studies
Reviewing the genetic studies and what these studies have given us, it appears that it is 
imperative to search for additional approaches to find genes for ADHD. As indicated 
above, ADHD, like any other psychiatric disorder, is a complex disorder from a genetic as 
well as from a behavioral perspective. As the genetic studies have not resulted in 
straightforward and replicated results, it is not to be expected, that there are direct links 
between parts of the DNA and the clinical phenotype. A potential way to simplify 
matters is the use of endophenotypes. These endophenotypes lay between the 
phenotype (i.e. the clinical representation of ADHD) and the genetic factors involved in 
ADHD. Most definitions of an endophenotype refer to it as a disease-related phenotype 
closer to the genes than its clinical symptoms, influenced by one or more risk genes 
that contribute to the disease (Gottesman and Gould, 2003), as shown in Figure 1. The 
potential advantage of using endophenotypes to study the relation between genes 
and a disorder is that fewer genes and/or stronger genetic effects may be related to the 
endophenotype and therefore the power to detect associations may be higher. Another 
advantage of using endophenotype approaches is that this can generate new insights 
into the relationships between risk genes and clinical phenotypes and therefore can aid 
in identifying the mechanisms underlying the disorder (Freedman et al., 1999).   
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According to Gottesman and Gould (2003), an endophenotype must meet the following 
criteria: 1. it is associated with the disorder in the population; 2. it is heritable; 3. it is 
primarily state-independent; 4. it co-segregates with the clinical disorder in families; 5. it 
is found in non-affected family members at a higher rate than in the general population. 
Although endophenotypes are used to simplify the complex relation between a clinical 
phenotype and the underlying genes, it is important to keep in mind what they 
represent. A recent review highlighted some of the important issues when interpreting 
studies with an endophenotypic approach (Kendler and Neale, 2010). It is, for example, 
vital to distinguish mediational models and liability-index models. The former assume 
that a genetic risk passes through the endophenotype (also called an intermediate 
phenotype in this case) to the disorder. The latter refer to models in which genetic 
Figure 1  Endophenotypes
A systematic overview of the pathway between genes and a (psychiatric) disorder is displayed above. 
Endophenotypes are placed between the genotype (genetic variation related to the disorder) and the 
phenotype (observable characteristics of the disorder). Examples of endophenotypes are  the size of, or 
activation in various brain structures.
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factors influencing the clinical disorder also influence the endophenotype, but these 
are independent effects. 
 While few studies have used neuropsychological measures as ADHD endophenotypes 
in genetic studies (Rommelse et al., 2008a; Rommelse et al., 2008b; Rommelse et al., 
2008c), potentially better endophenotypes for ADHD are measures of brain volumetry 
and activity of brain structures. These are highly heritable traits (e.g. (Mulder et al., 
2008)), and they are thought to be closer to the genes than the cognitive functions 
these brain structures are related to. 
 One of the first studies combining brain volumetric neuroimaging measures with 
genetics in ADHD was published in 1998 (Castellanos et al., 1998). This study in ADHD 
children did not find an effect of the dopamine receptor D4 gene (DRD4) on brain 
structures like the prefrontal cortex and caudate nucleus. A second study (Bobb et al., 
2005) also did not find effects of DRD4 on brain volume. However, both studies had to 
control for many comparisons they made. Using a targeted approach to study effects of 
DRD4 was more successful; Durston et al. studied the effects of ADHD risk genes only in 
those areas in the brain, where this gene has high expression. They found the group of 
ADHD children carrying the DRD4 7-repeat allele, considered to be the risk allele for 
ADHD, to have increased grey matter volume in the prefrontal cortex when compared 
with ADHD children carrying the 4-repeat allele (Durston et al., 2005). A study by Shaw 
and coworkers, however, showed opposite results; participants carrying the 7-repeat 
allele had more cortical thinning compared with subjects not carrying this allele. Later, 
this finding was confirmed in a study with adult ADHD patients (Monuteaux et al., 2008). 
Interestingly, patients carrying the 7-repeat allele in the Shaw study showed a better 
clinical outcome, and in previous studies the presence of the 7-repeat allele was 
associated with better cognitive performance (Boonstra et al., 2008; Swanson et al., 
2000). Although this appears counterintuitive, these studies give useful information on 
how genes affect the phenotype; this shows us that risk genes for psychiatric disorders 
do not have to affect all aspects of the disorder. A few other ADHD candidate genes 
have been the subject of brain volumetric imaging genetics studies in ADHD patients: 
in children with ADHD, the risk genotype of the DAT1 gene (homozygosity for the 
10-repeat allele) was associated with smaller caudate nucleus volumes (Durston et al., 
2005; Shook et al., 2011). Variations in NET1 and DRD1 were not associated with brain 
volumes in childhood ADHD (Bobb et al., 2005).
 There is only a handful of imaging genetic studies in ADHD using measures of 
functional brain imaging. These studies are generally smaller sampled compared to the 
structural imaging genetics studies (Brown et al., 2011; Brown et al., 2010; Bédard et al., 
2010; Durston et al., 2008). The most studied gene in relation to brain activation is the 
DAT1 gene. The area in the brain where this gene is highly expressed is the striatum, and 
therefore most studies have looked for effects of variation in the DAT1 gene on striatal 
functioning. In children with ADHD, one study found lower striatal activation during 
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response inhibition to be associated with carriership of the homozygous 10-repeat 
genotype compared to people carrying the 9-repeat allele (Durston et al., 2008). 
Another study found the opposite (Bédard et al., 2010), while a third found homozygous 
10-repeat carriers to have increased activation in frontal, medial, and parietal regions 
(Braet et al., 2011). These differential effects could be due to false positive or negative 
findings, but also to the different cognitive paradigms used in the three studies. A 
fourth study measured striatal activity during reward processing and reported that 
having two copies of a DAT1 risk haplotype for ADHD (10-repeat allele combined with a 
6-repeat allele in another DAT1 variant located in intron 8) leads to decreased striatal 
activation in ADHD children but to increased striatal activation in healthy children 
compared to having one copy of the risk haplotype (Paloyelis et al., 2012). So far, there 
have not been any functional studies on the effects of the DAT1 gene on striatal 
functioning in adults with ADHD. Variation of DAT1 was, however, studied in adult ADHD 
patients during working memory and cognitive interference and gene effects were 
found on prefrontal cortex activity and anterior cortex activity, respectively (Brown et 
al., 2011; Brown et al., 2010). 
 Functional neuroimaging genetics is still an upcoming field of research in ADHD, 
and in adult ADHD these kinds of studies are rare. However, such studies are of great 
importance to understand why and how certain genes are related to a complex disorder 
such as ADHD. Fortunately, study samples are growing and now starting to reach the 
size needed to perform adequately powered studies of single genes (Mier et al., 2010; 
Munafò et al., 2008). What we can learn from the previously published (mostly 
underpowered) imaging genetics studies, is that defining target brain regions of interest 
is important and necessary to find significant associations, because effects of genes are 
small even at the brain level and can be expected to be strongest in regions where the 
gene is highly expressed. Another important lesson from these early studies is that 
interpreting the effects of genes on imaging measures is made easier when behavioral 
measures are added to the analysis. Having larger or smaller brain volumes or decreased 
or increased brain activity does not immediately explain the associations with the 
disorder or with the risk alleles. For example, in a study by Braet and coworkers, the DAT1 
risk allele was associated with increased activity and was interpreted as more effort 
needed to perform the task at hand (Braet et al., 2011), whereas in other studies decreased 
activity associated with the DAT1 risk allele was thought to explain the observed 
deficient cognitive performance (Durston et al., 2008). For most activity patterns in the 
brain we do not yet know what they mean; does decreased activity in a certain brain 
structure reflect optimal or below average functioning? Adding behavioral results to 
the imaging genetics analysis and correlating these measures to activity patterns in the 
brain makes it easier to interpret the results and its implications. This way we can try to 
understand the whole pathway from gene, to brain functioning, related behavior and 
its relationship with the clinical phenotype.
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Aim of this thesis
The aim of my thesis was to investigate the role of genes in the clinical features of ADHD 
using endophenotype approaches. I did this by studying associations between endo-
phenotypes and ADHD candidate genes on the one hand, and by studying the 
association between the ADHD phenotype and potential endophenotypes on the 
other. In doing so, my work should contribute to a better understanding of how genes 
increase disease risk, but also provide more insights into the neurobiology of ADHD. 
The study population I investigated consisted of adult patients with ADHD. Those 
were chosen based on the fact that adult ADHD is the most severe form of the disorder, 
and is potentially phenotypically and genetically less heterogeneous as well as more 
genetically determined than childhood ADHD.
 In the first part of this thesis, I studied pathways from genes to the clinical disorder 
and its endophenotypes. In chapter 2, a genetic association study is reported between 
an ADHD risk gene and adult ADHD. A haplotype of one of the most studied genes in 
ADHD, the dopamine transporter gene DAT1, was earlier found associated with ADHD in 
children. We performed the first study of the association of this DAT1 haplotype with 
ADHD in adults. In chapter 3, the effect of this DAT1 haplotype was studied on striatal 
functioning, in an attempt to better understand, how this gene affects the ADHD 
phenotype. The DAT1 gene is highly expressed in the striatum, and this area in the brain 
is of great interest to ADHD research because of its behavioral correlates: impulsivity 
and reward processing. These are known to be impaired in patients with ADHD. In 
chapter 4, a relatively new risk gene for ADHD, the nitric oxide synthase gene NOS1, was 
studied in relation to striatal functioning and impulsivity. NOS1 was previously found 
associated with ADHD and other impulsivity disorders and is highly expressed in the 
striatum. Our aim was to study the association of brain and behavioral endophenotypes 
with this gene. Lastly, in chapter 5, another well-known ADHD risk gene, the dopamine 
receptor D4 gene DRD4, was studied for its effects on the ADHD endophenotypes 
working memory and associated prefrontal cortex activity.
 In the second part of this thesis I aimed at identifying additional endophenotypes 
for adult ADHD based on neuroimaging. In chapter 6, the association between current 
ADHD symptoms and total brain volume was tested. Previous studies had shown a 
decrease of total brain volume in clinically diagnosed ADHD. In this chapter, I used a 
dimensional approach to ADHD and correlated the number of disease symptoms with 
total brain volume in a large cohort of healthy adults. This to find out whether total 
brain volume could be an interesting endophenotype for future genetic studies in 
ADHD.
 In chapter 7 all studies presented in this thesis are summarized and in chapter 8 
I combined the information from all chapters and review, what we have learned from 
the studies going forward and backward on the pathways between genes and the disorder. 
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Study cohorts
For my studies, I used two cohorts: The first cohort is from the Dutch part of the 
International Multicentre persistent ADHD CollaboraTion (IMpACT). I set up the endopheno - 
type studies in this IMpACT-NL part by recruiting adult ADHD patients through the 
department of Psychiatry of the Radboud University Nijmegen Medical Center, through 
advertisement in local newspapers and via the website of ‘Balans’, a Dutch patient 
organization for ADHD. In addition, I recruited healthy comparison individuals via 
contacts of the patients and also through advertisement in local newspapers. 
Participants in this research project were invited for two sessions at the Donders Centre 
for Cognitive Neuroimaging (see Figure 2). The first session consisted of psychiatric 
interviews and blood withdrawal for DNA analysis. During this first session, patients 
were interrogated about meeting in- or exclusion criteria. Patients were included if they 
met DSM-IV-TR criteria for ADHD in childhood as well as adulthood. All subjects were 
assessed using the Diagnostic Interview for Adult ADHD (DIVA (Kooij and Francken, 
2007)). This interview focuses on the 18 DSM-IV symptoms of ADHD and uses concrete 
and realistic examples to thoroughly investigate whether the symptom is present now 
or was in childhood. In order to obtain information about ADHD symptoms and 
impairment in childhood, additional information is obtained from parents and school 
reports, whenever possible. Severity of ADHD was assessed by self-report using the 
ADHD DSM-IV rating scale (DuPaul et al., 1998). The Structured Clinical Interview for 
DSM-IV Criteria (SCID-I&II) was used for co-morbidity assessment and serves as a source 
to determine our exclusion criteria, i.e. psychosis and addiction in the last 6 months or a 
current diagnosis of major depression. Additional exclusion criteria were a full-scale IQ 
estimate less than 70 (assessed using the Wechsler Adult Intelligence Scale-III), neurological 
disorders, sensorimotor handicaps, non-Caucasian ethnicity and medication use other 
than psychostimulants or atomoxetine. An extra exclusion criterion for comparison 
subjects was a current or past neurological or psychiatric disorder according to SCID-I. 
Assessments were carried out by trained professionals (psychiatrist or psychologists). 
During the second session, cognitive domains relevant for ADHD were tested using 
computerized and paper/pencil tasks. Neuroimaging procedures were also executed 
on the second testing day (see Figure 2 for details). IMpACT-NL is an ongoing research 
program, which currently contains endophenotype data of over 150 ADHD patients and 
100 controls.
The second cohort I used for my work involved participants of the Brain Imaging Genetics 
(BIG) study. The BIG study was set up in 2007 as collaboration between the Human 
Genetics department of the Radboud University Nijmegen Medical Centre and the 
Donders Centre for Cognitive Neuroimaging of the Radboud University Nijmegen. In 
2010, the Max Planck Institute for Psycholinguistics in Nijmegen also joined. In BIG, 
relations between genes and brain structure and function are investigated in healthy 
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individuals (see for example (Bralten et al., 2011)). For this, a continuously growing 
database has been created with data of structural brain scans and DNA as well as 
cognitive and behavioral data derived from internet-based testing. The BIG assessment 
protocol contains the ADHD DSM-IV rating scale (DuPaul et al., 1998), and therefore data 
of self-reported ADHD symptoms were available, which I studied in conjunction with 
the neuroimaging data in this population-based study.
Figure 2  The IMpACT-NL study protocol
The IMpACT-NL study protocol is displayed above. Adult ADHD patients and healthy adult comparison 
subjects participating the IMpACT-NL study visited the psychiatry department of the Radboud University 
Nijmegen Medical Center on day 1 for psychiatric interviews and blood withdrawal. On the second day the 
Donders center for Cognitive Neuroimaging was visited for cognitive testing and various MRI scans.
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Part I
From genotype to endophenotype

2
Association of the dopamine transporter 
(SLC6A3/DAT1) gene 9-6 haplotype with adult ADHD
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Chapter 2
Abstract
ADHD is a neuropsychiatric disorder characterized by chronic hyperactivity, inattention 
and impulsivity, which affects about 5% of school-age children. ADHD persists into 
adulthood in at least 15% of cases. It is highly heritable and familial influences seem 
strongest for ADHD persisting into adulthood. However, most of the genetic research in 
ADHD has been carried out in children with the disorder. The gene that has received 
most attention in ADHD genetics is SLC6A3/DAT1 encoding the dopamine transporter. In 
the current study we attempted to replicate in adults with ADHD the reported 
association of a 10–6 SLC6A3-haplotype, formed by the 10-repeat allele of the variable 
number of tandem repeat (VNTR) polymorphism in the 3' untranslated region of the 
gene and the 6-repeat allele of the VNTR in intron 8 of the gene, with childhood ADHD. 
In addition, we wished to explore the role of a recently described VNTR in intron 3 of the 
gene. Two hundred sixteen patients and 528 controls were included in the study. We 
found a 9–6 SLC6A3-haplotype, rather than the 10–6 haplotype, to be associated with 
ADHD in adults. The intron 3 VNTR showed no association with adult ADHD. Our findings 
converge with earlier reports and suggest that age is an important factor to be taken 
into account when assessing the association of SLC6A3 with ADHD. If confirmed in other 
studies, the differential association of the gene with ADHD in children and in adults 
might imply that SLC6A3 plays a role in modulating the ADHD phenotype, rather than 
causing it. 
41
The dopamine transporter haplotype and adult ADHD
2
Introduction
Attention deficit hyperactivity disorder (ADHD) is among the most heritable and 
common behavioral disorders in childhood. It affects ~5% of school-age children. At 
least 65% of patients retain ADHD symptoms into adulthood, with at least 15% of them 
showing syndromal persistence (Faraone et al., 2006). The influence of familial (possibly 
genetic) factors on ADHD etiology appears to be stronger in adults than in children 
(Faraone et al., 2000).
 One of the most extensively studied genes in childhood ADHD is SLC6A3/DAT1 
encoding the dopamine transporter. A 40 base pair (bp) variable number of tandem 
repeats (VNTR) polymorphism in the 3' untranslated region (UTR) of the gene has 
received most attention. Meta-analysis of both family-based and case–control 
association studies in children with ADHD has indicated overrepresentation of the 
10-repeat allele of the VNTR in ADHD (Faraone et al., 2005). More recent meta-analyses 
have challenged this view, and have suggested heterogeneity in the findings (Li et al., 
2006; Todd et al., 2005; Yang et al., 2007).
 Recent work by us and others indicates that the 10-repeat allele of the 3' UTR VNTR 
might only increase ADHD risk in children in a haplotype with allele 6 of a VNTR in intron 
8 of the gene (Asherson et al., 2007; Brookes et al., 2006b). Both, the 3' UTR VNTR and the 
intron 8 VNTR have been suggested to influence the expression of SLC6A3. However, 
there is inconsistency in the findings of in vitro and in vivo studies investigating allele-
specific expression (Brookes et al., 2007; Spencer et al., 2005). This may suggest that 
neither VNTR is functional by itself, but (incompletely) tags an unknown functional site. 
It is likely that the haplotype of both VNTRs improves tagging of this functional variant.
A first study of the two SLC6A3 VNTRs in adults with ADHD, though of limited samples 
size, could not confirm the association of the 10–6 haplotype with the persistent form 
of the disorder (Brüggemann et al., 2007). In the current study we, again, attempted to 
replicate the haplotype association findings from childhood ADHD in a second sample 
of adult ADHD patients and also explored the role of a recently described additional 
VNTR in intron 3 of SLC6A3 (Mijyajima et al., 2006).
Participants
Patients (n=216) had been referred for assessment of ADHD to the outpatient clinic of 
GGZ Delfland in Delft, to Parnassia, psycho-medical centre in The Hague, or to the 
department of Psychiatry at the Radboud University Nijmegen Medical Centre in 
Nijmegen, The Netherlands. Subjects were included if a clinical diagnosis of adult ADHD 
with childhood onset was established. Part of the patients has been described before 
(Bekker et al., 2005; Kooij et al., 2005).
 Controls (n=528) were obtained from the Nijmegen Biomedical Study (NBS, 
www.nijmegen biomedischestudie.nl), a population-based survey conducted by the 
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Departments of Epidemiology & Biostatistics and of Clinical Chemistry of the Radboud 
University Nijmegen Medical Centre (Hoogendoorn et al., 2006). The control group was 
frequency-matched for gender with the patient group.
 Patients and controls were of Caucasian ethnic background. The study was approved 
by regional medical ethics committees. All participants completed written informed 
consent.
Diagnostic Assessments
Prior to inclusion, all patients underwent a standard clinical assessment consisting of a 
psychiatric evaluation by experienced psychiatrists using a semi-structured diagnostic 
interview for ADHD and comorbid disorders, the Dutch version of structured diagnostic 
interviews for retrospective diagnosis of childhood onset ADHD and current symptoms. 
For current ADHD symptoms during the last 6 months, also a Dutch version of the 
DSM-IV ADHD Rating Scale, based on the 18 DSM-IV items for ADHD, was used (DuPaul 
et al., 1998; Kooij et al., 2005). The ADHD Rating Scale has been used in epidemiologic 
and clinical research in adults in the United States and in The Netherlands (Kooij et al., 
2005; Murphy and Barkley, 1996). To be given a full diagnosis of adult ADHD, subjects 
had to (A) meet at least 6 out of 9 DSM-IV criteria of inattention and/or hyperactivity/
impulsivity for a diagnosis of ADHD in childhood and at least 5 out of 9 criteria in 
adulthood, (B) describe a chronic persisting course of ADHD symptoms from childhood 
to adulthood, and (C) endorse a moderate to severe level of impairment attributed to 
the ADHD symptoms. A cut-off point of 5 of 9 criteria was set for adult diagnosis of 
ADHD based on literature and epidemiological data using the same DSM-IV ADHD 
Rating Scale (Kooij et al., 2005). In order to obtain information about lifetime ADHD 
symptoms and impairment, the patient, the partner and, if available, the parents were 
interviewed. Information on school reports was examined in order to sustain the 
diagnosis in childhood. Diagnostic criteria have been described in more detail elsewhere 
(Bekker et al., 2005; Kooij et al., 2005). Table 1 shows the demographics of the patient 
sample. Controls were also screened for presence of current ADHD symptoms using the 
DSM-IV ADHD Rating Scale (Kooij et al., 2005) and were excluded if 4 or more symptoms 
were present.   
Genotyping and Statistical Analysis
Genotyping of the VNTRs in the 3' UTR and intron 8 has been described earlier (Boonstra 
et al., 2008; Brookes et al., 2006a). The 63 base pair (bp) VNTR in intron 3 of the gene was 
genotyped using a PCR-based method on 62.5 ng genomic DNA using 0.4 µM of 
forward (5'-GAAGTTGGCTGGTTGGTGAG-3') and reverse primer (5'-ACCAGAGTCCCCCT-
TACCAA-3'), respectively, 0.25 mM dNTPs and 0.5 U Taq DNA polymerase (Invitrogen, 
Breda, The Netherlands) in a buffer containing 60 mM Tris–HCl pH 9.5, 15 mM NH
2
SO
4
 
and 2 mM MgCl
2
. The cycling conditions for amplification involved 5 min at 92°C, 
43
The dopamine transporter haplotype and adult ADHD
2
followed by 35 cycles of 1 min 92°C, 1 min at 61°C and 1 min 72°C and an extra 10 min 
at 72°C. Analysis on a 2% agarose gel yielded distinct bands at 596 and 659 bp for the 
most common alleles 7 and 8. Generally, all three genotyping assays have been validated 
earlier and 5% duplicates and blanks were taken along as quality controls during 
genotyping. Hardy–Weinberg equilibrium (HWE) was assessed for all genotypes in all 
available samples using a χ2 statistic. Only the most common alleles/genotypes were 
taken into account in the haplotype analysis and the tests of association with ADHD. 
Genotype frequencies of the SLC6A3 polymorphisms were compared between cases 
and controls using a χ2 test. Odds ratios (ORs) and 95% confidence intervals (CIs) were 
estimated using SPSS (version 14.0). SLC6A3 haplotypes of the 3' UTR and intron 8 (and 
Table 1  Patient characteristics
Characteristics n Percentage
Number of subjects 216
Age (mean and range) 36 18–62
Males 105 48.6
Marital status
    Married/relationship 129 59.7
    Single/divorced/living with parents 84 38.9
    Unknown 3 1.4
Educational level
    Lower educational level 56 25.9
    High school 141 65.3
    University 15 6.9
    Unknown 4 1.9
DSM IV axis I disorder
    ADHD combined type 187 86.6
    ADHD hyperactive/impulsive type 8 3.7
    ADHD inattentive type 21 9.7
    Any comorbid axis I disordera 177 81.9
Multiple (≥ 2) comorbid axis I disordersa 91 42.1
Any mood disordera 129 59.7
Any anxiety disordera 74 34.3
Any substance use disordera 49 22.7
Bulimia Nervosaa 9 4.2
Co-morbid Borderline Personality Disorderb 35 17.9
aPast or present.  bData available for 206 subjects.
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intron 3) VNTRs with ADHD were estimated using the haplo.em function implemented 
in the haplo.stats package (Schaid et al., 2002) which computes maximum likelihood 
estimates of haplotype probabilities, together with posterior probabilities of haplotype 
pairs for each subject. Haplotype association analyses were done using the haplo.score 
function implemented in haplo.stats. Briefly, this package computes score statistics to 
test associations between haplotypes and a trait, and allows adjustment for other 
determinants. This analysis was corrected for multiple testing by applying the simulate 
= TRUE parameter in haplo.score which gives simulated p values. These simulated 
haplotype score statistics are calculated from a permuted re-ordering of the trait (ADHD 
status) and SLC6A3 polymorphisms. We used 1,000 permutations for all the analyses.
Results
Genotype distributions of all three polymorphisms were in Hardy–Weinberg equilibrium 
(p>0.05). The overall haplotype distributions were significantly different in cases and 
controls. We found global evidence for association of SLC6A3 with adult ADHD (haplo.
score global p=0.01). This difference was not explained by the 10–6 haplotype, but 
rather by the 9–6 haplotype which was significantly more frequent in cases than in 
controls (haplotype-specific p=0.001) (Table 2). Inclusion of the intron 3 VNTR did not 
change the results (data not shown).
Discussion
Although the SLC6A3/DAT1 gene is the best-studied gene in childhood ADHD, only few 
studies have looked at this gene in adult ADHD genetics research. Only one earlier study 
has tried to replicate the 10–6 haplotype association with childhood ADHD in adult 
patients. This study, in 122 adult patients and 174 controls, did not find association with 
SLC6A3, neither with the 10–6 haplotype, nor with any other haplotype formed by the 
40 bp VNTR polymorphism in the 3' untranslated region of the gene and the 30 bp 
VNTR in intron 8 (Brüggemann et al., 2007). Using a larger sample, our data also suggest 
a lack of association with 10–6, but we find the adult disorder to be associated with the 
9–6 haplotype in SLC6A3. Our findings converge with recent data of the 3' UTR VNTR 
from a prospective 13-year follow-up study in 147 young adults with ADHD and 73 
controls, indicating that more ADHD symptoms and externalizing behaviors were 
present in the 9/10 than in the 10/10 genotype for the group as a whole (Barkley et al., 
2006). Interestingly, the effects of the genotype became more pronounced with 
increasing age of the participants. More individuals with a DSM diagnosis of ADHD in 
adulthood were also found among those having the 9/10 genotype (53%) than among 
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the 10/10 homozygous group (35%) (Barkley et al., 2006). Our own neuropsychological 
studies in a subset of 45 adults with ADHD from the current study also support the 
current findings in that the heterozygous 10-allele carriers (mostly 9/10) were shown to 
have slower inhibition during the Change task (Boonstra et al., 2008). Similar results were 
recently reported in 75 young healthy adults (Caldú et al., 2007).
 Rather than age being the factor modifying the association of SLC6A3 with ADHD, 
geographical origin might form an alternative explanation for the results of the current 
study. However, we do not think that this is the cause of our findings, given our recent 
findings within the IMAGE study, in which we were able to confirm the association of 
the 10–6 haplotype with childhood ADHD (Asherson et al., 2007). This sample contains 
Table 2   Genotype Analysis of the 3' UTR and Intron 8 and 3 VNTRs of the SLC6A3 
Gene and Haplotype Analysis for the 3' UTR and Intron 8 VNTRs
Frequency (%)
Genotypes Controls Cases Pearson χ2 
P-value
OR 95% CI
3’ UTR
  10/10 294 (58.0) 108 (50.7) 0.085 1
  10/9 191 (37.7) 89 (41.8) 1.27 0.91-1.8
  9/9 22 (4.3) 16 (7.5) 1.98 1.00-3.91
Intron 8
  6/6 306 (60.4) 128 (62.7) 0.731 1
  6/5 178 (35.1) 69 (33.8) 0.93 0.66-1.31
  5/5 23 (4.5) 7 (3.4) 0.73 0.30-1.74
Intron 3
  7/7 336 (63.9) 139 (65.0) 0.809 1
  7/8 176 (33.5) 71 (33.2) 0.975 0.695-1.369
  8/8 14 (2.7) 4 (1.9) 0.691 0.224-2.135
Haplotypes* Frequency (%)
Controls Cases Score test 
P-value
OR 95% CI
10-6 70.0 66.2 1
9-5 16.5 16.3 0.99138 1.06 0.77-1.46
9-6 6.4 11.7 0.00106 2.05 1.35-3.1
10-5 4.6 3.2 0.18033 0.74 0.39-1.42
Four haplotypes were found at frequencies above 1%, representing 97.4% of all haplotypes in the sample. 
* Haplo.score global p = 0.01.
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more than 300 families from The Netherlands, who also show the expected overtrans-
mission of the 10–6 haplotype to affected offspring, when analyzed separately from all 
other samples (unpublished results).
 Of course, our findings of the SLC6A3 9–6 haplotype association with adult ADHD 
are in need of replication, before we can judge if the association is really true. Actually, 
although SLC6A3 has been the subject of numerous studies in children, the evidence for 
the involvement of the gene in ADHD is still rather slim. Meta-analyses of the 3' UTR 
VNTR have suggested association of either of the two common alleles (10-repeat and 
9-repeat) or neither allele with the disorder and related phenotypes (Faraone et al., 
2005; Li et al., 2006; Todd et al., 2005; Yang et al., 2007). Even in those meta-analyses that 
did show association with ADHD, the significance of the findings was limited and far 
from reaching genome-wide levels of significance, though large numbers of patients 
were included. Clinical heterogeneity and environmental factors—but also age—might 
be important factors to take into account when assessing the association of SLC6A3 with 
ADHD.
 In conclusion, if confirmed in other studies, our data bear the intriguing suggestion 
that the SLC6A3 haplotype associated with ADHD in adults is different from the one 
associated with the childhood disorder. Since dopamine transporter density decreases 
during life (Spencer et al., 2005) and ADHD symptoms are known to change during 
adolescence (Biederman et al., 2000), the differential association of SLC6A3 with ADHD 
might reflect changing requirements on the dopaminergic system during life. 
Furthermore, regulation of the dopamine transporter is influenced by environmental 
factors like smoking, ethanol and several drugs (Madras et al., 2005), that are used more 
often by adults than by children. A differential association of the SLC6A3 gene with 
ADHD in children and in adults might imply that the gene plays a role in modulating the 
ADHD phenotype, rather than causing it.
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Abstract 
Attention deficit/hyperactivity disorder (ADHD) is a highly heritable disorder and several 
genes increasing disease risk have been identified. The dopamine transporter gene, 
SLC6A3/DAT1, has been studied most extensively in ADHD research. Interestingly, a 
different haplotype of this gene (formed by genetic variants in the 3’ untranslated 
region and intron 8) is associated with childhood ADHD (haplotype 10-6) and adult 
ADHD (haplotype 9-6). The expression of DAT1 is highest in striatal regions in the brain. 
This part of the brain is of interest to ADHD because of its role in reward processing is 
altered in ADHD patients; ADHD patients display decreased striatal activation during 
reward processing. 
To better understand how the DAT1 gene exerts effects on ADHD, we studied the effect 
of this gene on reward-related brain functioning in the area of its highest expression in 
the brain, the striatum, using functional magnetic resonance imaging. In doing so, we 
tried to resolve inconsistencies observed in previous studies of healthy individuals and 
ADHD-affected children. 
In a sample of 87 adult ADHD patients and 77 healthy comparison subjects, we 
confirmed the association of the 9-6 haplotype with adult ADHD. Striatal hypoactivation 
during the reward anticipation phase of a monetary incentive delay task in ADHD 
patients was again shown, but no significant effects of DAT1 on striatal activity were 
found. 
Although the importance of the DAT1 haplotype as a risk factor for adult ADHD was 
again demonstrated in this study, the mechanism by which this gene increases disease 
risk remains largely unknown.    
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Introduction
Attention-deficit/hyperactivity disorder (ADHD) is a very common and highly heritable 
neuropsychiatric disorder in childhood that is strongly persistent over time. 
Approximately 15% of patients still meet full ADHD criteria according to DSM-IV criteria 
in adulthood, and 40-60% remits only partially and has increased symptom counts and 
impaired functioning in adulthood (Faraone et al., 2006). ADHD has an average 
prevalence between 2.5 and 4.9% in the adult population (Simon et al., 2009). 
 The clinical phenotype of ADHD is characterized by symptoms of inattention, 
hyper activity and impulsivity (Frances, 2000). Neuropsychological theories have described 
three key domains that are deficient in ADHD. Besides executive dysfunctioning and 
timing problems, patients with ADHD often display reward and motivational problems 
(Sonuga-Barke, 2003; Sonuga-Barke et al., 2010). Evidence for these problems can be 
found on a behavioral level, where ADHD patients show altered performance on reward- 
related tasks, with steeper discounting rates and an aversion for delay of gratification 
being the most studied and replicated processes (Luman et al., 2005). In addition, 
neuroimaging studies have shown ventral striatal hypoactivation in ADHD patients 
(Hoogman et al., 2011; Scheres et al., 2007; Ströhle et al., 2008) during reward anticipation. 
 Linkage and association studies have identified several genes associated with 
ADHD (Franke et al., 2011). One of these genes is the SLC6A3/DAT1 gene, for which the 
association with ADHD was confirmed in meta-analyses of candidate gene studies in 
ADHD (e.g., (Gizer et al., 2009). The DAT1 gene, encoding the dopamine transporter, 
contains two frequently studied variable number of tandem repeat (VNTR) poly-
morphisms. One is a 40 base pair (bp) VNTR in the 3' untranslated region (UTR); the 
9-repeat and 10-repeat alleles are the most frequent alleles, here (VanNess et al., 2005). 
The second is the VNTR in intron 8, for which the 5 and 6 repeat alleles are most 
common. The 10-6 haplotype of these VNTRs has been shown to increase risk for ADHD 
in childhood (Asherson et al., 2007; Brookes et al., 2006). A different haplotype, the 9-6 
haplotype, was found associated with ADHD in adults (Franke et al., 2008; Franke et al., 
2010). This could be due to the association of the 9-6 haplotype with a more severe and 
persistent form of ADHD, already present in childhood, but overrepresented in the adult 
patients. Also, environmental factors known to influence dopamine transporter regulation 
like smoking, result in age-dependent associations with DAT1. 
 Dopamine transporters are predominantly found in the striatum and are responsible 
for synaptic clearance of dopamine there (Volkow et al., 1998). Genetic variation of the 
DAT1 gene might lead to individual variation in the availability of dopamine transporters 
and subsequently in dopamine levels. This was evidenced by Single-Photon Emission 
Computed Tomography (SPECT) and Positron Emission Tomography (PET) studies 
showing the 10-repeat allele to be associated with lower availability of striatal dopamine 
transporters (potentially leading to higher dopamine levels) than the 9-repeat allele 
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(Shumay et al., 2011; van de Giessen et al., 2009). However, some smaller sampled studies 
propose the opposite (e.g., (Heinz et al., 2000), and a meta-analysis of these studies has 
also stayed inconclusive (Costa et al., 2011). A recent publication by Shumay and co - 
workers suggests that there is differential decay of dopamine transporter expression with 
age for different DAT1 genotypes, also including the 9-6 and 10-6 haplotypes (Shumay 
et al., 2011). The 9-repeat homozygotes showed a steeper decline of DAT availability 
with increasing age. This could be an alternative or additional explanatory factor for the 
differential association of DAT1 haplotypes with ADHD in children and adults. 
 To better understand how variation in the DAT1 gene affects the phenotype, several 
studies have investigated the association of this gene with brain responses and behavior. 
Most of these studies were directly aimed at striatal activation and some of its behavioral 
correlates, reward processing and response inhibition. Three studies in healthy adults 
found lower reward-related striatal activation to be associated with homozygosity for 
the 10-repeat of the 3’ UTR VNTR compared to 9-repeat carriership, two other studies 
did not find an effect of DAT1 genotype (Table 1). In children with ADHD, one study 
found lower striatal activation to be associated with the homozygous 10-repeat 
compared to 9-repeat carriership (Durston et al., 2008), whereas another study found 
the opposite (Bédard et al., 2010). So far, there have not been any functional studies on 
the effects of the DAT1 gene on striatal functioning in adults with ADHD, nor have any 
studies investigated the role of the DAT1 VNTR haplotype on striatal functioning. 
To learn more about the role of DAT1 in adult ADHD, in the current study we tried to 
replicate the association of the 9-6 haplotype and adult ADHD. To resolve the inconsis-
tencies between previous genetic neuroimaging studies of DAT1, we also studied striatal 
brain responses, for which ADHD patients and controls performed a reward anticipation 
task inside a Magnetic Resonance Imaging (MRI) scanner, a task known to robustly 
induce striatal activation (Hoogman et al., 2011; Knutson et al., 2001). Given the previous 
studies, we expected (1) an association between the 9-6 haplotype and adult ADHD, 
and (2) the striatal hypoactivation previously shown in ADHD patients to be explained 
by variation in the DAT1 gene. 
Experimental procedures
Participants
One hundred and sixty-five individuals (87 adult ADHD patients, 77 comparison subjects) 
from the Dutch cohort of the International Multicentre persistent ADHD CollaboraTion, 
IMpACT (Sánchez-Mora et al., 2010), participated in this study. 
 All participants underwent cognitive testing and neuroimaging. The ADHD patients 
and the age-, gender- and IQ-comparable group of healthy subjects were recruited 
from the department of Psychiatry of the Radboud University Nijmegen Medical Centre 
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and through advertisements. Patients were included if they met DSM-IV-TR criteria for 
ADHD in childhood as well as adulthood. All subjects were assessed using the Diagnostic 
Interview for Adult ADHD (DIVA) (Kooij, 2010). This interview focuses on the 18 DSM-IV 
symptoms of ADHD and uses concrete and realistic examples to thoroughly investigate 
whether the symptom is present now or was in childhood. In order to obtain information 
about ADHD symptoms and impairment in childhood, additional information was 
obtained from parents and school reports, whenever possible. The Structured Clinical 
Interview for DSM-IV Criteria (SCID-I) was used for co-morbidity assessment. Assessments 
were carried out by trained professionals (psychiatrist or psychologists). In addition, a 
quantitative measure of clinical symptoms was obtained using the ADHD-DSM-IV Self 
Rating scale (Kooij et al., 2005).
 Exclusion criteria for participants were psychosis, addiction in the last 6 months, 
current major depression (assessed with SCID-I), full-scale IQ estimate less than 70 
(Wechsler Adult Intelligence Scale-III), neurological disorders, sensorimotor handicaps, 
non-Caucasian ethnicity and medication use other than psychostimulants or 
atomoxetine. Additional exclusion criteria for comparison subjects were a current or 
past neurological or psychiatric disorder according to SCID-I. Twenty-seven (31%) ADHD 
patients were medication-naïve at the time of the trial. Patients who used ADHD 
medication (methylphenidate (n=50), atomoxetine (n=3) and dextroamphetamine 
(n=7)) were asked to withhold their medication 24 hours prior to testing. Subjects had 
to refrain from smoking prior to and during testing, because smoking results in global 
reductions of brain activity and increased dopamine concentrations in the striatum 
(Brody, 2006). The effects of smoking were controlled for by taking smoking habits (yes/
no) into account in our analysis. 
 This study was approved by the regional ethics committee. Written informed 
consent was obtained from all participants. 
Genotyping
DNA was isolated from EDTA blood samples. Genotyping of the 40 base pair VNTR in 
the 3’ UTR and the VNTR in intron 8 of SLC6A3/DAT1 were carried out as described before 
(Franke et al., 2008) at the department of Human Genetics of the Radboud University 
Nijmegen Medical Centre. Haplotypes were calculated using the Haplostats package (R 
version 2.12.0) (Schaid et al., 2002). For the behavioral and functional data analysis, risk 
haplotype (9-6) carriers were compared with non-carriers. To increase comparability 
with previous studies (see Table 1) reporting the effect of the 40 base pair VNTR in the 
3’ UTR, we also compared 9R carriers to 10/10 homozygotes. 
fMRI Reward Anticipation Paradigm
Subjects were scanned while performing a modified Monetary Incentive Delay task 
(which has shown to induce striatal activation (Hermans et al., 2010; Knutson et al., 2001)) 
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to study neural responses to reward anticipation (Supplement 1). The current sample is 
an expansion of an earlier published sample (ADHD: 63 versus 87 (72% overlap), 
comparison subjects: 41 versus 77 (53% overlap)), in which this task was applied 
(Hoogman et al., 2011). Subjects were asked to respond as quickly as possible to a target 
by pressing a button. Prior to this target a cue (duration 3.5-8.5 sec) was given to indicate 
whether a reward could be obtained or not. After each target response the outcome 
was displayed. Subjects could gain 1 Euro in the reward condition and no money during 
the no-reward condition if they responded between 270 and 500 ms after target-onset. 
This response window was individually adjusted (Supplement 1). The task consisted of a 
practice trial, after which the purpose of the task was again briefly summarized, followed 
by 50 trials in which reward and no-reward cues were randomly displayed. The 
experiment lasted 12 minutes and 12 Euros could be gained. At the end of the 
experiment, the awarded money was shown on the screen and was transferred to the 
participant’s bank account. Reaction times in the reward and no-reward condition were 
the behavioral outcome measures. In addition to this task, participants performed other 
cognitive tasks inside and outside the MRI scanner.
Statistical analysis
Haplotype association with ADHD
To replicate the association of the 9-6 haplotype with ADHD, a chi-square test was 
performed comparing the presence of the 9-6 haplotype in ADHD patients with 
presence in controls. Part of the patient sample included in this analysis was also part of 
earlier publications investigating this association (overlap of ADHD patients between 
studies: n=17, no overlap in controls) (Franke et al., 2008; Franke et al., 2010). In addition, 
we studied the role of the 9-6 haplotype in patients with respect to ADHD severity by 
performing a t-test with the number of Hyperactive/Impulsive symptoms and the 
number of Inattentive symptoms as dependent variable and presence of the 9-6 
haplotype as grouping variable.
Behavioral analysis
A repeated measures general linear model was performed to assess the effect of cue 
(reward/no-reward) on response time. This general linear model was carried out with 
reaction times as dependent variable and reward/no-reward cue as within subject 
variable. To test the effect of the between-subject factors, ADHD status and DAT1 
haplotype (carrier/non-carrier) or 3’ UTR VNTR genotype (9R carrier/10R homozygous) 
were added to the model to identify group effects of cue-induced reaction times.
fMRI analysis
After preprocessing (for details on fMRI acquisition and preprocessing, see Supplement 
2), first-level analyses were performed for each subject to estimate 8 parameters of 
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interest with a general linear model for the events ‘cue’, ‘target’, ‘hit’, ’miss’ in both the 
reward and the no-reward condition. These events were modeled as event-related 
regressors, with duration 0 and convolved with the canonical hemodynamic response 
function in SPM5 (Wellcome Dept. of Cognitive Neurology, London). Additionally, 
realignment parameters were included to account for movement-related variability, and 
time-derivatives were used, which resulted in 14 additional regressors of no interest. 
Data were high-pass filtered using a cut-off of 1/128 Hz.
 To assess neural activation associated with reward anticipation, the reward and 
no-reward cues were contrasted (‘reward cue’ > ‘no-reward cue’). The contrast images 
for these events were submitted to a second-level random effect analysis with a full 
factorial 2x2x2 design: ADHD status (patient/healthy control), DAT1 haplotype or 
genotype and cue (reward vs. no-reward). Age and gender were included as covariates 
(Becker, 1999; Mell et al., 2009). For the whole brain analysis the main effect of cue was 
tested using a threshold of p<0.05, family-wise error corrected, and a cluster size 
threshold of 50 voxels. Because of our a priori hypothesis regarding the striatum, our 
region of interest was determined by taking the supra-threshold striatal activation in 
the whole brain analysis of our contrast of interest (‘reward cue’ > ‘no-reward cue’) main 
effect of cue. The beta weights of this region of interest were extracted using Marsbar 
(Brett et al., 2002) and used in the analysis to investigate group effects (ADHD status and 
DAT1 haplotype). 
 To replicate previous studies (Hoogman et al., 2011; Scheres et al., 2007; Ströhle et al., 
2008), which observed striatal hypoactivation in ADHD patients without taking the 
effect of DAT1 into account, a t-test was performed with ADHD status as independent 
variable and averaged task-related striatal activation as dependent variable. The effect 
of the DAT1 haplotype was subsequently determined by performing an ANOVA on 
task-related averaged striatal activation, including ADHD status and DAT1 haplotype as 
independent variables. In addition, the effect of the DAT1 3’ UTR VNTR genotype was 
tested in a similar way as the effect of the haplotype. All statistical tests were two-sided, 
unless stated otherwise. 
Results
Demographics of the sample of 87 adult ADHD patients and 77 comparison subjects 
are displayed in Table 2, genotype and haplotype distribution is shown in Table 3. 
Patients and controls did not differ on age, percentage men or estimated IQ (p>0.22). 
DAT1 risk haplotype (9-6) carriers did not differ from non-carriers on any of the 
demographic variables, neither did groups differ on such variables based on single 
VNTR genotypes (DAT1 3’ UTR and DAT1 intron 8; data not shown). Patients had higher 
ADHD scores compared with healthy controls (A: p<0.001, HI: p<0.001; see Table 2).
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ADHD and the DAT1 haplotype
A higher prevalence of the risk haplotype was found in adults with ADHD compared 
with healthy controls, [χ2=10.04, p=0.002, Table 3]. Also, patients carrying the DAT1 risk 
haplotype had more inattentive symptoms [t(85)=2.68, p=0.009], but not hyperactive/
impulsive symptoms [t(85)=0.61, p=0.54] than patients not carrying this haplotype. 
Within the healthy comparison group no symptom count differences based on haplo - 
type carriership were found. 
 Comparisons based on single VNTR genotypes showed higher inattentive symptom 
levels in ADHD patients carrying the DAT1 3’ UTR VNTR 9-repeat allele compared 
with ADHD patients homozygous for the 10-repeat allele [t(83)=2.79, p=0.007], but no 
differences in hyperactive/impulsive symptoms [t(83)=0.09, p=0.93]. There were no 
differences in ADHD symptom counts between patient groups based on DAT1 intron 
8 genotype or in any comparisons of single VNTR genotypes within the healthy 
comparison group. 
Modified Monetary Incentive Delay task
Subjects reacted faster in reward trials (mean= 250 ms) than no-reward trials (mean= 
289 ms), [F(1,161)=296.67, p<0.0001]. ADHD diagnosis (p=0.54), DAT1 haplotype/genotype 
(p=0.16/0.67) or the interaction of ADHD status and DAT1 haplotype/genotype (p=0.80/ 
0.82) did not affect cue-induced reaction time. 
 Task-related brain activation in the extended sample is similar as before (Hoogman 
et al., 2011), and is displayed in Supplement 3. In the whole brain analysis bilateral 
striatum, bilateral insula, right pre-supplementary motor area, left middle frontal gyrus 
and right superior frontal gyrus were more active during the anticipation of ‘reward 
cues’ relative to ‘no-reward cues’ (more details in Supplement 4). Further analysis 
focused on the bilateral striatal activation. Like in previous studies by others (Scheres et 
al., 2007; Ströhle et al., 2008) and in our smaller sample (Hoogman et al., 2011), the 
analysis without taking DAT1 haplotype or genotype into account showed ADHD 
patients to have lower task-related striatal activation compared to healthy subjects 
[t(162)=-2.32, p=0.02; Supplement 3]. 
Effect of DAT1 on striatal activation
Including both ADHD status and DAT1 haplotype in the whole brain effect of reward 
cue> no-reward cue, no effect of DAT1 haplotype was observed. Neither was there an 
effect of DAT1 haplotype in our region of interest, the bilateral striatum [F(3,160)=1.40, 
p=0.24; Figure 1]. There were also no significant interactions of DAT1 haplotype with 
ADHD status [F(3,160)=0.41, p=0.52], nor was there an effect on bilateral striatal activation 
when only the DAT1 3’ UTR VNTR genotype was considered [F(3,158)=.24, p=0.63]. An 
analysis only including patients who were medication-naive at the time of testing 
(n=26) did not result in significant effects of DAT1 haplotype (p=0.35) or genotype 
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(p=0.28) on striatal activation either. The same accounts for an analysis only including 
participants with no prior smoking habits (DAT1 haplotype [F(3,115)=.71, p=0.40]; DAT1 
genotype [F(3,115)=1.19, p=0.28]). 
Discussion
In the current study, the role of the dopamine transporter DAT1 gene in adult ADHD was 
investigated. First, the association between adult ADHD and the DAT1 VNTR haplotype 
was studied. Second, the functional effect of the DAT1 gene on reward-related striatal 
activation was investigated in ADHD patients and healthy controls. 
Table 3   DAT1 VNTR 3’UTR and intron 8 haplotypes and genotypes
Haplotype ADHD (n=87) Controls (n=77)
5-9 29 26
5-10 2 11
6-9* 25 7
6-10 112 110
6-11 3 0
13-10 1 0
14-10 1 0
14-11 1 0
Genotype ADHD (n=88**) Controls (n=77)
DAT1 3’UTR 9/9 7 4
 DAT1 3’UTR 9/10 38 25
 DAT1 3’UTR 10/10 38 48
 DAT1 3’UTR 9/11 2 0
 DAT1 3’UTR 10-11** 2 0
DAT1 intron8 5/5 2 3
 DAT1 intron8 5/6 26 31
 DAT1 intron8 6/6 56 43
DAT1 intron8 6/13 1 0
 DAT1 intron8 5/14 1 0
DAT1 intron8 6/14 1 0
*9-6 was indicated to be the risk haplotype and showed an association with ADHD. 
**The subject with 10-11 DAT1 3’UTR was not included in the analysis.
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 Previous studies have shown, that in contrast to childhood, where the 10-6 
haplotype of DAT1 is associated with ADHD, the 9-6 haplotype is associated with ADHD 
in adults (Franke et al., 2011). In the current study we confirmed this association. In that, 
we have to mention that a part of the sample investigated here was also part of earlier 
publications of this association (overlap of ADHD patients between studies: n=17, no 
overlap in controls) (Franke et al., 2008; Franke et al., 2010). We report here, for the first 
time, that this risk haplotype is also associated with more inattentive symptoms in the 
ADHD group. This fits well with previous findings in childhood ADHD, where an 
association between the DAT1 gene and attention problems was found in several 
studies (Bellgrove et al., 2005; Bellgrove et al., 2009; Loo et al., 2003).
 When studying the functional effect of the DAT1 VNTR haplotype and effects of the 
individual DAT1 genotypes on brain activation during a reward anticipation task, we 
found no effect on striatal functioning, neither in patients nor in controls. At best, there 
was a trend for striatum activity to be higher in carriers of the 9-6 risk haplotype in both 
groups (Figure 1). As shown in Table 1, several earlier studies had described such effects 
for the DAT1 3’ UTR VNTR polymorphism. In healthy individuals, our study equalizes the 
number of studies observing an effect (more activity in 9-repeat carriers, n=3) (Aarts et 
al., 2010; Dreher et al., 2009; Forbes et al., 2009) to those that did not (n=2+1) (Hahn et al., 
Figure 1   No effect of the DAT1 risk haplotype on reward-related striatal activation 
in patients and healthy controls
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2010; Nikolova et al., 2011). The former studies in patients were much smaller, investigated 
children and were contradicting each other in the direction of effects of the DAT1 gene 
(Bédard et al., 2010; Durston et al., 2008). It is expected that there are unknown factors 
that determine the effects of DAT1. One of these factors could be the specifics of the 
tasks used in the various studies. In the current study, the effect of the DAT1 gene was 
studied in the reward anticipation phase of a monetary incentive task (Knutson et al., 
2001), investigating the effects of motivation (reward > no reward) on a simple reaction 
time task. The study by Aarts et al. in 2010 found an effect of DAT1 3’ UTR VNTR genotype 
on reward anticipation when comparing high versus low reward (i.e., reward magnitude) 
in the context of a cognitively more demanding task (task-switching). The study by 
Dreher and colleagues, who also reported a significant effect of DAT1, also used a 
variation in reward magnitude (3 levels) and a probability factor during the anticipation 
phase (Dreher et al., 2009). Forbes used an alternative card guessing game involving a 
cognitive component; guessing whether the next card was going to be higher or lower 
than a given value (Forbes et al., 2009). This was followed, in correct trials by a reward. 
The differences in task demands might thus have caused the discrepancies between 
current and previous studies investigating DAT1 genotype effects on reward anticipation. 
Indeed, it has been suggested that the effects of striatal dopamine-dependent 
motivation are highly dependent on cognitive task demands (Aarts et al., 2010; Aarts et 
al., 2011). The missing cognitive component in our task might thus explain the absence 
of an effect of DAT1 on striatal activation. 
 Next to specificity of the task, heterogeneity of the study sample might also have 
an effect on the results. One of the sources of heterogeneity is comorbidity; ADHD is a 
highly heterogeneous disorder and co-morbid disorders are more often present than 
not in ADHD (Wilens et al., 2009). There is some evidence that the presence of one of 
these co-morbid disorders, conduct disorder, has an effect on the association between 
DAT1 and ADHD in children (Zhou et al., 2008): only in ADHD patients without co-morbid 
conduct disorder an association with DAT1 was observed, although this concerned 5 
single nucleotide polymorphisms of the DAT1 gene rather than the VNTRs tested in the 
current study.  In addition, in adult ADHD patients, the presence of co-morbid conduct 
disorder in childhood influences activity in various regions in the brain including the left 
caudate part of the striatum (Cubillo et al., 2011). Therefore, cognitive functions in ADHD 
patients with or without a specific comorbid disorder might be differently organized 
and thus effects of genes may have different effects. In future studies this should be taken 
into account. Although we did not have information on conduct disorder in our patients 
available, we took another source of heterogeneity into account, i.e. enviormental 
factors  known to affect dopamine transporter regulation in the striatum (Krause, 2008). 
However, controlling for smoking and long-term use of stimulant medication by 
excluding smokers and including only medication-naive subjects in the analysis did not 
result in the identification of significant effects of DAT1 on striatal functioning. 
64
Chapter 3
 In the current study we try to explain how genetic variation in DAT1 influences brain 
responses and consequently behavior. To understand this process, the intermediate 
neuromolecular step is also of importance: how are dopamine transporter (DAT) levels 
affected by genetic variation and by the environment, and do baseline DAT levels differ 
between patients and controls? Beyond effects of smoking and use of stimulants, 
regulation of DAT levels is far from clear (Costa et al., 2011; Dougherty et al., 1999; Dresel 
et al., 2000; Hesse et al., 2009; Jucaite et al., 2005; Krause et al., 2000; la Fougère et al., 
2006; Larisch et al., 2006; Spencer et al., 2005; Volkow et al., 2007). Nevertheless, we know 
that DAT1 is extremely variable in its genetic sequence and also highly sensitive to 
epigenetic regulation (Nieratschker et al., 2012; Shumay et al., 2010). Understanding such 
effects would strongly improve the analysis of DAT effects on behavior. PET studies like 
the recent one by Shumay and coworkers, identifying differential decay of DAT1 
expression for different genotypes (Shumay et al., 2011) might bring us a step closer to 
getting a clearer picture DAT1 function.
 Our study sample is the largest adult ADHD imaging genetics study to date and 
considered large enough to detect effects of single genetic variants (Hoogman et al., 
2011; Mier et al., 2010; Munafò et al., 2008). However, not all genetic effects are equally 
large, as exemplified by the study of Nikolova et al. in 2011 (Table 1), who investigated 
the effect of five polymorphisms of genes linked with dopaminergic functioning, 
including DAT1 (Nikolova et al., 2011). While the variation in these genes together 
explained nearly 11% of the variance in striatal activation, none of the genes by itself 
showed a significant association with striatal activation. These results would suggest 
that we might benefit from performing gene-wide or neurobiological pathway-wide 
analyses in the future to understand the polygenic effect on a neurobiological process 
(Bralten et al., 2011; Ruano et al., 2010). 
 In conclusion, the importance of the DAT1 haplotype as a risk factor for adult ADHD 
was again illustrated in this study. However, the mechanism by which DAT1 increases 
disease risk remains largely unknown. An early review of the effects of the DAT1 3’ UTR 
VNTR on neuropsychological functioning did not show convincing effects of this variant 
on any particular neuropsychological task (Rommelse et al., 2008). Although it is too 
early to give up on DAT1 effects on striatal activity for the reasons outlined above, other 
mechanisms should thus also be considered. To date, there are two studies investigating 
the effects of DAT1 on brain responses other than those of the striatum, both in adults 
with ADHD. One of them suggests that brain responses related to cognitive interference 
result in hypoactivation in the dorsal anterior cingulated cortex (ACC) in patients 
homozygous for the 10-repeat allele (Brown et al., 2010). A second study showed 
marginal suppressed effects of DAT1 in the left medial prefrontal cortex during a working 
memory task, and an interaction effect of diagnosis and genotype on dorsal ACC 
activity (Brown et al., 2011). Studying DAT1 and the ACC may thus provide additional 
insights on how DAT1 is related to ADHD. Importantly, the proposed mechanism of DAT1 
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may be one of modulating the ADHD phenotype instead of having a direct role in 
causing ADHD, as has been suggested several times (Franke et al., 2008; Kebir and 
Joober, 2011). In this case more attention should be given to studying the role of DAT1 in 
interaction with other genes. Finally, effects of genes are expected to be subtle, and 
therefore specific knowledge on neural correlates, external factors (like study design) 
and internal factors (like age) potentially influencing their effects are important to 
consider in neuroimaging genetics studies, and a sufficiently large sample size is of the 
essence. 
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Supplements to chapter 3
Supplement 2  fMRI acquisition and preprocessing
Imaging was conducted using a 1.5 Tesla scanner (Sonata Siemens, Munich, Germany). 
Whole brain functional imaging was performed using a gradient-echo echo-planar 
scanning sequence (35 axial slices, repetition time =2570 ms, echo time =35 ms, voxel 
size =3.5x3.5x3.0 mm, interslice gap= 0.5 mm, field of view=224 mm, flip angle= 90º). 
Before the acquisition of functional images, a high-resolution T1-weighted magnetiza-
tion-prepared rapid acquisition gradient echo (MP-RAGE) anatomical scan was obtained 
(176 saggital slices, repetition time= 2730 ms, echo time= 2.95 ms, voxel size=1.0x1.0x1.0 
mm, field of view= 256 mm). 
Supplement 1   Modified Monetary Incentive Delay (MID) task
Note The response window was individually adjusted in order to balance hits and misses. After a hit, 20 msec 
was subtracted from the maximum response time and 10 msec was added after a miss. This procedure 
resulted in comparable hit rates (35% for no-reward and 40% in the reward condition)
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 Blood-oxygen-level dependence time-series data were preprocessed and analyzed 
using SPM5 (Wellcome Dept. of Cognitive Neurology, London). The first 5 volumes were 
discarded to allow for T1-equilibrium. The remaining images were spatially realigned to 
the first volume to correct for head movement during scanning. Subjects were excluded 
when they had moved more than 4 mm in x, y or z direction. The patient and comparison 
groups did not differ in terms of the average amount of movement [t(102)=1.09, p=.28]. 
After realignment the images were spatially normalized to a standard echo-planar 
imaging (EPI) template centered in Talairach space (Ashburner and Friston 1997), and 
spatially smoothed with a Gaussian kernel of 8 mm full-width-half-maximum.
Supplement 3   Reward related striatal activation of ADHD adults and healthy 
controls
a) Whole brain effect of the contrast ‘Reward cues’> ‘No-reward cues’ at p
FWE
<0.05. The colored bar 
represents T-values. b) Effect of ADHD status on reward related striatal activation.
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Nitric Oxide Synthase genotype modulation of 
impulsivity and ventral striatal activity in ADHD  
and comparison subjects
Published as: Hoogman M, Aarts E, Zwiers M, Slaats-Willemse D, Naber M, Onnink M, 
Cools R, Kan C, Buitelaar J, & Franke B. (2011). Nitric Oxide Synthase genotype modulation 
of impulsivity and ventral striatal activity in Attention Deficit/Hyperactivity Disorder and 
comparison subjects. American Journal of Psychiatry, 168(10):1099-106.
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Abstract 
Objective: Attention deficit/hyperactivity disorder (ADHD) is a highly heritable disorder. 
The NOS1 gene encoding nitric oxide synthase is a candidate gene for ADHD and has 
been previously linked with impulsivity. In the current study we investigated the effect 
of a functional variable number of tandem repeat polymorphism in NOS1 (Ex1f-VNTR) 
on one of the cognitive deficits in ADHD, the processing of rewards. 
Method: A sample of 136 participants, consisting of 87 adult ADHD patients and 49 
comparison subjects, completed a reward-related impulsivity task, the Delay Discounting 
Task. One hundred four participants also underwent functional magnetic resonance 
imaging during a reward anticipation task. The effect of the NOS1 Ex1f-VNTR genotype 
on reward-related impulsivity and reward-related ventral striatal activity was examined. 
Results: ADHD patients had higher impulsivity scores and lower ventral striatal activity 
than did comparison subjects. The association between the short allele and increased 
impulsivity was confirmed. However, independent of disease status, subjects homo - 
zygous for the short allele of NOS1, the ADHD risk genotype, displayed higher ventral 
striatal activity than did subjects with the other NOS1 VNTR genotypes. 
Conclusions: We suggest that NOS1 influences impulsivity, and that its relation with 
ADHD is mediated through effects on this trait. Increased ventral striatal activity related 
to NOS1 may be compensatory for effects in other brain regions.  
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Introduction
Attention deficit hyperactivity disorder (ADHD) is a common neuropsychiatric disorder 
in childhood that often persists into adulthood. Approximately 15% of patients still 
meet full ADHD criteria according to DSM-IV in adulthood, and 40%-60% remit only 
partially and have increased symptom counts (Faraone et al., 2006). Despite substantial 
heritability, as shown by adoption and twin studies (Burt, 2009), identifying  genes for 
ADHD has proven difficult (Franke et al., 2009; Gizer et al., 2009). Only a handful of 
susceptibility genes have been identified to date, all of which increase ADHD risk with 
only small effect sizes (Gizer et al., 2009). This polygenic heritability, together with the 
heterogeneity of the ADHD clinical phenotype, is a complicating factor in the 
identification of ADHD genes. However, information on the function of those genes 
known to be associated with ADHD could help us identify the biological mechanisms 
underlying the disorder. 
 Understanding associations between genes and a complex disorder like ADHD 
may be made easier if the disorder is decomposed into intermediate phenotypes, such 
as neurocognitive measures. Conceivably, fewer genes will play a role in one of these 
intermediate neurocognitive phenotypes than in the entire clinical phenotype. Besides 
the well-known executive function problems, patients with ADHD often display 
abnormal sensitivity to reward (Sonuga-Barke, 2003), as evidenced by steeper temporal 
discounting rates, altered decision making and an aversion to delay of gratification in 
reward-related tests (Luman et al., 2005; Paloyelis et al., 2009; Scheres et al., 2008; Toplak 
et al., 2005). Temporal discounting is the patient’s preference to receive smaller rewards 
sooner rather than larger rewards later and is postulated to be an intermediate phenotype 
for impulsivity. Neuroimaging studies have shown engagement of alternative brain 
regions in decision making in ADHD patients (Ernst et al., 2003). A prominent feature is 
hypoactivation of the ventral striatum, a brain area with an important role in reward 
processing (McClure et al., 2004; Pothuizen et al., 2005), during reward anticipation 
(Scheres et al., 2007; Ströhle et al., 2008). Ventral striatal activity is also associated with 
impulsivity, a hallmark of ADHD (McClure et al., 2004; Ströhle et al., 2008). 
 Recently, the NOS1 gene was identified as a candidate gene for ADHD and other 
impulsivity disorders (Reif et al., 2009). A variant in this gene was also among the top 
findings of a genome-wide association study in ADHD (Franke et al., 2009).  NOS1 
encodes nitric oxide synthase 1. Nitric oxide, the product of this enzyme’s activity, acts 
as the second messenger downstream of the N-methyl-d-aspartate receptor and 
interacts with both the dopaminergic and serotonergic systems in the human brain. 
Nitric oxide inhibits monoamine transporters, thereby modulating the dopamine and 
noradrenalin concentration in the extracellular space (Kiss and Vizi, 2001). In addition, NOS1 
functions in neurite outgrowth suggesting an early influence on brain development (Chen 
et al., 2006). 
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Located on chromosome 12, the NOS1 gene has a complex structure, consisting of 28 
protein-coding exons with 12 alternative untranslated first exons referred to as exons 
1a-1l. In exon 1f, a variable number of tandem repeats (VNTR) polymorphism that alters 
gene expression is present (Reif et al., 2009). This exon has a relatively high expression in 
the brain, with high specificity for the basal ganglia, including the striatum. Since NOS1 
modulates tonic extracellular dopamine levels and phasic dopaminergic neuron spike 
activity, it might affect disorders with deficient striatal functioning (Reif, 2010). Targeted 
disruption of Nos1 in mice increased impulsivity and aggressiveness, reduced anxiety 
and impaired learning (Nelson et al., 1995; Wultsch et al., 2007). Human behavioral and 
imaging studies have shown NOS1 exon 1f-VNTR to be associated with hyperactive, 
impulsive, and aggressive behavior as well as hypofunctioning of the anterior cingulate 
cortex (Reif et al., 2009; Reif et al., 2011; Retz et al., 2010). 
 Although the NOS1 gene has been linked to ADHD, impulsivity, and modification of 
neurotransmitter levels in the striatum, effects of NOS1 genetic variation on striatal 
activity have not been investigated. The objective of the present study was to better 
understand the effect of this gene on neurobiological dysfunctioning in adult ADHD by 
exploring the influence of the exon 1f-VNTR on impulsivity and reward-related striatal 
activity in a large sample of adult ADHD patients (N=87) and healthy comparison 
subjects (N=49). Given the results of previous studies, we expected to find 1) higher 
impulsivity scores as well as 2) ventral striatal hypoactivation in ADHD patients relative 
to healthy comparison subjects, 3) increased impulsivity in homozygous carriers of the 
NOS1 exon 1f-VNTR short allele, and 4) modulation of ventral striatal activity by the exon 
1f-VNTR.
Method
Participants
One hundred and thirty-six individuals (adult ADHD patients, N=87: healthy comparison 
subjects, N=49) from the Dutch cohort of the International Multicentre persistent ADHD 
CollaboraTion, IMpACT (Sánchez-Mora et al., 2010), participated in this study. All 
underwent endophenotypic tests for adult ADHD, in which cognitive functioning and 
neuroimaging data were collected. The ADHD patients and an age-, gender-, and 
IQ-comparable group of healthy subjects were recruited from the department of 
Psychiatry of the Radboud University Nijmegen Medical Centre (Nijmegen, The 
Netherlands) and through advertisement. Patients were included if they met DSM-IV-TR 
criteria for ADHD in childhood as well as adulthood. All participants were assessed using 
the Diagnostic Interview for Adult ADHD (Kooij and Francken, 2007). This interview 
focuses on the 18 DSM-IV symptoms of ADHD and uses concrete and realistic examples 
to thoroughly investigate whether a symptom is currently present or was present in 
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childhood. In order to obtain information about ADHD symptoms and impairment in 
childhood, additional information was acquired from parent and school reports, 
whenever possible. The Structured Clinical Interview for DSM-IV (SCID-I) was used for 
comorbidity assessment. Assessments were carried out by trained professionals 
(psychiatrists or psychologists). In addition, a quantitative measure of clinical symptoms 
was obtained using the ADHD Rating scale-IV (DuPaul et al., 1998).
 Exclusion criteria for participants were psychosis, alcohol of substance addiction in 
the last 6 months, current major depression (assessed using SCID-I), full-scale IQ estimate 
≤70 (assessed using the Wechsler Adult Intelligence Scale-III), neurological disorders, 
sensorimotor disabilities, non-Caucasian ethnicity, and medication use other than psycho-
stimulants or atomoxetine. An additional exclusion criterion for healthy comparison 
subjects was a current or past neurological or psychiatric disorder according to SCID-I. 
Twenty-eight patients were medication naïve at the time of the trial. Patients who were 
receiving treatment with ADHD medication (methylphenidate (N=44), atomoxetine 
(n=4) and dextroamphetamine (N=11)) were asked to withhold use of their medication 
24 hours prior to testing. As a result of excessive movement during scanning (N=4), 
metal in the body or tattoos (N=25) and technical problems (N=3), the final sample size 
for the imaging part of the study was 104 (ADHD patients, N=63; healthy comparison 
subjects, N=41). This final sample included 19 medication naïve patients; 26 ADHD 
patients and 18 comparison subjects in this subsample were men. Participants had to 
refrain from smoking prior to and during testing (Brody, 2006). Indirect effects of 
smoking were controlled for by taking smoking habits (yes/no) into account in the 
analysis. 
 This study was approved by the regional ethics committee. Written informed consent 
was obtained from all participants. 
Genotyping
Genotyping of the exon 1f-VNTR was performed by sequence length analysis on a 
genetic analyzer (see Supplement 1). The resulting genotypes were converted to short 
(S) and long (L) alleles. The homozygous short allele (short-short [SS]) genotype has 
earlier been identified as a risk factor for psychiatric disorders (Reif et al., 2009), and 
therefore genotypes were stratified into an SS carrier group and a group of participants 
carrying at least one long allele (short/long [SL]/long/long [LL]) for the behavioral and 
functional data analysis.
Behavioral Task: Reward-Related Impulsivity 
The delay discounting task (Dom et al., 2006) was administered to measure reward-related 
impulsivity. On each trial of this task, participants had to choose between varying 
amounts of hypothetical immediate rewards and hypothetical delayed rewards. A total 
of 110 questions (such as, “Which do you prefer: 30 Euro 180 days from now or 2 Euro now?”) 
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were displayed on a screen. In successive questions, the amount of immediate money was 
increased until it equaled the delayed reward. This way, the personal point of indifference, 
where two options have equal subjective value to an individual, was determined for every 
participant. Indifference points were determined for three delayed reward conditions (10, 
30, and 100 euro) and five different delays (2, 30, 180, 365, and 730 days). By using a discount 
function, an impulsivity parameter (k) could be derived. Previous studies have shown that 
discounting curves fit well with hyperbolic functions (Mazur, 1987). The discount function 
for the task was as follows: V= a/(1 + kD). For this equation, “V” represents the present value 
of the delayed reward, in this case the indifference point, and “a” represents the delayed 
reward (10, 30, or 100 euro) at delay “D” (2, 30, 180, 365, or 730 days). Higher levels of k 
correspond to steeper discounting rates and higher levels of impulsivity (Richards et al., 
1999). The main outcome measure was the average k for 10 euro (k10), 30 euro (k30), and 
100 euro (k100) and the average score of all trials (kall). A logarithmic transformation was 
performed to normalize k values (log k).
Functional Magnetic Resonance Imaging (fMRI) Reward Anticipation 
Paradigm
To examine neural responses to reward anticipation, participants were scanned while 
performing a modified monetary incentive delay task, which has been shown to induce 
ventral striatal activity (Hermans et al., 2010) (see Supplement 2). Participants were asked 
to respond as quickly as possible to a target by pressing a button. Prior to display of this 
target, a cue (duration: 3.5-8.5 seconds) was given to indicate whether a reward could or 
could not be obtained. After each target response, the outcome was displayed. 
Participants could gain 1 euro in the reward condition and no money during the 
no-reward condition if they responded between 270 and 500 ms after target onset. This 
response window was individually adjusted (see Supplement 2). The task consisted of a 
practice trial, after which the purpose of the task was again briefly summarized, followed 
by 50 trials in which reward and no-reward cues were randomly displayed. The 
experiment lasted 12 minutes, and a total of 12 euro could be gained. At the end of the 
experiment, the awarded money was shown on the screen and transferred to the 
participant’s bank account. Reaction times in the reward and no-reward condition were 
the behavioral outcome measures.
Behavioral Analysis
Reward-related impulsivity
To assess the effects of ADHD status (ADHD patients relative to healthy comparison 
subjects) and NOS1 genotype (SS versus SL/LL) on reward-related impulsivity, analysis of 
variance (ANOVAs) were carried out using log(k10), log(k30), log(k100), and logkall as 
dependent variables, and age and gender were incorporated as covariates. Cohen’s d 
was calculated to identify effect size.
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Monetary incentive delay task
A repeated measures general linear model was performed to assess the effect of cue 
(reward/no-reward) on response time. This general linear model was carried out with 
reaction time as the dependent variable and cue as the within subject variable. The 
between subject factors ADHD status and NOS1 exon 1f-VNTR genotype were added to 
the general linear model to identify group effects of cue-induced reaction times. 
Cohen’s d was also calculated.
fMRI Analysis
After preprocessing (for details on fMRI acquisition and preprocessing, see the 
supplement 2), first-level analyses were performed for each participant to estimate 
eight parameters of interest with a general linear model for “cue”, “target”, “hit”, and 
“miss” events in both the reward and no-reward conditions. These events were modeled 
as event-related regressors, with a zero duration and convolved with the canonical 
hemodynamic response function in SPM5. Additionally, realignment parameters were 
included to account for movement-related variability, and time-derivatives were used, 
which resulted in 14 additional regressors of no interest. Data were high-pass filtered 
using a frequency cutoff of 1/128 Hz.
 To assess neural activity associated with reward anticipation, our contrast of interest 
concerned the reward and no-reward cue events. The contrast images for these events 
were submitted to a second-level random effect analysis, with the following full factorial 
2x2x2 design: ADHD status, NOS1 genotype, and cue (reward versus no-reward). Age 
and gender were included as covariates (Becker, 1999; Mell et al., 2009). For the whole 
brain analysis, the main effect of cue was tested using a threshold of p<.05 (family-wise 
error corrected) and a cluster size threshold of 35 voxels. Because of our a priori 
hypothesis regarding the ventral striatum, the resulting suprathreshold ventral striatal 
region in the whole brain analysis of the main effect of cue was defined as our region of 
interest. Defining this functional region for two groups with proven differential ventral 
striatal activity (such as ADHD patients and healthy  comparison subjects (Scheres et al., 
2007; Ströhle et al., 2008)) bears the risk of bias if the two groups are not equal in size (for 
details see (Kriegeskorte et al., 2009)). To prevent any selection bias in our study (in 
which the patient group was indeed bigger), we separately defined functional ventral 
striatal region for each diagnostic group and analyzed both groups to assess the effect 
of genotype. Cluster beta weights were extracted from these regions using MarsBaR 
toolbox (Brett et al., 2002). To replicate previous studies on striatal hypoactivation in 
ADHD patients, a one-sided ANOVA was performed, with ADHD status as an independent 
variable and ventral striatal activity as a dependent variable. Pearson’s correlations 
between ventral striatal activity and impulsivity were calculated. All statistical tests were 
two-sided, unless stated otherwise. 
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Results
Demographic characteristics of the study sample are presented in Table 1. There were 
no significant differences between groups based on ADHD status or NOS1 exon 1f-VNTR 
genotype with respect to gender, age, or IQ. ADHD patients and healthy comparison 
subjects showed the expected differences in self-reported ADHD symptoms (p<0.001) 
and an equal distribution of not otherwise specified exon 1f-VNTR genotype. Fifty-four 
patients fulfilled criteria for the combined ADHD subtype; 20 fulfilled criteria for the 
inattentive subtype; and 13 were characterized as hyperactive/impulsive. Within the 
patient group, medication use was equally distributed over the genotype subgroups 
(SS, SL/LL), with no differences in disease severity between medicated and never-medi-
cated patients. A similar distribution of characteristics was observed in the subsample 
of participants that underwent fMRI. In this subsample, 42% of ADHD patients and 24% 
of healthy comparison subjects were smokers, and smoking was equally distributed 
over the genotype groups (SS: 47%; SL/LL:32%). 
Behavioral Results
Reward-related impulsivity
ADHD patients showed higher levels of reward-related impulsivity than healthy comparison 
subjects on the delay discounting task (log(kall): F=7.15, df=1, 134, p=0.008). The strongest 
effect was found in the k100 condition in which the largest amount of money (100 euro) 
was discounted (p<0.0001). Log(k100) was not significantly correlated with ADHD severity. 
In the ADHD group, patients with the SS genotype had higher reward-related impulsivity 
scores than those with SL/LL genotypes (F=4.73, df=1, 85, p=0.03, Cohen’s d=0.60) 
(Figure 1). In the comparison group, the effect of genotype did not reach significance. No 
interaction of diagnosis and genotype was observed. Within the ADHD group, impulsivity 
was not significantly correlated with ADHD severity (number of ADHD symptoms).
Modified monetary incentive delay task
A main effect of cue on reaction time was found for the monetary incentive delay task 
(F=165.54, df=1, 104, p<0.0001). As expected, participants reacted faster in reward trials 
(mean response time: 243 ms) than in no-reward trials (mean response time: 284 ms) 
(Table 2). ADHD diagnosis, NOS1 genotype, or the interaction of both these factors did 
not affect cue-induced reaction time.
Functional Imaging Results
Brain regions activated in the “reward cue>no-reward cue” contrast are shown in Figure 2 
(also see Supplement 3). In the whole-brain analysis of the bilateral ventral striatum, the 
lateral prefrontal cortex, insula, left putamen, and left middle frontal gyrus were 
activated. Further analysis focused on bilateral ventral striatal activity.
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Reward-related ventral striatal activity
Bilateral average cluster activity in the ventral striatum for both the patient and comparison 
groups is shown in Figure 2. ADHD patients had lower ventral striatal activity than healthy 
comparison subjects during reward anticipation (F=3.43, df=1, 102, p=0.03), confirming 
findings in previous studies (13, 14).
 The functional region of interest that was defined based on striatal activity observed 
in the ADHD group (Figure 2) showed a significant effect of NOS1 genotype (F=4.75, 
df=1, 61, p=0.03, Cohen’s d=0.81); this same effect was seen in analysis based on the 
functional region of interest defined by activity in healthy comparison subjects (F=11.45, 
df=1, 39, p=0.002, Cohen’s d=1.03). For both definitions (in ADHD patients and healthy 
comparison subjects), carriers of the SS genotype showed higher activity than SL/LL 
genotype carriers (Figure 2).
 Ventral striatal activity did not differ between medicated and medication-naïve 
patients, nor was an effect of smoking observed among either patients or healthy comparison 
subjects.
Figure 1   Impulsivity Ratings on the Delay Discounting Task for Adult ADHD 
Patients and Healthy Comparison Subjects
Scores were higher in the ADHD group than in the healthy comparison group (less negative values [i.e., 
smaller bars] for log(k
100
) represent higher impulsivity). Within the patient group, those with the homozygous 
short allele (SS) genotype had higher impulsivity scores than carriers of the short-long (SL) allele or long-
long (LL) allele (F=4.73, df=1, 85, p=0.03).
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Figure 2   Ventral Striatal Activation in Response to Reward-Related Cue Events in 
Adult ADHD Patients and Healthy Comparison Subjects
The whole brain analysis (A) (y=6, z=-4, p<0.05 [family-wise error corrected]) of main effect of reward 
anticipation (“reward cue > no-reward cue” contrast) showing bilateral ventral striatal and frontal activity 
is depicted; the color bar represents T values. The mean beta weights (B) of the bilateral ventral striatum 
during the reward anticipation task for ADHD patients and healthy comparison subjects are shown. ADHD 
patients demonstrated hypoactivation of the ventral striatum relative to healthy comparison subjects. The 
bilateral ventral striatal functional regions of interest.
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Figure 2   Continued
(C) are displayed, as defined based on the activity patterns observed in both diagnostic groups (at y=10, 
p=.0005, uncorrected) (ADHD group [blue]: cluster size: left, 315 voxels, right, 151 voxels; healthy comparison 
group [red]: cluster size, left, 990 voxels, right, 1440 voxels). The mean beta weights of the bilateral ventral 
striatum during the reward anticipation task for the ADHD and healthy comparison groups stratified by 
NOS1 exon 1f-VNTR genotype (D) are depicted; results showed a genotype effect in both diagnostic 
groups, with the short-short genotype having higher striatal activation.
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Correlation between ventral striatal activity and impulsivity
The correlation between ventral striatal activity and impulsivity in the healthy comparison 
subjects (r=0.31, p=0.04) was significantly different (p=0.04) from the correlation in 
ADHD patients (Figure 3). 
Discussion
The NOS1 exon 1f-VNTR genotype influenced reward cue-related ventral striatal activity 
in the participants of this study, with the same direction of effect in both the ADHD and 
comparison groups. Genotype also modulated reward-related impulsivity levels in 
ADHD patients. The effect of the NOS1 genotype on reward-related impulsivity in the 
healthy comparison group was similar but did not reach statistical significance. A smaller 
subgroup with the short allele (N=11) may account for this failure to detect significance. 
The observed association of the NOS1 genotype with reward-related impulsivity in 
ADHD patients replicates earlier findings in patients with impulse control disorders 
compared with healthy subjects (Reif et al., 2011; Retz et al., 2010). Our results now 
Figure 3   Correlation Between Ventral Striatal Activation and Impulsivity in Adult 
ADHD Patients and Healthy Comparison Subjects
The scatter plot depicts the correlation between reward-related impulsivity scores (log[k
100
]) and ventral 
striatal activity.
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extend the effect of the NOS1 genotype to ventral striatal activity, a critical component 
of the underlying neurological substrate of impulsivity (Hariri et al., 2006). 
 The role of NOS1 in reward-related impulsivity observed in the behavioral analysis 
of this study as well as in several psychiatric disorders and the general population 
(Franke et al., 2009; Reif et al., 2006; Reif et al., 2009; Retz et al., 2010) suggests that the 
association of this gene with clinical phenotypes such as ADHD is mediated by its effect 
on this behavioral trait. Additionally, our finding that the genotype subgroup linked 
with higher reward-related impulsivity is associated with higher activity of the ventral 
striatum (which is consistent with previous research (Hariri et al., 2006)) corroborates 
NOS1’s role in impulsivity, since we now show that reward-cue-related impulsivity is 
positively correlated with ventral striatal activity in healthy subjects. 
 What appears discordant is the combination of increased ventral striatal activity in 
more impulsive healthy individuals with the reduced reward-related ventral striatal 
activity and no significant correlation with impulsivity in patients with ADHD, a disorder 
for which increased impulsivity is a hallmark (McClure et al., 2004; Ströhle et al., 2008). 
For healthy individuals, our findings match those of an earlier study conducted by Hariri 
et al. (Hariri et al., 2006), where impulsivity as measured by the delay discounting task 
was found to be positively correlated with ventral striatal activity. However, earlier 
studies with sample sizes smaller than that of our study reported a negative association 
in ADHD patients (Scheres et al., 2007; Ströhle et al., 2008). 
 Given the differences in findings for ventral striatal activity in ADHD patients and 
healthy individuals, one might have expected to observe a differential NOS1 genotype 
effect in the two groups or a gene-by-disorder interaction, as Durston et al. (Durston et 
al., 2008) found for the DAT1 gene. However, the finding of NOS1 genotype effects in the 
same direction in both groups shows that the NOS1 exon 1f-VNTR SS genotype related 
to ADHD does not contribute to ventral striatal hypoactivation in the disorder but acts 
on reward-related impulsivity. Thus, the ventral striatal hypoactivation in ADHD must be 
caused by something other than the NOS1 gene. One could consider altered baseline 
dopamine levels in the striatum in ADHD (Spencer et al., 2005) as a possible explanation, 
since positive correlations between striatal dopamine and ventral striatal activity exist in 
healthy subjects (Schott et al., 2008). In addition, the influence of other ADHD candidate 
genes such as the dopamine transporter gene (DAT1/SLC6A3) (Hahn et al., 2010), which is 
also associated with altered dopaminergic synthesis, or perhaps  an altered connectivity 
between the prefrontal cortex and striatum (Konrad et al., 2010) might play a role. Thus, 
one might hypothesize that the reduced ventral striatal activity is a compensatory 
mechanism to alleviate the effects of reduced prefrontal control.
 Combined consideration of intermediate phenotypes, neurobiological mechanisms, 
and molecular genetic effects may therefore elucidate mechanisms contributing to the 
clinical symptoms of ADHD more completely than the analysis of any of these parameters 
in isolation. Consistent with these expectations, functional effects of the NOS1 exon 
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1f-VNTR genotype were more readily observed (i.e., higher effect size) in brain activity 
(Cohen’s d range: 0.8-1.0) than at the behavioral level (Cohen’s d range: 0.3-0.6), in 
accordance with the view that the former is more proximal to genes. Dissecting the 
clinical ADHD phenotype into relevant, measurable traits such as motivational deficits 
and assessing genetic effects on these traits on a neurobiological level are necessary 
steps to elucidate the biological mechanisms underlying the disorder. 
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Supplements to chapter 4
Supplement 1  Genotyping of the NOS1 gene
DNA was isolated from EDTA blood samples. Genotyping of the Ex1f-VNTR was carried 
out at the department of Human Genetics of the Radboud University Nijmegen Med 
ical Centre. PCR was performed with 1 μl 10x PCR buffer II (Applied Biosystems, Nieuwerkerk 
a/d IJssel, The Netherlands), 1 μl of 25 mM MgCl
2
, 1 μl dNTPs (2.5 mM of each dNTP; 
GE Healthcare, Zeist, The Netherlands), 0.50 μl forward and reverse primer together 
(10 pmol/μl of each primer, VIC®-labeled 5’-CCCTGCGTGGCTACTACTACATT-3’ and 
5’-CTGGGCTCCAAAGCATACAT-3’ with ‘PIG’-tail; Applied Biosystems) and 0.08 μl 
AmpliTaq Gold polymerase (Applied Biosystems). The cycling conditions were: 12 min 
95 ºC, 10 amplification cycles of 30 sec at 94ºC, 54ºC for 30 sec and 72ºC for 1 min, 
followed by 22 cycles of 30 sec at 89ºC, 54ºC for 30 sec and 1 min at 72ºC, followed by 
a final 10 min at 72ºC. After the PCR, fragment length analysis was performed on the ABI 
prism 3730 Genetic Analyser (Applied Biosystems) and results were analyzed with 
GeneMapper® Software, version 4.0 (Applied Biosystems). After testing for Hardy- 
Weinberg equilibrium, the resulting genotypes were converted to short (S) and long (L) 
alleles (see table below). The frequency of the dichotomous NOS1 ex1f-VNTR genotype 
in Caucasian populations is as follows: SS=21.0%; SL=51.4%; LL=27.6% (n=7847 population- 
based subjects from Germany, Italy, Norway, Sweden, Estonia, Spain, The Netherlands 
and Austria) (Prof. Dr. A. Reif, personal communication).
NOS1 Ex1f-VNTRa
Short alleles Long alleles
Allele size Reif freq Allele size Reif freq
138 - 1 178 198 2
161 182 36 180 200 40
163 184 9 182 202 31
169 188 1 184 204 82
172 192 57 186 206 5
174 194 7
176 196 1
aDisplayed are the size of the alleles found in the current study sample (allele size), the corresponding allele 
size from the study of Reif et al. 2009 (Reif ) and frequency of these alleles in the current study sample (freq).
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fMRI acquisition and preprocessing
Imaging was conducted using a 1.5 Tesla scanner (Sonata Siemens, Munich, Germany). 
Whole brain functional imaging was performed using a gradient-echo echo-planar 
scanning sequence (35 axial slices, repetition time =2570 ms, echo time =35 ms, voxel 
size =3.5x3.5x3.0 mm, interslice gap= 0.5 mm, field of view=224 mm, flip angle= 90º). 
Before the acquisition of functional images, a high-resolution T1-weighted magnetiza-
tion-prepared rapid acquisition gradient echo (MP-RAGE) anatomical scan was obtained 
(176 saggital slices, repetition time= 2730 ms, echo time= 2.95 ms, voxel size=1.0x1.0x1.0 
mm, field of view= 256 mm). 
 Blood-oxygen-level dependence time-series data were preprocessed and analyzed 
using SPM5 (Wellcome Dept. of Cognitive Neurology, London). The first 5 volumes were 
discarded to allow for T1-equilibrium. The remaining images were spatially realigned to 
the first volume to correct for head movement during scanning. Subjects were excluded 
when they had moved more than 4 mm in x, y or z direction. The patient and comparison 
Supplement 2   Modified Monetary Incentive Delay (MID) task
Note The response window was individually adjusted in order to balance hits and misses. After a hit, 20 msec 
was subtracted from the maximum response time and 10 msec was added after a miss. This procedure 
resulted in comparable hit rates (35% for no-reward and 40% in the reward condition)
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groups did not differ in terms of the average amount of movement [t(102)=1.09, p=.28]. 
After realignment the images were spatially normalized to a standard echo-planar 
imaging (EPI) template centered in Talairach space (Ashburner and Friston, NeuroImage, 
1997), and spatially smoothed with a Gaussian kernel of 8 mm full-width-half-maximum.
Supplement 3   Brain regions more active for the ‘reward cue’ than the  
‘no-reward cue’
Region Size Side T-value x* y* z*
Lateral prefrontal cortex 67 R 5.69 34 46 28
Lateral prefrontal cortex 131 L 6.29 -36 44 30
Middle frontal gyrus 3407 L 8.53 -36 -10 54
Ventral Striatum 442 R 6.45 14 4 2
Ventral Striatum 281 L 6.81 -18 10 -4
Putamen 76 L 5.68 -22 -4 6
Insula 126 R 6.59 36 28 4
Insula 115 L 5.82 -42 10 14
Note: displayed here are the results of a second level full factorial analysis in SPM5 with a cluster threshold 
of 35 voxels. The T-value represents the value for local maxima at p<.05 (Family-wise-error corrected). *x, y 
and z refer to MNI coordinates. Size=number of voxels, R=right, L=left.
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Abstract 
Attention deficit/hyperactivity disorder (ADHD) is a frequently diagnosed and highly 
heritable disorder. Patients are often deficient in working memory, especially in spatial 
working memory processing. The prefrontal cortex (PFC) is an important neural correlate 
of working memory, and a well-established ADHD risk gene, the dopamine receptor D4 
gene (DRD4), is highly expressed there. In this study we investigated the association of 
DRD4 with spatial working memory performance and related PFC activity. 
 A sample of 124 participants, consisting of 79 adult ADHD patients and 45 healthy 
comparison subjects, completed a spatial n-back task during magnetic resonance 
imaging. The effect of the ADHD risk allele in DRD4, the 7R-allele, on working memory 
performance and related PFC activity was examined. 
 Patients performed worse relative to healthy comparison subjects on the task. The 
DRD4 7R-allele had a significant differential effect on working memory performance 
(p=.04) and -more strongly- on PFC activity (p=.004) in patients and comparison 
subjects: in the latter, this allele was associated with worse working memory 
performance and lower PFC activity, while in the patients the effect was reversed. 
 Our findings of differential effects of DRD4 on behavior in ADHD patients and 
healthy comparison subjects is consistent with earlier reports, we extend current 
literature by showing differential effects on brain activity. Differences in baseline 
dopamine levels observed in ADHD may underlie these results and may explain the 
beneficial effect of the allele on cognitive and behavioral intermediate phenotypes of 
ADHD. The current results contribute to a better understanding of the pathways from 
gene to disease in ADHD.
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Introduction
Attention Deficit/Hyperactivity Disorder (ADHD) is a frequently diagnosed psychiatric 
disorder, affecting 5-6% of children and 4% of adults (Polanczyk and Rohde, 2007). 
Genetic risk factors are involved in the etiology of ADHD, with heritability rates of 
around 76% (Faraone et al., 2005). ADHD is characterized by symptoms of inattention, 
hyperactivity and impulsivity. Patients are often impaired in several cognitive domains. 
One of these domains is working memory; meta-analyses of working memory 
performance have shown deficits in children as well as adults with ADHD (Boonstra et 
al., 2005; Hervey et al., 2004; Martinussen et al., 2005). Functional imaging studies in 
adult ADHD patients have focused solely on verbal working memory, so far. These 
studies showed altered ventrolateral prefrontal cortex, cerebellar and occipital activity 
in adult ADHD patients during verbal working memory tasks (Ehlis et al., 2008; Valera et 
al., 2010; Valera et al., 2005; Wolf et al., 2009). However, adults with ADHD seem to be 
particularly deficient in spatial working memory (Dowson et al., 2004). The area in the 
brain involved in spatial working memory is widely spread across the frontal lobe, more 
specifically the dorsolateral prefrontal cortex (dl-PFC) (D’Esposito et al., 1998; Owen et 
al., 1998). No reports of imaging studies of spatial working memory in adult ADHD 
patients have been published, yet.
 Working memory performance is modulated by several neurotransmitters in the 
PFC. Dopamine seems to play a particularly important role (Goldman-Rakic, 1996; 
Seamans and Yang, 2004), as evidenced, for example, by studies in which an association 
between baseline levels of dopamine and working memory capacity was shown 
(Cools et al., 2008). The stimulation of dopaminergic receptors results in an inverted 
U-shaped function between dopamine levels and working memory performance 
because both blockage and overstimulation of dopamine receptors impairs working 
memory performance (Arnsten et al., 1994; Zahrt et al., 1997). Therefore, inter-individual 
differences in working memory capacity and/ or baseline dopamine levels determine 
the optimal level of receptor stimulation for working memory performance. For 
example, Kimberg et al. (Kimberg et al., 1997) showed high performers on a working 
memory task to become impaired as a result of dopamine D2 receptor stimulation, 
whereas low performing subjects showed increased working memory performance. 
A similar result was found for D4 receptor stimulation, albeit in a mouse model (Zhang 
et al., 2004). 
 Besides psychopharmacological studies using dopaminergic agents to illustrate 
the role of dopamine in working memory performance, using genetic variation in 
dopaminergic genes also gives valuable information on working memory. For example, 
a variant in the dopamine transporter gene SLC6A3/DAT1 was found associated with 
working memory performance in healthy children (Stollstorff et al., 2010). Carriers of the 
9-repeat allele of this variant, associated with higher synaptic dopamine levels in the 
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striatum than the common 10/10 genotype (Heinz et al., 2000), had higher accuracy 
scores on a working memory task than the 10/10 genotype carriers. Another 
dopaminergic gene of interest for working memory and  ADHD is the DRD4 gene, which 
has been commonly found associated with ADHD (Li et al., 2006). The 7-repeat (7R)-allele 
of a 48 base pair (bp) variable number of tandem repeats (VNTR) polymorphism in exon 
3 is considered the ADHD risk allele (Faraone et al., 2005; Gizer et al., 2009; Thapar et al., 
2005). The DRD4 gene codes for the dopamine receptor D4, which is part of the D2-like 
family of receptors binding dopamine. The 7R-allele has been associated with 
suppressed gene expression (Schoots and Van Tol, 2003) and/or a blunted response of 
the receptor to dopamine (Asghari et al., 1995). D4 receptors are most predominantly 
expressed in prefrontal areas of the brain (Meador-Woodruff et al., 1996). In addition, D4 
knockout mice are characterized by decreased PFC metabolism (Michaelides et al., 
2010). Functional polymorphisms of the DRD4 gene would therefore be expected to 
have an effect on PFC functioning and, consequently, on working memory performance. 
 Given the clear evidence for the involvement of the DRD4 gene (and its functional 
exon 3 VNTR) in ADHD and a close relationship between D4 receptor stimulation and 
working memory performance, one would presume an evident role for the DRD4 gene 
in the working memory problems in ADHD patients. However, only a handful of studies 
have explored this relation, and with inconsistent results: a pilot study in an adult ADHD 
sample (n=45) found a protective effect of the 7R-allele on verbal working memory 
(Boonstra et al., 2008). Conversely, 7R-carriership had no effect on adolescents with 
ADHD (Rommelse et al., 2007), but their unaffected siblings carrying this allele displayed 
worse verbal working memory performance than non-carriers (Altink et al., 2011). 
Therefore, the role of the DRD4 gene in the working memory problems observed in 
ADHD patients is still far from clear. 
 Our objective was to study the association between DRD4 and working memory 
performance in ADHD patients more closely. In the current study, we therefore explored 
spatial working memory performance and corresponding brain activity in the dl-PFC as 
a function of DRD4 genotype in adult ADHD patients as well as healthy subjects. Based 
on previous studies, we expected differential effects of DRD4 genotype on working 
memory performance and associated dl-PFC activity in the two groups, as ADHD 
patients differ from healthy subjects on baseline dopamine levels, implicated in the 
pathogenesis of ADHD (Dougherty et al., 1999; Forssberg et al., 2006) and working 
memory capacity (Boonstra et al., 2005; Hervey et al., 2004; Martinussen et al., 2005).
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Methods and Materials 
Participants
One-hundred and twenty-four subjects (79 adult ADHD patients and 45 healthy 
comparison subjetcs) were recruited at the Department of Psychiatry of the Radboud 
University Nijmegen Medical Centre. Subjects were part of the IMpACT (Sánchez-Mora 
et al., 2010) sample. All subjects were assessed for ADHD characteristics using the 
Diagnostic Interview for Adult ADHD (DIVA (Kooij and Francken, 2007)), the Structured 
Clinical Interview for DSM-IV Criteria (SCID-I) was used for comorbidity assessment. In 
addition to the clinical interviews, a quantitative measure of clinical symptoms was 
obtained using the ADHD DSM-IV Self Rating scale (DuPaul et al., 1998). Assessments 
were carried out by trained professionals (psychiatrist or psychologist). Patients eligible 
for the study met DSM-IV-TR criteria for ADHD in childhood as well as adulthood. 
 Exclusion criteria were psychosis, addiction in the last 6 months, current major 
depression (assessed with SCID-I), full-scale IQ estimate less than 70 (Wechsler Adult 
Intelligence Scale-III (Wechsler, 1997)), neurological disorders, sensorimotor handicaps, 
non-Caucasian ethnicity and medication use other than psychostimulants or 
atomoxetine. Additional exclusion criteria for healthy comparison subjects were a 
current or past neurological or psychiatric disorder according to SCID-I.
 Twenty-two patients were medication-naïve at the time of the trial (see Table 1). 
Patients on ADHD medication used methylphenidate (n=46, 81%), atomoxetine (n=3, 
5%) or dextroamphetamine (n=8, 14%); they were asked to withhold their medication 24 
hours prior to testing. After complete description of the study to the subjects, written 
informed consent was obtained. This study was approved by the regional ethics 
committee.
Genotyping
Genotyping of the DRD4 48 bp VNTR was carried out by the Department of Human 
Genetics of the Radboud University Nijmegen Medical Centre. The procedures were 
described earlier (Kooij et al., 2008). The DRD4 48 bp VNTR is a multi-allelic polymorphism 
for which 7 different alleles were identified in our sample (Supplement 1). Genotypes 
were recoded based on carriership and non-carriership of at least one 7R-allele. 
Spatial N-back task
Subjects underwent magnetic resonance imaging (MRI) while performing an N-back 
spatial working memory (SWM) task adapted from Owen and coworkers (Owen et al., 
1998) (for task design see Supplement 2). White squares were presented on a screen on 
9 possible spatial locations (a grid of 3 by 3). Subjects were asked to press a button with 
their right index finger when the location of the square was the same as the one before 
the last (2-back condition) and respond at every square regardless of their previous 
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location in the 0-back condition. The task consisted of 10 epochs each including 15 
stimuli in the 2-back condition. In addition, 2 epochs of 0-back were added before and 
2 after the 2-back condition as a control condition. The duration of the stimulus 
presentation was 500 msec, with an inter-stimulus interval (ISI) of 1300 msec. In between 
the epochs a fixation point was presented for 5000 msec. The task was extensively 
explained prior to testing and one practice trial was included in the experiment. The 
total experiment length was about 8 minutes. Spatial working memory performance 
was defined as (number of correct responses/total number of targets)-(number of false 
positives/total number of non-targets (Snodgrass and Corwin, 1988)).
fMRI acquisition and preprocessing
Imaging was conducted using a 1.5 Tesla MRI scanner (Sonata Siemens, Munich, 
Germany). Whole brain functional imaging was performed using a gradient-echo 
echo-planar scanning sequence (35 axial slices, repetition time = 2570 ms, echo time = 
35 ms, voxel size = 3.5 x 3.5 x 3.0 mm, interslice gap = 0.5 mm, field of view = 224 mm, 
flip angle = 90°). Before the acquisition of functional images, a high-resolution 
T1-weighted 3D MP-RAGE anatomical scan was obtained (176 saggital slices, repetition 
time = 2730 ms, echo time = 2.95 ms, voxel size = 1.0 x 1.0 x 1.0 mm, field of view = 256 
mm). BOLD time series data were preprocessed and analyzed using SPM5 (Wellcome 
Dept. of Cognitive Neurology, London). The first 5 volumes were discarded to allow for 
T1 equilibrium. The remaining images were spatially realigned to the first volume to 
correct for head movement during scanning. Patients and healthy comparison subjects 
did not differ in terms of the average amount of movement in x, y and z direction 
[t(122)=1.02, p=0.31]. After realignment the images were spatially normalized to a 
standard EPI template centered in Montreal Neurological Space, and spatially smoothed 
with a Gaussian kernel of 8 mm FWHM. 
Spatial working memory performance analysis
Spatial working memory scores were normalized using arcsin transformation (Howell, 
2010). To assess the effect of DRD4 genotype on working memory performance, a 
univariate general linear model (GLM) was carried out with spatial working memory 
score as dependent variable and genotype (7R carriers and 7R non-carriers) and 
diagnostic group (ADHD patients and healthy comparison subjects) as independent 
variables. Age and gender were included as covariates. Five subjects (2 (3%) ADHD 
patients and 3 (7%) healthy comparison subjects) were excluded after completing the 
spatial working memory task because of inadequate performance, that is, performance 
more than two standard deviations below the average score (0.81).
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fMRI analysis
After preprocessing, first-level analyses were performed for each subject to estimate 
two parameters of interest with a GLM for the epochs ‘0-back’ and ‘2-back’. These 
epochs were modeled by using a boxcar convolved with the hemodynamic response 
function in SPM5 (Wellcome Dept. of Cognitive Neurology, London). Additionally, 
realignment parameters were included to account for movement-related variability, 
which resulted in six additional regressors of no interest. Data were high-pass filtered 
using a cutoff of 1/128 Hz. To assess neural activity associated with spatial working 
memory, contrast images for 2-back and 0-back epochs were submitted to a 
second-level random effect analysis with a full factorial 2x2x2 design including Group 
(ADHD patients/healthy comparison subjects), DRD4 48 bp VNTR genotype (7R 
carriers/7R non-carriers) and condition (2-back/0-back). Age and gender were included 
as covariates. 
 For the whole brain analysis the main effect of condition was tested using a 
threshold of p<.05, family-wise error (FWE) corrected. Given our specific hypothesis on 
dl-PFC activity, we performed a region of interest (ROI) analysis. The dl-PFC was defined 
as Brodmann area 9 and 46 bilaterally, using the Toolbox WPU PickAtlas (Maldjian et al., 
2004; Maldjian et al., 2003). The mean beta weights of the contrast ’2-back > 0-back’ 
were extracted from our ROI using Marsbar (Brett et al., 2002). The effect of DRD4 
genotype on dl-PFC activity was examined using a univariate general linear model 
(GLM) with dl-PFC as dependent variable and genotype and diagnostic group as 
independent variables. To calculate correlations between task-related activity and 
working memory performance, the extracted beta weights from the dl-PFC were 
correlated with working memory scores using Pearson’s correlations. All statistical tests 
were two-sided, unless stated otherwise. 
Results
Demographics of the study sample are displayed in Table 1. There were no significant 
differences between diagnostic or genotype groups with respect to gender, age or IQ. 
ADHD patients and healthy comparison subjects showed the expected differences in 
ADHD symptoms. Fifty subjects fulfilled criteria for the combined ADHD subtype, 21 for 
the inattentive subtype and 6 were characterized as hyperactive/impulsive. Disease 
severity (number of ADHD symptoms) did not differ between patients using medication 
and medication-naïve patients [t(75)=-.55, p=.59]. 
Spatial working memory performance
ADHD patients had significantly lower spatial working memory scores than healthy 
comparison subjects [F(1,115)=5.93, p=0.02, Figure 1a]. In a combined analysis of all 
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participants, DRD4 genotype did not significantly affect working memory performance 
[F(1,115)=0.09, p=0.77], but there was a significant interaction effect of genotype and 
diagnostic group [F(5,113)=4.30, p=0.04, Figure 1b]. In the healthy comparison group, 
lower spatial working memory scores were found in the 7R-carriers compared with 
healthy comparison subjects without the 7R-allele [F(1,38)=4.60, p=0.04]. In ADHD 
patients, the 7R-carriers performed better than subjects without the 7R-allele, although 
this did not reach significance [F(1,73)=0.78, p=0.37].  
Functional imaging results
The whole brain analysis for the contrast 2-back>0-back showed the expected significant 
bilateral prefrontal activity covering the dl-PFC (Figure 2). Significant activation was also 
seen in the inferior parietal lobe, angular gyrus, cerebellum, supplementary motor area, 
insula and precuneus (for details see Supplement 3). 
Region of interest analysis: dl-PFC activity
Since we had specific predictions about the dl-PFC, we further explored the activity in 
this region. 
 Figure 3 shows the mean of the beta weights in the anatomically defined region of 
the dl-PFC across groups. Dl-PFC activity of ADHD patients did not differ from that of 
Figure 1   The effect of DRD4 genotype on spatial working memory performance in 
ADHD patients and healthy comparison subjects
(a) ADHD patients perform worse relative to healthy comparison subjects (HC) on the spatial N-back task. 
(b) Diagnosis (ADHD versus HC) and DRD4 genotype (7R-carrier versus no 7R-carrier) interact on spatial 
working memory performance.
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Figure 2   Brain activation during spatial working memory
Displayed is the whole brain activation for the contrast 2back > 0back for the whole sample at p <.05 (FWE-
corrected), z=28 mm, y= 14 mm. Colored bar represents T-values.
Figure 3   The effect of DRD4 genotype on dl-PFC activity in ADHD patients and 
healthy comparison subject
Diagnosis (ADHD  patients versus healthy comparison subjects (HC)) and DRD4 genotype (7R-carrier versus 
no 7R-carrier) interact to affect dorsolateral prefrontal brain activity during a spatial working memory task.
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healthy comparison subjects [F(1,117)=.07, p=.79]. Neither was there a main effect of 
DRD4 genotype [F(1,117)=.53, p=.47]. Consistent with expectation, we did observe a 
strong interaction between DRD4 genotype and diagnosis on dl-PFC activity 
[F(1,115)=8.87, p=.004]. In ADHD patients, higher dl-PFC activity in 7R-carriers compared 
to non-7R carriers was observed [F(1,75)=4.76, p=.03], whereas in healthy comparison 
subjects the effect of DRD4 genotype was in the opposite direction [F(1,40)=5.23, p=.03]. 
Dl-PFC activity of medication-naïve patients (n=22) did not differ from that of previously 
medicated patients (n=55) [F(1,75)=1.74, p=.19], neither was there an interaction between 
medication use and genotype on dl-PFC activity [F(1,75)=1.44, p=.24].
Discussion
This study investigated the association between the 48 base pair VNTR of the DRD4 
gene and spatial working memory performance in adult ADHD patients, not only 
studying the effect of genotype on performance, but also on task-related dl-PFC activity. 
We found deficient spatial working memory performance in ADHD patients and a 
significant differential effect of the DRD4 7R-allele on spatial working memory 
performance and associated dl-PFC activity in ADHD patients and healthy comparison 
subjects.
 The findings of differential effects of DRD4 on working memory in patients and 
healthy subjects are highly reminiscent to the observations of Zhang et al. in rats, who 
found differential effects of D4 receptor stimulation on working memory performance 
for different baseline working memory levels (low versus high performers) (Zhang et al., 
2004). In the current study, DRD4 also had a differential effect on groups who are known 
to differ on working memory performance (ADHD patients and healthy comparison 
subjects). These differential effects were seen both at the level of behavior as well as 
associated brain activity. According to Zhang and coworkers, this differential effect may 
be based on differential baseline dopamine activity in the low and high performers, 
which is likely to cause the differentiation between patients and controls in our case as 
well, since dopaminergic dysregulation is observed in ADHD (Forssberg et al., 2006). 
Therefore our findings may imply that variation in D4 receptor activity, caused by 
genetic variation in DRD4, has differential effects on working memory performance 
dependent on basic working memory capacity and/or baseline dopamine. Based on 
our findings in this large sample of ADHD patients and controls, we thus propose that 
the blunted response of the 7R-allele is detrimental for spatial working memory in 
healthy subjects. In these, supposedly having optimal dopamine levels compared to 
ADHD patients, the less effective D4 receptors encoded by the 7R-allele might lead to 
suboptimal dopamine signaling and, consequently, decreased PFC activity. In other 
words, when considering the inverted u-shaped relation between dopamine and 
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working memory (Cools and D’Esposito, 2011), carrying a 7R-allele shifts you from an 
optimal level in the middle of the curve, to the left, downwards on the curve (Figure 4, 
adapted from (Cools and D’Esposito, 2011)). In ADHD patients the effect is reversed: the 
inefficiently working D4 receptors, in a background of the suboptimal dopamine 
signaling linked to ADHD (Forssberg et al., 2006; Stahl, 2010), might cause optimization 
of spatial working memory (Figure 4). Importantly, our results are in line with a previous 
study in healthy subjects in which the 7R-allele was associated with ineffective PFC 
activity during working memory (Herrmann et al., 2007), increased inferior frontal 
activity (Gilsbach et al., 2012) and other studies showing a beneficial effect of the 
7R-allele on cognitive performance and clinical outcome in ADHD patients (Shaw et al., 
2007; Swanson et al., 2000). 
Figure 4   The effect of the 7R-alelle on the inverted-U shaped relation between 
working memory performance and dopamine
Previous studies have shown that too little and too much dopamine impairs working memory performance. 
If we consider the dopamine levels in healthy comparison subjects (line 1a) to be optimal for working 
memory performance in contrast with ADHD patients (line 2a), the blunted dopaminergic receptor 
functioning associated with the 7R-allele might shift a healthy individual to less optimal dopamine levels 
for working memory performance (line 1b). In ADHD patients the effect of the 7R-allele might, however, 
result in an optimization of dopaminergic functioning for working memory performance (line 2b).
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Some caution is required regarding our interpretation of the data, as we did not find a 
significant genotype effect within the ADHD group on a behavioral level. However, we 
did see a genotype effect on working memory-related brain activity. Consistent with 
theories regarding intermediate phenotypes (Gottesman and Gould, 2003) as well as 
our own experiences (Hoogman et al., 2011), effects of genes are more readily observed 
when analyzing brain activity than at a behavioral level, in accordance with the view 
that the former is more proximal to genes (Franke et al., 2009).
 This study fills essential gaps in the current knowledge on functional effects of an 
important ADHD risk gene, the DRD4 gene. Through this type of studies, a better 
understanding of the associations between deficits seen in ADHD patients and ADHD 
candidate genes will emerge, which will increase our understanding of how genetic 
factors contribute to ADHD pathology.
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Supplements to chapter 5
Supplement 1  Allele frequencies of the DRD4 exon 3 48 bp VNTR
DRD4 VNTR allele (# of repeats) ADHD 
(n=158)
Controls 
(n=90)
2 13 14
3 6 3
4 105 61
5 3 0
6 2 0
7 27 10
8 2 2
Supplement 2   Spatial working memory paradigm
Displayed is the 2back condition of the spatial working memory paradigm. Trials are presented sequentially 
for 0.5 seconds with a 1.3 second inter trial interval. The circled event is a target (square is at the same 
location as 2 trials back), other events are non-targets.
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Supplement 3  Brain regions more active for the 2back than the 0back condition
Region Size Side T-value x* y* z*
Inferior parietal lobe 1136 L 7.94 -28 -52 -42
Prefrontal cortex 1092 L 7.33 -48 28 38
1268 R 7.17 44 18 32
Angular gyrus 808 R 7.01 38 -58 50
Cerebellum 224 L 7.00 -36 -60 -28
227 L 6.15 -4 -74 -26
Supplementary motor area 269 R 6.20 4 18 50
Insula 215 R 6.15 34 28 -4
Precuneus 66 R 6.03 8 -62 52
Note: displayed here are the results of a second level full factorial analysis in SPM5 of clusters larger than 50 
voxels. The T-value represents the value for local maxima at p<.05 (FWE corrected). *x, y and z refer to MNI 
coordinates. Size=number of voxels, R=right, L=left.
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Abstract
Background: Reduced total brain volume is a consistent finding in children with 
Attention Deficit/Hyperactivity Disorder (ADHD). In order to get a better understanding 
of the neurobiology of ADHD, we take the first step in studying the dimensionality of 
current self-reported adult ADHD symptoms, by looking at its relation with total brain 
volume. 
Methodology/Principal Findings: In a sample of 652 highly educated adults, the 
association between total brain volume, assessed with magnetic resonance imaging, 
and current number of self-reported ADHD symptoms was studied. The results showed 
an association between these self-reported ADHD symptoms and total brain volume. 
Post-hoc analysis revealed that the symptom domain of inattention had the strongest 
association with total brain volume. In addition, the threshold for impairment coincides 
with the threshold for brain volume reduction.
Conclusions/Significance: This finding improves our understanding of the biological 
substrates of self-reported ADHD symptoms, and suggests total brain volume as a 
target intermediate phenotype for future gene-finding in ADHD.
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Introduction
Attention Deficit/Hyperactivity Disorder (ADHD) affects 1–4% of adults and has an even 
higher prevalence in children (Polanczyk and Rohde, 2007). Structural magnetic 
resonance imaging (MRI) studies in children with ADHD have found reductions of 
around 3% in total brain volume (Castellanos et al., 2002) as well as in specific (sub-) 
cortical brain regions (Valera et al., 2007). Brain volumetry studies in adult ADHD patients 
mainly reported reductions of brain volume in the prefrontal cortex (Almeida et al., 
2010; Cubillo and Rubia, 2010), caudate nucleus (Almeida Montes et al., 2010; Seidman et 
al., 2010) and amygdala (Frodl et al., 2010), as well as a marginal increase of nucleus 
accumbens volume (Cubillo and Rubia, 2010). Only some of these findings have been 
replicated to date (Perlov et al., 2008; Seidman et al., 2010).
 Currently, ADHD is thought to be the extreme of a continuum of behavior in the 
population (Chen et al., 2008). This was illustrated, for example, by work of Lubke et al., 
in which attention problems in children vary along a severity continuum from mild to 
severe; children with ADHD were at the extreme of the continuum (Lubke et al., 2009). 
Further evidence for dimensionality can be found in studies in which neurobiological 
characteristics associated with ADHD show evidence for dimensionality. The study of 
Shaw et al. showed the reduced cortical thinning with increasing ADHD severity (Shaw 
et al., 2011). However these studies concern childhood ADHD, dimensionality of ADHD 
symptoms in adulthood has not been investigated in this regard.
 In order to get a better understanding of the neurobiology of ADHD, we take the 
first step in studying the dimensionality of current adult ADHD symptoms, by 
investigating the association between a biological construct of ADHD, brain volume, 
and current self-reported ADHD symptoms in an adult population. In addition, ADHD is 
a highly heritable disorder (Faraone et al., 2005) yet gene-finding approaches have been 
relatively unsuccessful in ADHD to date (Franke et al., 2009) potentially due to its 
diagnostic/phenotypic and genetic complexity, and given the high heritability of brain 
structure (Peper et al., 2007), this study might aid in characterizing total brain volume as 
a target intermediate phenotype to improve gene-finding.
Materials and Methods
Participants
In this study, 652 subjects aged 18–35 years from the Brain Imaging Genetics (BIG) study 
at the Donders Institute for Brain, Cognition and Behavior of the Radboud University 
Nijmegen Medical Centre were included. The BIG study is a study of self-reported 
healthy individuals included into earlier imaging studies at the Donders Centre for 
Cognitive Neuroimaging. Structural imaging data of these studies were pooled for 
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which subjects had to give their consent. About 80% of the subjects have their consent 
to include their structural imaging data. Subjects were of European Caucasian descent 
and generally highly educated (more information on inclusion of subjects see (Franke et 
al., 2010)). The study was approved by the medical ethical committee (CMO regio 
Arnhem/Nijmegen) and all participants provided written informed consent prior to 
participation.
Behavioral measures
Assessment of ADHD symptoms was performed through internet-based testing, as part 
of an electronic questionnaire and test battery. Subjects were asked to complete the 
ADHD DSM-IV-TR Rating Scale for current symptoms in adults (Kooij et al., 2005). 
Symptoms were reported over the last 6 months. Participants had to answer 23 
questions on a 4-point scale (never, sometimes, often, very often). The 23 current item 
scores were recalculated to the original 18 DSM-IV-TR ADHD criteria. There are 5 
symptoms that are scored based on two items in the questionnaire because these 
symptoms contain double statements in the DSM-IV-TR criteria. For example, the 
symptom ‘often fails to give close attention to details or makes careless mistakes in 
schoolwork, work or other activities’, is referred to in the questionnaire by two questions 
‘fail to give close attention to details in work’ and ‘make careless mistakes in work’. The 
18 ADHD criteria consist of 9 symptoms related to the inattentive (IA) symptom domain 
and 9 symptoms to the hyperactive/impulsive (HI) symptom domain. A symptom was 
considered to be present whenever the answer ‘often’ or ‘very often’ was given. In this 
way, the variables IA-symptoms (range 0–9), HI-symptoms (range 0–9) and total ADHD 
symptoms (range 0–18) were derived.
Imaging
Subjects were scanned at 1.5 Tesla (n = 302) and 3 Tesla (n = 350) MRI scanners and 
T1-weighted structural magnetic resonance imaging data (3D MPRAGE) were acquired 
(more information on the image acquisition can be found in Supplement 1). All scans 
covered the entire brain and had a voxel-size of 1×1×1 mm3. To calculate total brain 
volume, raw DICOM MR imaging data were converted to NIFTI format using the 
conversion as implemented in SPM5 (http://www.fil.ion.ucl.ac.uk/spm/software/spm5/). 
Normalizing, bias-correcting, and segmenting into gray matter, white matter, and 
cerebrospinal fluid was performed using the VBM toolbox (VBM5.1 Toolbox version 1.19) 
in SPM using priors (default settings). This method uses an optimized VBM protocol 
(Ashburner and Friston, 2000; Good et al., 2001) as well as a model based on Hidden 
Markov Random Fields (HMRF) developed to increase signal-to-noise ratio (Cuadra et al., 
2005). Total volume of gray matter, white matter, and cerebrospinal fluid was calculated 
by adding the resulting tissue probabilities. Total brain volume was defined as the sum 
of white matter and gray matter volume.
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Statistical analysis
The relation between self-reported ADHD symptoms and total brain volume was 
studied using linear regression analysis adjusting for age, gender and MRI field strength 
(1.5T or 3T). In order to explore effects of the distinct ADHD symptom domains on total 
brain volume, a similar analysis was performed including either Hyperactivity/Impulsivity 
(HI) symptom count or Inattentive (IA) symptom count as an independent variable. 
Permutation tests were performed to overcome multiple testing problems (see 
Supplement 1). As a downstream analysis, the association between ADHD symptom 
count and gray matter volume (correcting for white matter volume) and white matter 
volume (correction for gray matter volume) were performed.
 In addition, we tested whether total brain volume of subjects with 6 or more 
self-reported ADHD symptoms in either one symptom domain or 6 or more symptoms 
in both domains (the equivalent of the cut-off for an ADHD diagnosis according to the 
DSM-IV-TR), differed from that of subjects with 4–5 self-reported ADHD (IA and/or HI) 
symptoms (4 being the threshold for increased impairment (Kooij et al., 2005)) and/or 
subjects with 3 or less self-reported ADHD symptoms (IA and/or HI). Linear regression 
analysis was performed to assess the effect of this stratification on total brain volume, 
including age, gender and field strength as covariates. Individual groups were compared 
in post-hoc analyses. Finally, voxel-based morphometry (VBM) was performed to assess 
potential localized differences between these groups (for details see Supplement 1).
Results
The demographics of the participants are displayed in Table 1. Overall, 37 subjects (5.6%) 
reported 6 or more current HI- or IA-symptoms in our study, where 6 would be the 
threshold for a DSM-IV-TR diagnosis of ADHD (for frequency tables of the ADHD symptom 
counts see Supplement 2).
Table 1   Demographics of the study sample (n=652)
Age (mean ± SD; range) 22.5 ± 3.2 years (range 18-35)
Male 38.0%
Education
        High school degree 17.1%
        Bachelor student 12.8%
       Master or PhD student 70.1%
ADHD symptoms (mean ± SD) 2.8 ± 2.7
Subjects were healthy individuals based on self-report
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The total number of self-reported ADHD symptoms was significantly associated with 
total brain volume (β = −.08, p
nominal
= 0.007, p
empirical
=0 .014). The regression coefficients 
of the total number of self-reported ADHD symptoms were similar in the two 
Figure 1   Distribution of total brain volume (TBV) and adult self-reported ADHD 
symptoms in a healthy sample (n = 652)
(a) TBV is associated with the total number of self-reported ADHD symptoms. Of the two ADHD symptom 
domains, mainly the attentive domain contributes to TBV: (b) inattentive symptoms (β =2.09, p
nominal
 = 0.007, 
p
empirical
 = 0.013), and (c) hyperactive/impulsive symptoms (β =2.06, p
nominal
 = 0.064, p
empirical
 = 0.123). (d) Total 
brain volume across groups based on the number of self-reported ADHD symptoms. The group with 3 
or less self-reported symptoms differed from the intermediate group and from the group with a number 
of ADHD symptoms corresponding to the ADHD diagnosis (≥6 in either of the two domains). *Total brain 
volume was adjusted for age, gender and field strength.
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independent samples scanned at different MRI field strengths (1.5T: β = −0.07; 3T: β =
−0.09). Brain volume decreased with an increasing number of self-reported ADHD 
symptoms (Figure 1a). Total brain volume variation was mainly explained by IA-symptoms 
(β = −.09, p
nominal
= 0.007, p
empirical
= 0.013), rather than by HI- symptoms (β = −0.06, 
p
nominal
= 0.064, p
empirical
= 0.123) (Figure 1b and 1c). The association was not explained by 
education level (p = 0.26). Neither total gray or white matter volume were associated 
with the number of self-reported ADHD symptoms (gray matter β = −0.002, p
nominal
=
0.92, p
empirical
= 0.10, white matter β = −0.04, p
nominal
= 0.05, p
empirical
= 0.99).
 Grouping of individuals based on DSM-IV-TR criteria (≥6 self-reported symptoms, 
n = 37 more details in Supplement 2) and known impairment threshold (4–5 self-reported 
Figure 1   Continued
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symptoms, n = 82) (Kooij et al., 2005) and comparing them to subjects with ≤3 self- 
reported symptoms (n = 533) showed significant differences between groups (p = 0.008 
and p = 0.04, respectively), indicating that the threshold for brain volume reduction 
coincides with the threshold for functional impairment in patients (Figure 1d).
 There were no significant differences in the local gray or white matter volumes 
assessed by the VBM analysis (both p(cluster)>0.05, data not shown) in our large sample. 
Indicating that brain volume was globally affected.
Discussion
This study shows (a) that current ADHD symptoms in healthy adults, assessed by self- 
report as a continuum in the population and therefore largely independent of disease 
or treatment, has a neurobiological substrate; reduced total brain volume, (b) that this 
substrate is global rather than localized in the brain, and (c) that the threshold for 
impairment coincides with the threshold for brain volume reduction in patients.
 The results of this study match the results of a previous study in healthy children 
and adolescents showing cortical thinning, not corrected for total brain volume, to be 
associated with symptoms of ADHD (Shaw et al., 2011), and therefore supporting a 
dimensional aspect of biological substrates of ADHD.
 Total brain volume reductions were global rather than localized in the brain. This 
suggests general mechanisms affecting brain development in neuron number, number of 
neurites and/or neuronal connections. This is also consistent with hypotheses based on 
findings from genome-wide association studies in ADHD implicating neuronal migration 
and neurite outgrowth in disease etiology (Franke et al., 2009; Poelmans et al., 2011).
 This study shows that self-reported inattention symptoms are the main predictor of 
total brain volume reductions. This could be explained by the known association between 
inattention and processing speed (Solanto et al., 2007) and associations between the 
latter and brain volume reductions (Fjell and Walhovd, 2010). However, this study was 
not designed to study causative effects of brain volume reductions. Therefore, future 
studies with a better suited design would be necessary to provide additional information.
 While this is the largest study of its kind and also the first to show neurobiological 
dimensionality of self-reported ADHD symptoms in an adult population, it also has a 
number of limitations. Firstly, we used a self-report measure of adult ADHD symptoms. 
Self-report measures are likely to be less accurate than interviews, but for the ADHD 
rating scale we know from research in patients that it has a substantial correlation with 
diagnostic assessment by a clinician (Sandra Kooij et al., 2008). A second potential 
limitation is the unavailability of other psychiatric symptom ratings to look at the 
specificity of our results. Although this was not our prime objective, it would be very 
informative to find out if symptoms of other psychiatric disorders are also associated 
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with total brain volume or whether this association is specific for ADHD symptoms. 
Based on the study findings, suggesting a stronger role for inattentive symptoms one 
might hypothesize that depression and other disorders featuring such symptoms might 
also affect brain size. Thirdly, intelligence might be an important factor for total brain 
volume studies, since some studies have found moderate correlations between 
intelligence and total brain volume (Witelson et al., 2006). In the current study, direct 
intelligence measures were unavailable, but we used education level as a proxy. 
Education did not significantly contribute to the association between total brain volume 
and self-reported ADHD symptoms in this study. In addition, our entire sample is highly 
educated (mainly university students), which probably results in low variance in IQ 
measures. It is therefore not likely that IQ measures would change our findings.
 Finding genes for ADHD has been proven difficult, our findings, in combination 
with those of previous studies showing brain volume to be heritable (Peper et al., 2007), 
indicate that total brain volume may be a target intermediate phenotype for future 
genetics studies directed at the identification of yet unknown ADHD risk genes.
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Supplements to chapter 6
Supplement 1  Methods
Image acquisition
1.5T: All images were acquired at 1.5T Siemens Sonata and Avanto scanners (Siemens, 
Erlangen, Germany), using small variations to a standard T1-weighted 3D-MPRAGE 
sequence (TR 2300 ms, TI 1100 ms, TE 3.03 ms, 192 sagittal slices, field of view 256 mm). 
These variations included TR/TI/TE/slices of 2730/1000/2.95/176, 2250/850/2.95/176, 
2250/850/3.93/176, 2250/850/3.68/176, and the use of GRAPPA parallel imaging with an 
acceleration factor of 2. All scans covered the entire brain and had a voxel size of 1x1x1 
mm3. 3T: All images were acquired at 3T Siemens Trio and TrioTim scanners (Siemens, 
Erlangen, Germany), using small variations to a standard T1-weighted 3D MPRAGE 
sequence (TR 2300 ms, TI 1100 ms, TE 3.93 ms, 192 sagittal slices, field of view 256 mm). 
These variations included TR/TI/TE/slices of 2300/1100/3.03/192, 2300/1100/2.92/192, 
2300/1100/2.96/192, 2300/1100/2.99/192, 1940/1100/3.93/176, 1960/1100/4.58/176, and 
the use of GRAPPA parallel imaging with an acceleration factor of 2. 
Permutation Analysis
Analyses were performed using TBV and three different ADHD scores (Total number of 
ADHD symptoms, IA-symptoms and HI-symptoms) as dependents (covariates). In order 
to account for correlations among the phenotype and among the ADHD scores, 
permutations were performed to assess the experimental p-value. Permutations were 
performed by randomly reordering the records of ADHD scores of subjects over the 
records of TBV and covariates of subjects, leaving intact the link of covariates (age, 
gender, field strength) with TBV, and the correlation structure among the ADHD scores. 
Permutations were repeated 10,000 times. Within each permutated data set, all the 
models were refitted and p-values for association of the ADHD scores with TBV were 
obtained. Finally, the experimental p-value for a given nominal p-value was obtained by 
counting in how many permutations one or more of the analyses exceeded the nominal 
p-value. When analyses are independent there is a higher chance for one or more 
analyses within a permutation to randomly exceed a certain p-level, than when analyses 
are dependent. 
Voxel-Based Morphometry
Preprocessing: Diffeomorphic image registration was performed using the DARTEL 
toolbox in SPM (Ashburner, NeuroImage, 2007). First, all images were realigned to templates 
created from 556 in-house datasets. Second, Jacobian scaled (‘modulated’) images were 
calculated and subsequently transformed to MNI space using affine transformation. 
Finally, all data were smoothed with an 8 mm FWHM Gaussian smoothing kernel.
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Analysis: Data analysis was performed in SPM using the gray and white matter images. 
After grouping all data sets into 3 groups of ADHD symptoms (≥6 symptoms, 4-5 
symptoms, and ≤3 symptoms), images with poor quality or artifacts were identified 
using the outlier analysis routine implemented in the VBM toolbox. Images that showed 
a deviation of more than 1.5 times the interquartile range from the median were 
discarded from further analysis.
Statistical analysis was performed using a GLM approach in SPM. A full-factorial ANCOVA 
was applied using ADHD symptom group. The participants’ age, sex, total brain volume, 
and MRI scanner protocol were added to the model as covariates. F-tests were 
performed assessing the differences between the ADHD symptom groups. Cluster 
statistics were corrected for non-stationarity. Results were considered significant at 
p(uncorrected)<0.001 with a subsequent cluster statistics threshold p(cluster)<0.05.
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Supplement 2   Self-reported ADHD symptoms in an adult population (n=652)
Displayed are the number of subjects in this study (frequency) with their numbers of total self-reported 
ADHD symptoms (a) and numbers of self-reported Inattentive symptoms and Hyperactive/Impulsive 
symptoms (b). (c) Displayed are subjects with 6 or more self-reported symptoms in both domains (upper 
bar), the number of subjects with 6 or more self-reported HI symptoms but less than 6 symptoms in the IA 
domain (middle bar) and the number of subjects with 6 or more self-reported IA symptoms but less than 6 
symptoms in the HI domain (bottom bar).
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Summary 
Attention-deficit/hyperactivity disorder (ADHD) is a common neuropsychiatric disorder 
in childhood that often persists into adulthood. Approximately 15% of patients still 
meet full ADHD criteria according to the DSM-IV in adulthood, and 40-60% remits only 
partially and has increased symptom counts in adulthood (Faraone et al., 2006). Despite 
substantial heritability, finding genes for ADHD has proven difficult (Franke et al., 2009; 
Gizer et al., 2009). This thesis was aimed at 1) identifying associations between genes 
and the disorder; 2) understanding how known ADHD genes are related to the ADHD 
phenotype by using the endophenotype model, and 3) learn more about the 
neurobiology of ADHD and identify new endophenotypes to make gene finding easier. 
In the chapter 2 of this thesis the attempt was made to replicate the previously found 
association of a DAT1/SLC6A3 haplotype in childhood ADHD, in a sample of adult ADHD 
patients. This haplotype was formed by the 10-repeat allele of the variable number of 
tandem repeat (VNTR) polymorphism in the 3’ untranslated region of the gene and the 
6-repeat allele of the VNTR in intron 8 of the gene. Meta-analysis of the most common 
alleles in the 3 UTR VNTR (9-repeat allele and 10-repeat allele) have both shown an 
association with the disorder as well as lack of an association with the disorder. 
 To study the association of this haplotype with the disorder, 216 adult ADHD 
patients and 528 healthy controls were included and genotyped for the DAT1 haplotype. 
The results showed the 9-6 haplotype, rather than the 10-6 haplotype, to be associated 
with adult ADHD. Finding this differential association of this haplotype with childhood 
and adult ADHD is in line with earlier reports suggesting age to be an important factor 
to be taken into account when assessing the association of DAT1 with ADHD. Dopamine 
transporter density decreases during life, therefore this differential association with the 
DAT1 gene might reflect this change of requirements on the dopamine system. In 
addition, some environmental factors (e.g. smoking) influence the regulation of the 
dopamine transporters and might therefore have different effects on adults with ADHD. 
All this would imply that the DAT1 gene plays a role in modulating the ADHD phenotype 
rather than causing it.
To better understand how the DAT1 gene exerts effects on ADHD, the effect of this gene 
was studied on brain functioning using functional magnetic imaging (fMRI) in chapter 3. 
More specifically, brain activity was studied in the striatum because of the high 
expression of DAT1 in this part of the brain. In addition, the striatum is of interest to 
ADHD because of its role in reward processing, which is altered in ADHD. 
 This study had two aims: first to replicate the association of the risk haplotype (9-6) 
with adult ADHD and study its relationship with ADHD symptoms. The second aim was 
to investigate the effect of the 9-6 risk haplotype on striatal functioning as previous 
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studies had shown inconsistencies in the effect of DAT1 on brain functioning in healthy 
as well as ADHD patients.
 In a sample of 87 adult ADHD patients and 77 healthy comparison subjects, we 
confirmed the association of the 9-6 haplotype with adult ADHD. In addition, in patients 
carrying the risk haplotype more inattentive symptoms were observed. 
While analyzing the striatal responses in our study sample we found decreased striatal 
activity during reward anticipation in ADHD patients compared with controls, which 
was also shown in previous studies. However, we failed to find an effect of DAT1 on 
striatal responses in both groups. This equalizes the number of studies observing an 
effect of DAT1 to those that did not.
 In trying to explain the absence of an effect, we should keep in mind that effects of 
genes are expected to be subtle, and therefore specific knowledge on neural correlates, 
external factors (like study design) and internal factors (like age) potentially influencing 
their effects are not to be forgotten. Although the importance of the DAT1 haplotype as 
a risk factor for adult ADHD was again demonstrated in this study, the mechanism by 
which this gene increases disease risk remains largely unknown. Considering this is one 
of the largest imaging genetics studies in adult ADHD, reporting the absence of an 
effect in such a large sample emphasizes the need for alternative hypotheses in trying 
to understand the neurobiological mechanisms underlying the effect of this important 
gene in ADHD research.
Based on the previous studies showing an association of the Nitric Oxide Synthase 
(NOS1) gene with ADHD and impulsivity disorders and its predominant expression in the 
ventral striatum, this gene appeared a good candidate gene to study to study in 
chapter 4. The aim of this study was to investigate the effect of the functional variable 
number of tandem repeat polymorphism in NOS1 (Ex1f-VNTR) on ventral striatal 
activation and its behavioral component: the processing of rewards. 
 A sample 87 adult ADHD patients and 49 healthy comparison subjects were 
included and performed a reward anticipation task inside the MRI scanner and a delay 
discounting task (a measure of impulsivity) outside the scanner. ADHD patients had 
lower ventral striatal activation and higher impulsivity scores than did comparison 
subjects. When studying the effect of the NOS1 polymorphism, an association of the 
short allele with performance on the delay discounting task was found, confirming the 
link between the short allele of NOS1 and increased impulsivity. This short allele of NOS1 
was also associated with increased ventral striatal activation, both in patients and in 
controls. 
 What appeared discordant was the increased ventral striatal activation shown in 
subjects with the risk allele for ADHD, while ADHD is characterized by decreased ventral 
striatal activation. This would imply that the decreased ventral striatal activity in ADHD 
patients is caused by something else. One could consider altered baseline dopamine 
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levels in the striatum in ADHD as a possible explanation, since positive correlations 
between striatal dopamine and ventral striatal activity exist in healthy subjects (Schott 
et al., 2008). 
 We therefore conclude NOS1 influences impulsivity, and that its relation with ADHD 
is mediated through effects on this trait. In addition, this study also showed larger effect 
sizes of the gene on neurobiological measures (striatal activation) than on behavioral 
measures (impulsivity) and therefore illustrates the value of the working model of 
endophenotypes (Figure 1, chapter 1). 
The association between the 48 base pair VNTR of the DRD4 gene and spatial working 
memory performance and task-related dorsolateral prefrontal activity was subject of 
chapter 5. The 7-repeat allele of the DRD4 gene had been identified as an ADHD risk 
allele in many previous studies. However, in behavioral studies, presence of the 7-repeat 
allele had shown beneficial effects in ADHD patients. To unravel how DRD4 exerts its 
effect on working memory we used fMRI to study the effects of DRD4 on prefrontal 
activity during a spatial working memory task. 
The results showed deficient spatial working memory performance in ADHD patients 
and a significant differential effect of the DRD4 7R-allele on spatial working memory 
performance and associated dl-PFC activity in ADHD patients and healthy controls.
 These differential effects of DRD4 on behavior in ADHD patients and controls are 
consistent with earlier reports, and in this study we extended current literature by 
showing differential effects on brain activity as well. We suspect differences in baseline 
dopamine levels observed in ADHD to underlie these results, which can explain the 
beneficial effect of the allele on cognitive and behavioral intermediate phenotypes of 
ADHD. Considering ADHD a multi-factorial disorder, genes related to the disorder could 
have multiple effects on the phenotype and these effects may range from beneficial as 
to negative.
Chapter 6 had a different approach from the other chapters. Here we studied the 
relation between clinical features of ADHD and a possible endophenotype of ADHD 
(chapter 1, Figure 1; bottom up). ADHD is thought to be the extreme of a continuum of 
behavior in the population, which is partly illustrated by the dimensionality of neuro-
biological characteristics associated with ADHD: in children with ADHD cortical thinning 
was associated with a categorical measure of ADHD symptoms/severity. Knowing that 
adult ADHD is also characterized by reduced brain volumes, our aim was to study the 
dimensionality of self-reported ADHD symptoms in an adult population in relation to 
total brain volume.   
 In a sample of 652 healthy adult subjects, a negative correlation between self- 
reported ADHD symptoms and Total Brain Volume (TBV) was found. The symptom 
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domain of inattention showed the strongest association with TBV. Our search to find 
specific areas in the brain to relate to the number of ADHD symptoms did not result in 
significant findings. 
 This study showed that current self-reported ADHD symptoms have a neurobio-
logical substrate, which is global rather than localized in the brain. In addition, the 
threshold for impairment in patients (>4 ADHD symptoms) coincided with the threshold 
for brain volume reductions in patients. These results, in combination with studies 
showing brain volume to be heritable illustrate the potential of TBV as an endophenotype 
for future studies.
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General Discussion 
This thesis maps the pathways from genes to the clinical disorder in adult ADHD. The 
model of endophenotypes (Figure 1, chapter 1) was used as a working model to study 
relations between genes, endophenotypes of ADHD (either neurobiological or 
behavioral/cognitive) and clinical features of the disorder. By going up and down these 
paths, the aim was to learn more about how genes related to the disorder increase 
disease risk and affect the disorder, learn more about the neurobiology of ADHD and 
define new endophenotypes to make gene finding in ADHD easier. The second chapter 
of this thesis illustrates the fact that relationships between genes and the disorder are 
not always straightforward in showing that a different risk haplotype was associated 
with adult ADHD than with ADHD in childhood. The successive chapters in part one of 
this thesis aim to unravel the associations between ADHD risk genes and neurobiologi-
cal/cognitive endophenotypes of ADHD. The second part of this thesis is about how the 
clinical phenotype of ADHD is associated with neurobiological measures, in this case 
total brain volume.
 In this final chapter, I discuss the results of the studies in this thesis in light of current 
views on endophenotypes, dimensionality of ADHD, sample size requirements for 
genetic imaging studies and clinical implications for ADHD diagnosis and treatment.
Using the endophenotype model: the upside 
In this thesis, I used the concept of endophenotypes to better understand how genes 
involved in ADHD affect the disorder. Previous studies had already shown the advantage 
of using endophenotypes to understand the genetics of a disorder. Due to their 
quantitative character, endophenotypes are considered to be more powerful from a 
statistical point of view as compared with the categorical definitions of the clinical 
phenotype. Also, fewer genes are thought to be involved in endophenotypic traits than 
in clinical disorders. Consequently, the use of an endophenotype opens the possibility 
of studying the underlying mechanisms of a disorder with its genes involved. In addition, 
considering the model displayed in Figure 1, chapter 1, higher effect sizes of genes are 
expected for brain phenotypes such as activity in a specific brain structure compared 
to the effect sizes of genes for clinical measures. With this prior knowledge I studied 
brain activity in the striatum and prefrontal cortex in conjunction with its behavioral 
correlates, behavioral impulsivity and working memory performance, respectively, as 
endophenotypes of ADHD in part one and total brain volume in part two of this thesis. 
 In the studies described in part one of this thesis, the effects of three ADHD 
candidate genes on endophenotypes of ADHD were studied. These three studies have 
illustrated that effects of genes can 1) have an indirect effect on the disorder (NOS1, 
chapter 4), 2) be absent in larger samples compared to the previously published smaller 
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sampled studies (DAT1, chapter 3) and, 3) depend on the clinical phenotype (DRD4, 
chapter 5). These different studies have shown distinct ways of affecting the disorder, 
and by doing so, resulted in little pieces of information about the ADHD phenotype and 
therefore add to the completion of the puzzle about the neurobiology and genetics of 
ADHD.
 Next to providing more information about how genes affect the disorder, these 
studies have also generated three other important issues that can be taken forward. 
First, we had chosen to study effects of candidate genes on more than one 
endophenotype, or in other words, more steps on the pathway between gene and 
disorder were studied. For example in the study described in chapter 4 studying the 
effects of NOS1, not only striatal activity but also the behavioral substrate of this area in 
the brain, impulsivity, was studied. Without including this behavioral trait in our analysis, 
the interpretation would have been more difficult because the effect we found on brain 
activity was not what was expected. Also in the DRD4 study (chapter 5), the behavioral 
component was vital for understanding how DRD4 affected the phenotype. In this case, 
the effect found on prefrontal activity was difficult to understand because previous 
research has not been conclusive about a beneficial or detrimental effect of decreased 
prefrontal activity. Therefore, it is highly recommended to study more steps on the 
pathway in order to understand how genes affect the disorder. 
 Secondly, studying the effects of genes in both an affected group and an unaffected 
group can shed a new light on how risk genes affect the disorder. This was nicely 
illustrated in the NOS1 study, where the effect of the gene was in the same direction in 
both the affected as well as the unaffected group. This suggested a general effect on 
impulsivity and its neurobiological components and through the effect on this trait, 
NOS1 is linked to ADHD. In the DRD4 study the effect was in the opposite direction in the 
ADHD group compared with the healthy control group. Hence, the conclusion was 
drawn that additional disease characteristics, such as altered baseline dopaminergic 
functioning, interact with the effect of the gene.   
 Finally, we know effects of genes are small and attempts to increase power to 
detect these effects are necessary. Two ways of increasing power have come up in 
studies in this thesis. The obvious one is to increase sample size and is discussed 
elsewhere in this chapter. Another way to increase the likelihood of finding effects of 
genes is using powerful endophenotypes. Chapter 4 shows higher effect sizes for brain 
activity than for behavioral traits. This therefore not only supports the schematic 
representation of endophenotypes in Figure 1 (chapter 1) but also highlights the value 
of using imaging measures as endophenotypes. 
In part two of this thesis, endophenotypes were studied in a bottom-up approach, 
starting from the clinical phenotype and going up. Endophenotypes not only serve the 
purpose of understanding the effect of genes on the disorder but also increase the 
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chance of gene finding. In chapter 6, total brain volume was suggested to be an 
endophenotype of ADHD by showing a correlation with the number of self-reported 
ADHD symptoms. In that, total brain volume meets one of the criteria of an 
endophenotype. In addition, previous studies have shown total brain volume to be a 
heritable trait (Peper et al., 2007), and it is also likely to be an state independent trait. 
Therefore, although the other criteria for an endophenotype need to be studied in 
future studies, total brain volume might be a potential good endophenotype for 
genetic studies. A genome wide association meta-analysis of total brain volume has 
already shown a suggestive association with a SNP within DDR2 (Stein et al., 2012). In 
future studies DDR2 can be a candidate gene in endophenotype, and clinical phenotype 
studies in ADHD to further study the role of this gene and the involvement of total brain 
volume in ADHD.
In conclusion, the studies in this thesis have shown endophenotypes to be valuable for 
the study of the genetics of complex heritable disorders, not using them is like treating 
ADHD as a black box; we will remain unknowing about what happens on the pathway 
between genes and disorder. To increase our understanding of the disorder, studying 
effects of genes on more aspects of the pathway, in both affected and unaffected 
subjects and by using large enough sample sizes and powerful endophenotypes will be 
necessary. Next to understanding the mechanisms of genes, endophenotypes can also 
be used in the process of gene finding. 
Using the endophenotype model: the downside 
The model of endophenotypes has proven to be useful in this thesis in teaching us 
more about the genetics and neurobiology of ADHD, but some caution is warranted. 
There is the risk of oversimplification of the model. For example, genes are often 
expressed in many parts of the brain and it is therefore unlikely that one gene only 
affects one endophenotype (e.g. (Matsumoto et al., 2003)) or only one disorder (Ronald 
et al., 2008). In a landmark paper about the concept of endophenotypes, this is referred 
to as the problem of multivariance (Kendler and Neale, 2010). In addition, not only can 
single genes affect multiple endophenotypes, single endophenotypes can also be 
linked to multiple disorders (Figure 1). For example, reward-related impulsivity or related 
striatal activity is also known to be associated with substance use disorders (Hyatt et al., 
2012), not just with ADHD. Therefore, going beyond the boundaries of the model will 
generate more information about specific and shared genetics as well as specific and 
shared neurobiology of psychiatric disorders. 
 
A second issue with simplification of the model is also pointed out by Kendler and 
Neale. We assume endophenotypes to be phenotypes closer to the etiology of the 
disorder than the clinical phenotype. This does not preclude that they are also influenced 
Figure adapted from Kendler and Neale. Displayed is the problem of multivariance where multiple genes affect 
multiple endophenotypes (EP) and multiple endophenotypes can affect various disorders.
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by the environment. In part one of this thesis, I have only considered a genetic etiology; 
however, environmental factors are also known to contribute to ADHD and subsequently 
can affect its endophenotypes. Not finding an effect of the DAT1 gene on striatal 
functioning (chapter 3) could also be due to the fact that environmental factors affect 
the endophenotype or interact with genes to affect the endophenotype (Kendler and 
Neale, 2010). In sum, we should be aware that when using the model of endophenotypes, 
we should not consider that we are only working with single pieces of the puzzle but 
rather parts of the puzzle that overlap with other parts of the puzzle.  
 Next to oversimplification of the model, there is also the risk of causality assumptions: 
it is, for example, vital to distinguish mediational models and liability-index models. The 
former assume that a genetic risk passes through the endophenotype (also called an 
intermediate phenotype in this case) to the disorder. The latter refers to models in which 
genetic factors influencing the clinical disorder also influence the endophenotype, but 
these are independent effects. 
 Therefore, it is vital that, mainly for reasons of oversimplification and causality, we 
are reminded that the endophenotype model is a working model. For future research it 
is essential to go beyond the borders of this model. For example by studying effects of 
genes on target endophenotypes in different disorders (Figure 2a) we will learn more 
about the specificity of genes and neurobiological defects for each disorder. Also by 
studying effects of multiple genes on one endophenotype (Figure 2b) or effects of 
single genes on several unrelated endophenotypes (Figure 2c) should be considered 
next steps in unraveling pathways from gene to disorder. 
Figure 1   The problem of multivariance of endophenotypes
Figure adapted from Kendler and Neale. Displayed is the problem of multivariance where multiple genes 
affect multiple endophenotypes (EP) and multiple endophenotypes can affect various disorders.
Gene A Gene B Gene C
EP A EP B EP C
Disorder A Disorder B Disorder C
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8A dimensional approach to ADHD in genetic studies In psychiatry, the DSM-IV-TR (APA, 2000) is the handbook according to which the 
psychiatric disorders are classified. This handbook uses a categorical approach; if you 
meet the criteria for the disorder you are diagnosed with the disorder, if you do not 
meet all required criteria, you will not get a formal diagnosis, even if you have some of 
the symptoms. In ADHD, you have to meet a fixed number of criteria (for details see Box 
1 in chapter 1), to which belong a number of symptoms: you need six out of nine of 
these symptoms to be diagnosed with ADHD. Consequently, individuals just below this 
threshold will not get an ADHD diagnosis. However, studies of these sub-threshold 
patients have shown similar deficits as those seen in ADHD in this group as well. For 
example sub-threshold patients have (milder) neuropsychological deficits (Faraone et 
Figure 2   Alternative models to unravel the pathway between genes and disorder
Note EP = Endophenotype
Gene A
EP A
Disorder A Disorder B Disorder C
Gene BGene A Gene C
EP A
Disorder
Gene A
EP BEP A EP C
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a
c
b
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al., 2006), an increased risk of externalizing disorders and various behavioral problems 
(Cho et al., 2009), even though they do not have the full disorder. 
 Assuming ADHD genes to (partly) cause the deficits seen in ADHD, we can expect 
that the sub-threshold group characterized by the same deficits (although possibly 
milder), could also carry genetic risk factors related to these deficits and therefore also 
to ADHD. Recently, support for this was shown in the study of Larsson and coworkers, in 
which they showed a strong genetic link between the extreme and the sub-threshold 
variation of DSM–IV based assessments of ADHD (Larsson et al., 2012). This illustrates the 
fact that, by only studying above-threshold, clinical ADHD patients we miss out on 
valuable information for genetic studies. 
 To prevent such los of information, we can study ADHD from a dimensional point 
of view. This would mean that the complete spectrum of ADHD traits is taken into 
account, from having no ADHD symptoms at all, having intermediate levels of ADHD 
symptoms, to having the full disorder. Shaw and co-workers published an important 
study in 2011 using this approach. They found the delay of thinning of the cortex to be 
associated with a dimensional classification of childhood ADHD symptoms (Shaw et al., 
2011). In chapter 6, we found similar results using a dimensional approach. In the study 
described in this chapter, a clear negative correlation between the number of ADHD 
symptoms and total brain volume was shown in the general population. Previous 
categorical approaches in ADHD patients had shown similar associations between 
ADHD and total brain volume (Castellanos et al., 2002). 
 Using this dimensional approach has several advantages. First, the dimensional 
approach fits well with a population based study. This has the advantage that large 
samples can be studied which results in increased power to detect effects. Subtle and 
sub-threshold effects are therefore more likely to be found. This increased power also 
opens the possibility to study the distinct symptom domains separately, which in a 
recent meta-analysis have been shown to have distinct genetic etiology (Nikolas and 
Burt, 2010). In future studies, the individual contribution of the symptom domains can 
be studied using this dimensional approach in order to extend our understanding of 
ADHD from a genetic as well as a neurobiological perspective.
 Another advantage of using a dimensional approach to ADHD is that by performing 
studies like the one in chapter 6, we can get a clear picture of how the trait behaves 
across the whole spectrum of the disorder. For example, in chapter 6 it was shown that 
total brain volume for subjects with zero to four ADHD symptoms is relatively stable, 
however total brain volumes starts to decrease in subjects with five or more ADHD 
symptoms. This could possibly contribute to validity studies of clinical diagnostics in 
determining where the threshold for clinical and subclinical ADHD needs to be set. 
Knowing how a trait behaves is also important for the understanding of the genetic 
factors linked to this trait. As was proposed by Thapar and coworkers, it might be the 
case that we can distinguish genetic risk factors for dimensional traits of ADHD and 
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genetic factors related to the clinical disorder (Thapar et al., 2006). Therefore, also for 
finding ADHD genes and understanding how they are related to ADHD, it is informative 
to know whether a certain trait is behaving in a linear way with relation to ADHD (e.g. 
when a trait has a strong correlation with the number of ADHD symptoms) or only 
deviates from normal in the above threshold or clinical group. 
 In conclusion, using a dimensional approach by studying the whole continuum of 
ADHD can help to find endophenotypes of ADHD, increases our chances of finding 
subtle or sub-threshold effects and shows us how an ADHD trait behaves with respect 
to the whole ADHD spectrum. This is potentially beneficial for gene finding and learning 
more about the neurobiology of ADHD. This does leave the question, whether we 
should stay with ADHD as a categorical disorder in genetic studies or if we should 
always approach ADHD from a dimensional perspective. Here, I have discussed 
advantages of using a dimensional approach. However, many studies using a categorical 
approach have resulted in successful gene finding, as they compare the extremes of the 
continuum, and therefore will remain just as important (Faraone et al., 2005). To unravel 
the genetics of ADHD, both approaches are additive in expanding our knowledge and 
therefore should both exist in future gene finding attempts. 
Sample size imaging genetics studies
Effects of genes are small, and in order to find genes associated with disorders as 
complex and heterogeneous as ADHD, large study samples are needed. This was 
illustrated by the meta-analysis of genome wide association studies (GWAS) in ADHD 
where a sample size of 2,064 trios, 896 cases, and 2,455 controls was not sufficient to 
find genome wide significant hits (Neale et al., 2010). One of the reasons for not finding 
significant effects is the extremely low threshold for significance, which is set to 5x10-8, 
because of correction for the multiple tests performed (Hoggart et al., 2008; Risch and 
Merikangas, 1996). When studying the effects of specific genes on endophenotypes 
with an a priori hypothesis for an imaging genetics design, it is not necessary to study 
cohorts this large because there is no need to correct for the thousands of tests done in 
GWAS studies. But what is a reasonable sample size for imaging genetics studies?
 The first functional imaging genetic studies in ADHD were very small sampled (e.g. 
n=20 in (Durston et al., 2008)), however, these studies showed that by using prior 
knowledge of gene expression, significant effects were found for ADHD genes in 
regions with high expression of the gene, and no effects in regions where the gene has 
low expression. In 2008, Munafo et al. performed a meta-analysis on imaging genetics 
studies of a single genetic variant in the serotonin transporter and concluded that the 
minimal number of subjects to be included in such a study should be 70 (assuming 
equal genotype groups) to achieve 80% power to detect an association with brain 
activity at the level of p= 0.05 (Munafò et al., 2008). In addition, the work by Mier and 
coworkers showed similar numbers (Mier et al., 2010). One of the reasons for not 
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replicating the DAT1 effect on striatal activation in chapter 3 could therefore be due to 
the limited sample size in the previously published studies, because only one of the 
seven studies met the minimal sample requirements set by the Mier and Mufano 
meta-analyses.
 Power to detect genetic effects also depends on the type of endophenotype being 
studied. In chapter 4, the effect sizes were investigated for the effects of NOS1 on brain 
functioning and a behavioral measure. In keeping with the idea that brain activity is 
closer to the genes than cognitive or behavioral measures (Figure 1, chapter 1), it was 
shown that the effect size for the brain functioning endophenotype was larger than for 
the behavioral endophenotype. This was also shown in a meta-analysis of genetic 
association studies for neuroimaging and cognitive measures in schizophrenia (Rose 
and Donohoe, 2012). They reported imaging measures to have mostly medium or large 
effects, whereas cognitive measures commonly show small effects. They also conclude 
risk variants for schizophrenia to have greater penetrance at the level of brain structure 
and brain functioning than at the level of cognitive measures. Therefore, sample size 
requirements might be higher for behavioral/cognitive endophenotypes than for 
imaging endophenotypes. However, this does not mean that we should not study 
cognitive or behavioral endophenotypes. We have learned from chapter 4 that 
interpreting effects of genes is made easier when a combination of brain functioning 
and behavioral measures is studied, as was discussed previously in this chapter.
 Taken together, although the effects of genes are expected to be small, combining 
functional brain measures and behavioral measures to study effects of genes might be 
the ideal way to unravel how genes are linked to the disorder. We should still aim for 
large sample sizes (n>70), but choosing the right endophenotypes to study is just as 
essential: we should think smart and big!
Clinical implications
Some results of this thesis can be of importance for clinical diagnostics and treatment. 
The current version of the Diagnostic and Statistical Manual of Mental Disorders, the 
DSM-IV-TR, does not have ADHD criteria specifically aimed at adults, which makes it 
difficult to diagnose patients later in life. For example, how does one rate an adult on 
the following criteria: ‘often runs about or climbs excessively in situations in which it is 
inappropriate’? Currently, a revised version of the DSM is scheduled to be released in 
May 2013, and there have been debates about adapting the definition of adult ADHD. It 
is proposed to lower the threshold of symptoms to be met for an adult ADHD diagnosis 
and to increase the age of onset (www.dsm5.org). Research has already shown that 
ADHD symptoms decrease or alter over the course of life, but these patients are still 
impaired (Haavik et al., 2010). In chapter 6, we found support for the lowering of the 
number of symptoms to meet for an adults ADHD diagnosis by showing that the 
threshold of impairment, suggested to be at 4 symptoms instead of 6 (Kooij et al., 2005), 
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coincides with a reduction of total brain volume. Also in this study, we showed that the 
sub-threshold group (having 4-5 symptoms) did not differ from the group with 6 or 
more self-rated ADHD symptoms on total brain volume. Although more research is 
needed, lowering the threshold of symptoms for an adult ADHD diagnosis seems to be 
a next step towards the optimal ADHD diagnosis.
 Methylphenidate, being the primary treatment in ADHD, makes it important to 
study the effects of the DAT1 gene more carefully, because variation in DAT1 was 
associated with methylphenidate responses and therefore also treatment outcome 
(Kooij et al., 2008; Stein et al., 2005), although studies are not consistent (Contini et al., 
2010). Two of the studies in this thesis have generated new information about the 
effects of this gene, the first being the differential haplotype associated with ADHD in 
childhood ADHD and ADHD in adulthood, the second being the absence of an effect of 
DAT1 gene on striatal functioning in adult ADHD. Taking these results as a starting point 
for future studies specifically aimed at effects of DAT1 in adult ADHD might result in a 
better understanding of methylphenidate responses and successful treatment.
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Wat is ADHD?
ADHD staat voor Attention Deficit Hyperactivity Disorder en is een psychiatrische stoornis 
die zich in de kindertijd ontwikkelt. De symptomen die bij ADHD horen kunnen worden 
onderverdeeld in twee domeinen: symptomen van inattentie en symptomen van hyper-
activiteit/impulsiviteit. Om te voldoen aan de criteria voor een ADHD diagnose binnen 
de huidige classificatie van DSM-IV moeten er 6 van de 9 symptomen van één van beide 
domeinen aanwezig zijn. Daarnaast gelden er nog een aantal andere criteria zoals het 
aanwezig zijn van de symptomen voor het zevende levensjaar en aantoonbare beperkingen 
in meerdere sitiaties (school, thuis of op de sportvereniging). Onderzoek heeft laten 
zien dat 5 á 6 procent van de bevolking ADHD heeft. Mensen met een ADHD diagnose 
hebben vaak nog co-morbide stoornissen zoals een depressie of een verslaving.
Hoewel ADHD is bekend als stoornis in de kindertijd, vertoont ongeveer de helft van 
deze kinderen vertoont nog verscheidene ADHD symptomen in hun volwassen leven 
en voldoet 15 procent aan de volledige diagnostische criteria van ADHD op volwassen 
leeftijd. Het komt ook voor dat volwassen patiënten pas op latere leeftijd een ADHD 
diagnose krijgen. In dat geval worden er indien mogelijk schoolrapporten bekeken en 
heteroanamneses bij ouders afgenomen om vast te stellen of er in hun kindertijd sprake 
was van ADHD, een voorwaarde voor de diagnose ADHD volgens de DSM-IV.
 ADHD bij volwassenen uit zich op een iets andere manier dan in de kindertijd; de 
hyperactiviteit neemt af, maar de rusteloosheid neemt toe. Er is een aantal onderzoeken 
gedaan waaruit blijkt dat het aantal symptomen nodig voor een ‘volwassen‘ ADHD 
diagnose lager zou moeten zijn dan bij kinderen. In de nieuwe versie van het handboek 
van de psychiatrie, de DSM-5, zal dit worden aangepast van 6 naar 4 symptomen voor 
volwassen. Vergelijkbaar met kinderen met ADHD, vertonen de volwassenen met ADHD 
veel co-morbide stoornissen. Concluderend kan gezegd worden dat de groep ADHD 
patiënten zeer heterogene is door de diversiteit aan symptomen en de aanwezigheid 
van co-morbide stoornissen. 
De behandeling van ADHD, in de regel met medicatie en gedragsbehandelingen, is in 
feite gericht op symptoom bestrijding en niet op genezing. Dit komt doordat we nog 
niet precies weten hoe ADHD ontstaat en welke mechanismen er precies gestoord zijn. 
Een beter begrip van deze mechanismen is nodig om de behandelingen te kunnen 
optimaliseren waardoor er verbeteringen kunnen optreden in het beloop van de 
stoornis. Het nader bestuderen van het brein en de moleculaire componenten en hun 
invloed op ADHD symptomen kunnen hieraan een bijdrage leveren.
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Cognitie en het brein 
ADHD patiënten worden gekenmerkt door verschillende cognitieve problemen. Deze 
cognitieve problemen kunnen grofweg worden ingedeeld in twee groepen; problemen 
met de uitvoerende functies zoals cognitieve controle en motivationele problemen 
zoals het anders reageren op beloning en straf. De ‘Dual Pathway’ theorie van Sonuga- 
Barke die deze twee domeinen beschrijft werd later nog uitgebreid met een derde 
component; een gestoorde temporele informatieverwerking. 
 De neurobiologische substraten van deze cognitieve problemen werden ook onder - 
zocht middels beeldvormend hersenonderzoek, zoals MRI scans. Zowel de structurele 
als functionele imaging studies lieten zien dat er in frontale, striatale en cerebellaire 
gebieden afwijkingen zijn gevonden bij ADHD patiënten. Daarnaast bleek uit neuro-
chemische imaging studies dat onder andere het dopamine systeem gestoord is bij 
ADHD patiënten. 
Hoe ontstaat ADHD?
Voor een groot deel is ADHD erfelijk bepaald. Uit onderzoek met tweelingen is gebleken dat 
genetisch factoren voor ongeveer 70 tot 80 procent verantwoordelijk zijn voor het 
ontstaan van ADHD. Ook zijn er enkele omgevingsfactoren bekend die de kans op 
ADHD verhogen, zoals alcoholgebruik tijdens de zwangerschap en een laag geboorte 
gewicht. 
 Door het uitvoeren van grote genoom-wijde associatie (GWAS) en koppeling 
(linkage) studies werden enkele genen geïdentificeerd voor ADHD. Ook werden er op 
basis van neurobiologische theorieën enkele specifieke genen gevonden die betrokken 
zijn bij ADHD. Voorbeelden hiervan zijn de dopamine genen DAT1 en DRD4. Het nadeel 
van deze grote genetische studies is dat er gecorrigeerd moet worden voor de 
hoeveelheid testen dat wordt uitgevoerd, waardoor de grens voor significantie erg laag 
ligt. Daarnaast zijn de effecten van individuele genen zo klein dat ze moeilijk te vinden 
zijn. Mede door deze factoren is het tot nog toe moeilijk gebleken genen voor ADHD te 
identificeren.
Endofenotypen
Ondanks de voortgang in de technische mogelijkheden en de toename van de 
groepsgrote die beiden de kans zouden moeten vergroten op het vinden van genen 
voor ADHD, hebben de genetische ADHD studies ons nog niet opgeleverd wat we 
hadden gehoopt. Er zijn nog maar weinig directe verbanden gevonden tussen genen 
en het klinische fenotype en replicatie van de gevonden resultaten blijkt lastig. Door de 
complexiteit van de stoornis met zijn vele gedrags- en genetische componenten valt 
het niet te verwachten dat we directe verbanden zullen vinden tussen variatie in 
gedeeltes van het DNA en het (heterogene) klinische fenotype. Het lijkt daarom 
noodzakelijk dat er additionele methoden moeten worden aangewend om ons verder 
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te helpen in de zoektocht naar genen voor ADHD. Een van die methoden is het gebruik 
van endofenotypen.
 Endofenotypen liggen tussen het genotype en het fenotype in. Het zijn meetbare 
kenmerken die erfelijk bepaald zijn en een deel van de genetische lading delen met de 
stoornis. Het voordeel van het bestuderen van endofenotypen is dat er minder genen 
bij betrokken zijn, en het daardoor makkelijker is genen te vinden die betrokken zijn bij 
deze sub-kenmerken van de stoornis. Bovendien genereert het bestuderen van 
associaties tussen endofenotypen en genen nieuwe inzichten in hoe genen betrokken 
zijn bij de stoornis. Endofenotypen zijn vaak kwantitatief van aard in tegenstelling tot 
het aan/of afwezig zijn van de stoornis, het fenotype. Dit heeft tot gevolg dat het 
endofenotype grotere variatie heeft en maakt het ook makkelijker om effecten van 
genen te vinden. 
Het doel van het onderzoek in dit proefschrift
We weten dat ADHD in hoge mate erfelijk bepaald is, maar we weten nog niet goed 
welk effect genen precies hebben op het ontwikkelen van ADHD. Het doel van het onder- 
 zoek beschreven in dit proefschrift is het beter begrijpen van de associaties tussen ADHD 
genen en de stoornis. Aangezien de weg van genetische variatie naar het effect op de 
stoornis lang is, ontleden we ADHD in meetbare kenmerken van ADHD, endofenotypen. 
Door deze methode te gebruiken hopen we naast het beter begrijpen van hoe genen 
het risico op ADHD verhogen ook meer te leren over de neurobiologie van ADHD. 
 Dit proefschrift bestaat uit twee delen; in deel I (hoofdstuk 3 t/m 5) worden de 
associaties tussen bepaalde kandidaat genen en endofenotypen van ADHD bestudeerd. 
Deel II (hoofdstuk 6) richt zich op de relatie tussen een endofenotype van ADHD en het 
klinische fenotype. 
 Om onze onderzoeksdoelen te verwezenlijken werd de Nederlandse tak van het 
International Multicentre persistent ADHD genetics Collaboration (IMpACT) opgericht. 
Volwassenen met ADHD werden uitgenodigd om neuropsychologische taken uit te 
voeren, structurele en functionele imaging te ondergaan en DNA af te staan. Tevens 
werden er psychiatrische interviews afgenomen om het klinische fenotype goed in 
kaart te brengen. De voorkeur voor volwassenen met ADHD had te maken met het feit 
dat de erfelijke component hoger en minder heterogeen wordt geacht voor deze groep 
dan voor kinderen met ADHD. Ook werd er een grote groep gezonde mensen 
onderzocht die hadden deelgenomen aan de Brain Imaging Genetics (BIG) studie. Dit is 
een langlopende en grootschalige studie naar de rol van genen op hersenkenmerken.
De belangrijkste bevindingen uit dit proefschrift
De eerste studie in dit proefschrift beschrijft het onderzoek naar een van de meest 
onderzochte genen in ADHD. Uit de resultaten bleek dat het 9-6 haplotype van het 
dopamine transporter gen (DAT1) vaker wordt gevonden bij volwassen met ADHD dan 
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mensen zonder ADHD (hoofdstuk 2). Dit is opvallend omdat er bij kinderen met ADHD 
een ander risico haplotype van dit gen werd gevonden in eerdere studies (10-6). Naar 
mate men ouder wordt veranderd de dopamine transporter dichtheid en dat zou een 
verklaring kunnen zijn voor deze verschillen in de associatie met ADHD in kindertijd en 
volwassenheid. Daarnaast zouden er enkele omgevingsinvloeden zoals roken, invloed 
kunnen hebben op dit effect. Deze resultaten suggereren dat DAT1 een rol speelt in de 
modulatie van ADHD in plaats van dat het ADHD veroorzaakt.
 De effecten van het 9-6 haplotype van het DAT1 gen werden verder onderzocht 
door te kijken naar verschillen in het brein (hoofdstuk 3). Dit gen komt voornamelijk in 
het striatum tot expressie en daarom werd er gekeken naar de effecten van dit gen op 
de activatie in het striatum. Het striatum speelt een grote rol in ADHD want het is 
betrokken bij beloning en straf, gestoorde functies bij ADHD-ers, en ADHD patiënten 
worden vaak gekenmerkt door afwijkingen in activatie en grootte in het striatum. De 
deelnemers aan de IMpACT studie voeren een beloningstaak uit in de MRI scanner 
zodat we de striatale activatie konden meten. Er werden geen verschillen gevonden 
voor ADHD patiënten met het risico haplotype en mensen zonder het haplotype, noch 
in gezonde deelnemers met en zonder het 9-6 haplotype. Effecten van genen zijn klein en 
subtiel, het vinden van effecten zal daarom erg afhankelijk zijn van kleine variaties in 
bijvoorbeeld de test procedures. Het blijft onduidelijk hoe dit haplotype geassocieerd 
is met ADHD en welke effect het heeft op het fenotype. 
 Daar waar we geen effect vonden voor het DAT1 gen, werden er wel effecten 
gevonden van het NOS1 gen op striatale activatie (hoofdstuk 4). Dit gen had onze 
interesse vanwege de getoonde associatie met impulsiviteitstoornissen en zijn expressie 
in het striatum. De risicovariant voor impulsiviteitstoornissen liet een verhoogde 
striatale activatie en een verhoogde score op een impulsiviteitstaak zien, zowel in 
patiënten als in controles. Deze resultaten passen goed in de huidige literatuur over 
impulsiviteit en striatale activatie; hoe impulsiever hoe hoger de activatie. De resultaten 
passen minder goed bij de studies die laten zien dat volwassenen met ADHD een 
verlaagde striatale activatie vertonen. We denken daarom dat NOS1 een effect heeft op 
impulsiviteit en door het effect op impulsiviteit ook geassocieerd is met ADHD.
 Een derde en laatste hoofdstuk over de associatie tussen een ADHD kandidaat gen 
en een endofenotype van ADHD toont de resultaten van de effecten van het dopamine 
receptor d4 gen (DRD4) op werkgeheugen prestaties en de daarbij behorende 
prefrontale activatie (hoofdstuk 5). Er bleek een interactie effect van groep (ADHD/
controles) met genotype (aanwezigheid 7-repeat allel/ afwezigheid 7-repeat allel). De 
ADHD groep met de risicovariant (7-repeat allel) had een beter score op de spatiële 
werkgeheugentaak en hogere frontale activatie dan de ADHD groep zonder het 7R allel. 
Bij de controles was dit effect omgekeerd. Deze tegengestelde gedragseffecten van de 
aanwezigheid van het 7R allel op werkgeheugen in de verschillende groepen zijn 
vergelijkbaar met eerdere studies, de effecten op frontale activatie zijn nieuw. De verschillen 
163
Nederlandse Samenvatting
in baseline dopamine niveaus die eerder werden gevonden bij ADHD patiënten zouden 
de resultaten kunnen verklaren. Het 7-repeat allel is geassocieerd met een gedempt 
effect op de dopamine respons. In patiënten zou deze gedempte respons een positief 
effect kunnen hebben op het aanwezige afwijkende dopaminerge functioneren 
waardoor zij optimale dopamine niveaus hebben voor het uitvoeren van de 
werkgeheugen taak. Bij controles zou deze gedempte respons een negatief effect 
kunnen hebben op een al optimaal functionerend dopamine systeem. ADHD is een 
multifactoriële stoornis en genen betrokken bij deze stoornis kunnen meerdere effecten 
hebben op het fenotype, zowel positief als negatief.
In deel II van het proefschrift werd er gekeken naar hoe klinische eigenschappen van 
ADHD zich verhouden tot kenmerken in de hersenen (hoofdstuk 6). In een grote groep 
gezonde volwassen deelnemers aan de BIG studie werd een negatieve correlatie 
gevonden tussen het aantal zelfgerapporteerde ADHD symptomen en hun totale 
hersenvolume. Het domein van de inattentie symptomen vertoonde de sterkste 
associatie. Er wordt aangenomen dat ADHD het uiteinde van een continuüm van 
gedrag in de populatie is. Dit werd al eerder ondersteund door de dimensionaliteit van 
neurobiologische eigenschappen van ADHD. De resultaten uit hoofdstuk 6 passen hier 
goed bij; zelfgerapporteerde ADHD symptomen hebben een neurobiologisch substraat, 
welke niet specifiek gelokaliseerd is maar een globaal effect heeft in het brein. Er werd 
ook gevonden dat de grens voor klinische beperkingen (>4 symptomen) samen viel 
met de reductie in totaal hersenvolume. Deze studie toont aan dat het totale 
hersenvolume een potentieel endofenotype is voor ADHD en gebruikt kan worden in 
studies naar genetische effecten van ADHD. 
Wat kunnen we leren van de resultaten uit dit proefschrift
In dit proefschrift is geprobeerd de verbindingen tussen genotype en fenotype voor de 
stoornis ADHD te onderzoeken. Het werkmodel voor dit onderzoek bestond uit het 
bestuderen van de associaties tussen endofenotypen van ADHD met bekende genen 
van ADHD maar ook met het klinische fenotype (zie figuur 1 in hoofdstuk1). 
Het gebruik van endofenotypen als werkmodel heeft voor- en nadelen. Het voordeel is 
dat we meer te weten komen over hoe genen zich associëren met de stoornis. In dit 
proefschrift hebben we gevonden dat; 1) genen een indirect effect kunnen hebben op 
de stoornis (NOS1, hoofdstuk 4), 2) de effecten van genen niet zo voor de hand liggend 
zijn als men op basis van de eerdere literatuur zou verwachten (DAT1, hoofdstuk 3) en, 3) 
effecten van genen afhankelijk kunnen zijn van het klinische fenotype (DRD4, hoofdstuk 5). 
Al deze informatie samen vormt een klein stukje van de ADHD puzzel waardoor we 
deze stoornis steeds beter gaan begrijpen. 
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 Er kwamen nog enkele belangrijke aspecten van endofenotype onderzoek naar 
voren uit dit proefschrift. Endofenotype studies met zowel een gedrag als een imaging 
component dragen ertoe bij dat het interpreteren van de effecten makkelijker wordt. 
Daarnaast genereren genotype-endofenotype studies belangrijke informatie als er 
naast de aangedane groep ook wordt gekeken naar het effect in een gezonde groep. 
We onderzoeken deze genen omdat ze betrokken zijn bij het ontstaan van stoornissen 
en ziektes, maar ook in de gezonde populatie hebben deze genen effecten die kunnen 
bijdragen aan een beter begrip van het effect van de specifieke genen (zoals in de DRD4 
studie). En tot slot, genen bleken hogere effect sizes te hebben op imaging maten dan 
op gedrag maten en daarom zeer bruikbaar voor endofenotype onderzoek. 
 Het nadeel van het werkmodel van dit proefschrift is dat het een simplificatie is van 
de werkelijkheid. De kans is klein dat een enkel gen slechts effect heeft op één 
endofenotype of slechts één stoornis. Daarnaast zijn er endofenotypen die verbonden 
zijn aan meerdere stoornissen. De striatale activatie die veel in dit proefschrift als 
endofenotype is gebruikt, blijkt niet alleen met ADHD geassocieerd te zijn maar ook 
met verslavingsstoornissen. Ons beperken tot de minimale verbindingen van één gen 
aan één endofenotype aan één stoornis heeft dus tot gevolg dat we ons beperken en 
belangrijke informatie missen. Daarnaast wordt er in dit model geen rekening gehouden 
met omgevingsfactoren. We weten dat ADHD, en dus ook zijn endofenotypen door 
omgevingsfactoren wordt beïnvloed. Een laatste aspect van simplificatie van het model 
is de aangenomen causaliteit. Het model gaat uit van effecten van genen via de 
endofenotypen op de stoornis. Het is goed mogelijk dat individuele genen onafhankelijk 
van elkaar het endofenotype en het fenotype beïnvloeden. Voor toekomstig onderzoek 
zal het zich buiten de grenzen van dit model begeven, additionele informatie opleveren 
en daarmee een completer beeld van de stoornis. 
De meeste psychiatrische studies vergelijken groepen patiënten met groepen controles 
op verschillende maten zoals op hersenvolumes of cognitieve maten. Van deze categoriale 
benadering hebben we al veel geleerd over ADHD. ADHD bestuderen vanuit een 
dimensionale benadering en daarmee het hele spectrum bekijken, genereert nieuwe 
informatie (hoofdstuk 6). Met deze benadering verhogen we de kans op het vinden van 
subtiele effecten en effecten net onder de drempelwaarde. Het voordeel van een 
dimensionale benadering is dat ADHD kenmerken in grote bevolkingsgroepen kunnen 
worden bestudeerd en daarmee de statistische power omhoog gaat voor het vinden van 
effecten, zoals in hoofdstuk 6. Daarnaast kunnen we leren hoe bepaalde ADHD trekken 
zich over het hele spectrum gedragen: is er een lineair verband tussen het volume van 
een specifiek hersengebied en het aantal ADHD symptomen, is er sprake van een 
drempelwaarde waarboven er geen extra effect is van de hersenmaat, of is juist sprake 
van een exponentieel verband? Deze informatie draagt bij aan een betere kennis van de 
neurobiologie van ADHD is daarmee ook bevorderlijk voor het vinden van genen. 
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Effecten van genen zijn klein zoals veelvuldig aangehaald in dit proefschrift. Het is 
daarom van belang om grote groepen te bestuderen om zo genoeg power te hebben 
om daadwerkelijk genetische effecten te vinden. Meta-analyses van genetische imaging 
studies hebben al laten zien dat er een minimale groepsgrote van 70 subjecten nodig is 
voor het vinden van een associatie tussen genetische variatie en hersenactiviteit. Een 
van de redenen voor het niet kunnen repliceren van het eerder gevonden DAT1 effect 
op striatale activatie zou kunnen zijn dat de eerdere studies niet aan die minimale eisen 
voldeden. In toekomstige genetische imaging studies is het dan ook aan te raden om 
deze factor te minimaliseren en groepen van groter dan 70 subjecten, met een gelijke 
verdeling van genotype, te includeren.
Dit proefschrift was niet gericht op het genereren van klinische implicaties. Toch kunnen 
er indirect voor de klinische praktijk enkele aspecten worden opgepakt. De grens voor 
een ADHD diagnose bij volwassenen ligt nu bij 6 symptomen van een van beide symptoom 
domeinen. De nieuwe DSM-5 die in 2013 uitkomt bevat naar alle waarschijnlijkheid een 
nieuwe verlaagde ondergrens voor de diagnose bij volwassenen. Het onderzoek in dit 
proefschrift laat zien dat ook op neurobiologisch niveau daar ondersteuning voor te vinden 
is (hoofdstuk 6).
 Een ander aspect voor de klinische praktijk heeft te maken met de meest 
voorgeschreven ADHD medicatie, methylfenidaat. In dit proefschrift werd veel aandacht 
besteed aan het DAT1 gen. Variatie in het DAT1 gen heeft een effect op de werking van 
de dopamine transporters. Dit is vergelijkbaar met de werking van methylfenidaat die 
de dopamine transporters blokkeert. In dit proefschrift werd aangetoond dat er een 
andere DAT1 variant geassocieerd was met ADHD in volwassenen dan bij kinderen met 
ADHD en dat er een eerder getoond effect van DAT1 op striatale activatie afwezig was 
in volwassenen met en zonder ADHD. Deze resultaten kunnen een startpunt zijn voor 
toekomstige studies gericht op effecten van DAT1 in volwassen welke kunnen leiden tot 
een beter begrip van de respons op methylfenidaat die kunnen leiden tot een betere 
behandeling van ADHD.
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De overstap van Amsterdam naar Nijmegen voor mijn promotieonderzoek was een van 
mijn beste keuzes ooit. Dat is voor een groot deel te danken aan al die fijne mensen 
waar ik mee heb samengewerkt, en ook door de mensen buiten het werkende leven 
die er voor me waren. Deze mensen ga ik nu allemaal bedanken! 
Allereerst wil ik alle deelnemers aan het IMpACT en het BIG project heel hartelijk danken 
voor hun deelname en medewerking. Zonder jullie medewerking bestaat er geen 
onderzoek. Het lijkt soms oneerbiedig om mensen te transformeren naar data maar zo 
zwart-wit is het niet, jullie hebben een zeer grote inspirerende werking waarvoor heel 
veel dank!
 
Jan, ook al heb ik er drie, jij was de enige promotor vanaf dag 1! Jij kunt dingen in gang 
zetten en van afstand overzicht houden en meedenken. Dank voor je snelheid, daadkracht 
en je grote kennis van zaken.
Barbara, dit proefschrift heeft heel veel aan jou te danken. Jij was mijn dagelijks 
begeleider en wat een ontzettende fijne tijd heb ik gehad dankzij onze samenwerking. 
Jij denkt mee en motiveert. Ik heb heel veel van je geleerd en ben ook echt enthousiast 
geworden voor de genetica, een voor mij totaal onbekend veld toen ik begon met mijn 
promotieonderzoek. Ook heb je me laten kennismaken met de internationale IMpACT 
groep en me gestimuleerd om naar veel congressen te gaan. Jouw manier van (samen)
werken is een inspiratie voor mij en ik hoop dat wij dat nog veel samen zullen doen in 
de toekomst.
Roshan, promotor nummer drie. Onze kennismaking vond plaats toen ik al een tijdje aan 
de gang was, maar kwam op het juiste moment. Jouw kennis van imaging kwam 
meteen heel goed van pas. Ik heb veel geleerd van je gedetailleerde kennis en manier 
van onderzoek doen. Je oratie gaf me veel inspiratie en heeft mij nog een laatste zetje 
gegeven voor het afronden van mijn proefschrift.
Alejandro, co-promotor en fijne collega. Jouw overtuigingskracht en duidelijke mening 
houden me scherp. Ik leer van jou nog steeds heel veel over genetica analyses waarvoor 
mijn dank. Oh, en die dank wil ik ook uitspreken voor mij altijd voor laten gaan als we 
een deur door moeten! 
Voorzitter Professor Kessels, professor Reif en professor Hagoort, hartelijk dank dat jullie 
zitting hebben willen nemen in de manuscriptcommissie. Prof. Reif, I’m very honored 
that you’re attending the ceremony in Nijmegen. Aan alle leden van de corona; dank 
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voor de tijd die jullie hebben besteed aan mijn proefschrift en voor het voeren van de 
oppositie. 
Esther, co-auteur en grote hulp bij de imaging analyses. Heel veel dank voor je grote 
bereidwilligheid om te helpen, voor je enthousiasme en voor je kennis van zaken.
  
Bij het opstarten van het IMpACT-NL project is een aantal mensen heel belangrijk 
geweest: Dorine Slaats-Willemse (neuropsychologie), Marcel Zwiers (imaging) en Cees 
Kan (klinische aspecten). Door het toevoegen van jullie specifieke kennis aan het project 
is het een heel mooi multidisciplinair onderzoek geworden. Ik heb fijn met jullie 
samengewerkt! 
 
Natuurlijk ook heel veel dank aan het lab van antropogenetica van het Radboud, jullie 
(Angelien, Marlies, Remco, Johanne, Marina, Mascha en Saskia), zijn echt de leukste 
groep mensen om mee te werken. Altijd zijn jullie bereid om te helpen en ook nog op 
een hele prettige manier. Gelukkig gaat onze samenwerking met veel van jullie gewoon 
verder voor het BIG project.
Andere mensen die ik wil bedanken omdat zij hebben bijgedragen aan het optimale 
verloop van IMpACT zijn, Jan Leijtens en Jos van Helvoirt voor het prikken, en Paul 
Gaalman voor de hulp bij de MRI-scanner. En voor het optimale verloop van BIG, Mark 
Rijpkema en Sabine Kooijman (en nog meer dank dat ik jullie werk heb mogen 
voortzetten).
Marten, jij werd mijn opvolger voor het IMpACT project, uiteraard was ik blij dat jij de 
dataverzameling van mij kon overnemen zodat ik eindelijk kon gaan schrijven. Langzaam 
werd me duidelijk wat jouw geheime wapen is: wat heb jij een humor! Mail of bel me 
gerust voor hulp bij jouw IMpACT papers, maar dan wel met een droge opmerking er bij! 
Niet te vergeten ook dank aan alle stagiaires op het project, Susanne, Kim, Cynthia, 
Femke, Famke, Elske en Mwalima als assistente.
Het was heel gezellig op de afdeling psychiatrie met kamergenoten Karin, Glenn, 
Matthijs, Rianne, Rose en Karlijn maar ook met de andere collega onderzoekers van de 
afdeling: Maaike, Marieke A en L, Arnt, Boudewijn, Janna, Marloes, Coby, Suzan, Esmé, 
Desiree, Denise en ook daar buiten Janita, Jeanette, Martine, Marieke, Anouk, Jolanda, 
Daphne, Ellen, Geert, Daniel en Andrieke (vergeet ik iemand, dan sorry!). Het was fijn om 
het lief en leed van het onderzoekersbestaan met jullie te delen.
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Sandra Kooij en Marije Boonstra, bedankt dat jullie me wegwijs gemaakt hebben in de 
ADHD wereld. Ik ben begonnen met dossiers doorspitten bij jullie in Den Haag. Dat 
heeft me meteen duidelijk gemaakt waar het om draait bij ADHD.
Many thanks also to all the IMpACT members. All the past meetings and communications 
have been very inspirational!  
En dan al mijn lieve vrienden, te beginnen met mijn paranimfen:
Karin; de overstap van mij van Amsterdam naar Nijmegen werd door jou heel makkelijk 
en prettig. Doordat ik bij jou op de kamer kwam kende ik meteen (alle ins en outs van) 
iedereen waardoor ik me snel al helemaal thuis voelde in het Nijmeegse. De ontelbare 
gezellige etentjes (ook met Jouke), uitjes, stapavondjes, spinuurtjes, amstel gold races, 
Thialf bezoeken, wintersport (“OMG hij is open”), en ja uiteindelijk ook het carnaval maar 
ook de momenten dat je er was als het even niet zo gezellig was. Bedankt voor AL je 
steun en gezelligheid!
Maaike; naast alle gezelligheid met Kaatje, waren vooral de afgelopen twee jaar echt 
heel bijzonder. Ik ben ZO blij dat we alle dingen van ons bizarre parallel lopende leven 
konden delen. Helaas heeft al dat geklets er wel toe geleid dat onze tennis/golf carrière 
een beetje in het slop is geraakt. Who cares! Straks wordt Gemert de ideale tussenstop, 
en daar kijk ik heel erg naar uit! Wanneer doen we weer een good old gesprek aan het net? 
Lieve Lonneke, jij bent er al meer dan 20 jaar! Er is niets wat ik hier kan opschrijven dat 
recht doet aan onze vriendschap. Al zoveel jaar delen we lief en leed, jij voelt als ‘thuis’ 
en bent zo belangrijk! Woonde je maar op fiets-afstand…
Rose en Karlijn (Ross en Kareltje); kamergenoten van het laatste uur maar bovenal (a)
vrimibo maatjes. Thee, kersjes en chocola tijdens het werk; naamkettinkjes, wijntjes en 
lange klets buiten het werk waren de ingrediënten. Het resultaat: onuitwisbare herinneringen 
aan een boeiende periode en heel veel lol, saamhorigheidsgevoel en gezelligheid. Dat jullie 
maar snel ook promoveren, feestjes met jullie zijn een gegarandeerd succes! En Ross, ik 
moet jou ook nog voor iets anders bedanken!
Cathelijne; fijn dat we de Donders dingen konden delen maar, nog fijner waren natuurlijk de 
talloze gezellige etentjes en theetjes. Gelukkig kun jij ook heel snel een feestje bouwen!
Rietriet-vrienden Guus, Hans, Mayo, Ruud, Daan, Rienk, Steph en Wilbert: jarenlang 
waren we goed voor zoveel gezelligs, ontelbaar veel gezellige uitstapjes, skivakanties, 
BBQ’s, feestjes, borrels, concerten en niet te vergeten al die oud-en-nieuws. En Wilbert, 
wat wordt de volgende uitdaging? 
Alwin bedankt voor al het bijzondere en de familie Vos voor alle interesse.
Amsterdammers Mirjam en Marjolein, de jaarlijkse weekendjes weg zijn te kort om alles 
te bespreken, en we zijn er eentje vergeten dit jaar! Maar alle promoties, GZ en KP 
opleidingen zijn bijna achter de rug dus meer tijd voor leuks? 
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Pap en Monique, ook al ben ik wat verder weg gaan wonen, jullie stonden meteen klaar 
om te helpen verhuizen. Bedankt voor het vertrouwen dat jullie altijd in mij hebben. Al 
heel vroeg lieten jullie mij mijn keuzes maken, en daar heb ik me altijd goed bij gevoeld. 
Fons, je bent een inspiratie voor mijn werk maar belangrijker nog, je bent gewoon mijn 
lieve grote kleine broer. Opa en Wil & Susan, bedankt voor het gevoel dat jullie me geven 
als jullie (soms via-via) zeggen trots op me te zijn. En ook de nieuwe familie Cocky, Joris, 
Anne-marie, Donna en Jay, wat leuk om jullie erbij te hebben voor het laatste en leukste 
stukje! 
Wat ontzettend blij ben ik met het rijke leven met al die fijne mensen om me heen, 
helaas zijn er veel bijzondere mensen niet meer bij maar hun invloed is onuitwisbaar en 
zeker bij deze mijlpaal. Mam: Als je had geweten naar welke middelbare school ik ben 
gegaan was je al heel trots geweest, dat weet ik zeker, daarom is deze promotie ook een 
beetje voor jou.
En tot slot, lieve Walter, zo blij ben ik met jou! Dank voor de liefste te zijn, je positiviteit 
en je onuitputtelijke energie die mij motiveert. Gelukkig ben ik met het volgende hoofdstuk 
dat voor ons saampjes is!
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